April 2–6, 2008 Gaylord Texan, Dallas, Texas Texan, Dallas, Texas Spring ’08 Clinical Meetings...

$: April 2–6, 2008 Gaylord Texan, Dallas, Texas Texan, Dallas, Texas Spring ’08 Clinical Meetings @::E ^h i]Z aVg\Zhi YZiZXi^dc egd\gVb ^c i]Z Jc^iZY HiViZh [dg `^YcZn Y^hZVhZ#$
April 2–6, 2008Gaylord Texan, Dallas, Texas

Spring ’08 Clinical Meetings

www.keeponline.org

© 2007 Astellas Pharma US, Inc. PRG00266-MK-R0-12/06

At Astellas, we are committed to uncovering new possibilities in immunology through broad scale research aimed at new product development.

Through the transference and sharing of scientifi c knowledge, we work in partnership with healthcare professionals like you to positively impact patient care.

Our goal remains clear: Enhance the practice of transplantation.

It is our passion and our priority.

Your Partner in Transplantation

PG

F-0288

AST A

bstracts/A

merican

Jou

rnal o

f Transp

lantaio

n A

dB

leed Size

: 9.25"w x 12.25"h

Trim

Size: 9"w

x 12"h

Live Size: 8"w

x 11"hPrin

ts: 4C —

•C •M

•Y •K

Mech

anical resized

from

PGF-0163 b

y CF

2.22.2008 08020023kafA04_280.indd

By Author

www.gethomedialysis.com

A Must Read !!! This book answers a myriad of questions about chronic

kidney disease and dialysis. The answers are expertly woven

into the humerous heartfelt journey of 50 year old Cledus B.Washington. If you have questions, this book has answers !

That Damn Dialysis

Visit Booth #636

QUALITY DIALYSIS has been providing Staff-AssistedHome Dialysis services to Texas for over thirteen years.Founded in 1993, the founder’s goal and mission has alwaysbeen to educate patients and their families about chronic kidneydisease, and provide professional, quality services to clients inthe home. Our wellness team consist of experienced socialworkers, renal dietitians, registered nurses, and bio-medicaltechnicians under the direct supervision of Nephrologist.Quality Dialysis offers home dialysis services in the Central, Southwestern and Northeastern regions of Texas. We consider it our privilege and your choice to provide homedialysis services to you.

Experience dialysis in the comfort of your home!

890 East Travis La Grange, TX 78945

4007 Greenbriar Drive, Suite E Stafford, TX 77477

1034 Shady Trail, Suite 112 Dallas, TX 75229

www.gethomedialysis.com979-968-3800 281-491-4009 214-295-7344

www.claybarpublishing.com 1-888-491-9533

Quality Dialysis

Cindy Barclay

C

M

Y

CM

MY

CY

CMY

K

NKF_AD_Full_Page rev 2.pdf 3/3/08 3:39:36 PM

Association of Mineral Metabolism,Vitamin D Therapy, and Calcimimetics onChronic Kidney Disease Patient SurvivalA CME-CERTIFIED SYMPOSIUM at the NKF 2008 Spring Clinical Meetings

Sponsored by theNational Kidney

Foundation

Wednesday, April 2, 20087:30 PM – 9:30 PM

Gaylord TexanDallas, TexasGrapevine Ballroom D

Supported by an unrestrictedmedical educationalgrant from Abbott.

PROGRAM OVERVIEWThis symposium will provide an overview of recent evidence on altered mineralmetabolism occurring in chronic kidney disease and therapeutic regimens thatrestore mineral homeostasis in chronic kidney disease patients. The session willalso discuss the impact of altered mineral metabolism on cardiovascular riskfactors and maximizing therapy to improve survival. Current information willfocus on important differences between nonselective and selective vitamin Dreceptor activator therapy, that not only include suppression of parathyroidhormone and regulation of calcium balance, but also examine nonclassicalactions of vitamin D receptor activators and how they impact cardiovascular andbone health. In addition, the session will provide an understanding ofcalcimimetic use in treating secondary hyperparathyroidism in chronic kidneydisease patients, and the impact of calcimimetics on risk factors and survival.

LEARNING OBJECTIVES• Understand the impact of disordered mineral metabolism on risk factors and

survival in chronic kidney disease patients.

• Discuss the differences between nonselective and selective vitamin D receptoractivators and how their use impact survival in chronic kidney diseasepatients.

• Review the mechanism of action of calcimimetic therapy, its role in therapy ofsecondary hyperparathyroidism, and long-term benefits on risk factors andsurvival in chronic kidney disease.

TARGET AUDIENCE: This CME-certified symposium is directed towardsnephrologists and clinicians who treat patients with chronic kidney disease.

HOW YOU WILL LEARN: This CME activity will be a live symposium consistingof lectures with panel audience participation

ACCREDITATION STATEMENT: The National Kidney Foundation is accreditedby the Accreditation Council for Continuing Medical Education to providecontinuing medical education for physicians.

DESIGNATION STATEMENT: The National Kidney Foundation designates thiseducational activity for a maximum of 1.5 AMA PRA Category 1 Credit TM.Physicians should only claim credit commensurate with the extent of theirparticipation in the activity.

The National Kidney Foundation is an approved provider of continuing nursingeducation by the New York State Nurses Association, which is accredited as anapprover of continuing nursing education by the American Nurses CredentialingCenter’s Commission on Accreditation.

This program is pending approval with the American Academy of Nurse Practitioners.

DECLARATION OF DISCLOSURE: It is the policy of the National KidneyFoundation to ensure balance, independence, objectivity, and scientific rigor inall CME activities. Faculty participating in this activity are required to discloseto the audience any relationship they may have with the commercial supportersof this activity or with any other commercial organizations whose products ordevices may be mentioned in their presentations.

UNLABELED / INVESTIGATIONAL USE DECLARATION: During theirpresentations, faculty may discuss an unlabeled use or an investigational usenot approved for a commercial product. Each faculty member is required todisclose this information to the audience when referring to an unlabeled orinvestigational use.

FACULTYMyles Wolf, MD, MMScAssistant Professor of MedicineHarvard Medical School; Renal UnitMassachusetts General HospitalBoston, Massachusetts

Stuart Sprague, DOChief, Division of Nephrology andHypertension, EvanstonNorthwestern HealthcareProfessor of MedicineNorthwestern UniversityFeinberg School of MedicineChicago, Illinois

Daniel Coyne, MDProfessor of MedicineDivision of Renal DiseasesDirector, HemodialysisChromalloy American Kidney CenterDirector, Outpatient Renal ClinicsCo-Director, Renal FellowshipTraining ProgramWashington UniversitySchool of MedicineDivision of Renal DiseasesSt. Louis, Missouri

AGENDA

Wednesday, April 2, 2008

7:30 PM Registration

8:00 PM Welcome and IntroductionMyles Wolf, MD, MMSc

8:05 PM “Associations of Mineral Metabolism with Patient Survival”Daniel Coyne, MD

8:30 PM “Impact of Vitamin D therapy on Patient Survival”Myles Wolf, MD, MMSc

8:55 PM “Does Direct Modulation of the Calcium Sensor AffectPatient Survival?”Stuart Sprague, DO

9:20 PM Q&A/Discussion

REGISTRATION: You must be registered for the NKF 2008 Spring ClinicalMeetings to attend this symposia and receive credit.

DISCLAIMER: The faculty, National Kidney Foundation, and Abbott do notrecommend the use of any pharmaceutical, diagnostic test, or device outside of thelabeled indications as approved by the FDA. Please refer to the official prescribinginformation for each product for approved indications, contraindications, andwarnings.

545-074-01-08-SC-Program-Ad-v5:NKF-1 Advertisement 2/27/08 4:11 PM Page 1

The Impact of Glycemic Control in Patientswith Diabetes and Chronic Kidney Disease

A Symposium and Breakfast during theNational Kidney Foundation 2008 Spring Clinical Meetings

Agenda

6:00 AM Registration and Breakfast

6:30 AM Welcome and IntroductionMartin J. Abrahamson, MDMedical Director and Senior Vice PresidentJoslin Diabetes CenterAssociate Professor of MedicineHarvard Medical SchoolBoston, MA

6:40 AM Glycemic Control in Patients with CKDMark S. Roberts, MD, MPPProfessor of Medicine, Health Policy and Management and Industrial EngineeringChief, Section of Decision Sciences and Clinical Systems ModelingDepartment of MedicineUniversity of Pittsburgh School of MedicinePittsburgh, PA

7:00 AM How Low Should You Go? Martin J. Abrahamson, MD

7:20 AM When and How to Use Insulin in Patients with Chronic Renal FailureArturo R. Rolla, MDEndocrinologist, Beth Israel Deaconess Medical CenterAssociate Clinical Professor of MedicineHarvard Medical School and Tufts University School of MedicineBoston, MA

7:40 AM Case Studies / Panel Discussion / Question and Answer SessionAll Faculty

8:00 AM Closing RemarksMartin J. Abrahamson, MD

Sponsored by the National Kidney Foundation

Supported by an educational grant from

Target Audience Nephrology professionals

Educational MethodThis CME activity will be a live symposium consisting of lectures and paneldiscussion with audience participation.AccreditationThe National Kidney Foundation is accredited by the Accreditation Council forContinuing Medical Education to provide continuing medical education forphysicians. DesignationThe National Kidney Foundation designates this educational activity for amaximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should onlyclaim credit commensurate with the extent of their participation in the activity. The National Kidney Foundation is an approved provider of continuing nursingeducation by the New York State Nurses Association, which is accredited asan approver of continuing nursing education by the American NursesCredentialing Center's Commission on Accreditation. This program is pending approval with the American Academy of NursePractitioners.Declaration of DisclosureIt is the policy of the National Kidney Foundation to ensure balance,independence, objectivity, and scientific rigor in all CME activities. Facultyparticipating in this activity are required to disclose to the audience anyrelationship that they may have with the commercial supporters of this activityor with any other commercial organizations whose products or devices maybe mentioned in their presentations.Unlabeled/Investigational Use DeclarationDuring their presentations, faculty may discuss an unlabeled use or aninvestigational use not approved for a commercial product. Each facultymember is required to disclose this information to the audience whenreferring to an unlabeled or investigational use.Disclaimer The faculty, National Kidney Foundation, and Novo Nordiskdo not recommendthe use of any pharmaceutical, diagnostic test, or device outside of thelabeled indications as approved by the FDA. Please refer to the officialprescribing information for each product for approved indications,contraindications, and warnings.

Thursday, April 3, 2008 | 6:00 AM – 8:00 AM | The Gaylord Texan | Grapevine Ballroom B | Grapevine, Texas

Program PurposeDiabetes is currently the fifth leading cause of death in the United Statesand is associated with significant morbidity due to associatedmacrovascular and microvascular complications, particularly chronickidney disease (CKD). In both diabetes and CKD there is evidence thatidentifying individuals early in the disease continuum can reducemorbidity and mortality. Yet experts estimate that fewer than 1 in 4patients with diabetes receive the minimum annual testing in preventivecare for blood glucose and lipid levels. Management of diabetes inpatients with CKD may be complicated as many medications may requiredosage adjustment or may be contraindicated, thus it is essential to haveunderstanding of the most effective treatment approaches for achievingtight glycemic control in these patients. Patient compliance is essentialfor an impact on patient outcome to be realized. This symposium willaddress considerations in managing patients with CKD and diabetes.Specifically the impact of strict glycemic control on outcome andstrategies for enhancing patient compliance with these complicatedmedical regimens will be discussed.

Program ObjectivesAt the conclusion of this program participants should:• Describe optimal glycemic targets and the impact of glycemic control

on outcomes in different stages of CKD• Develop an optimal clinical management plan of diabetes in patients

with different stages of CKD• Simplify the complex medication regimens in patients with CKD and

diabetes in order to improve compliance

Symposium Registration• Pre-registration for this symposium is not required.

We recommend arriving at the symposium early. Seating is limited andwill be available on a first come, first serve basis.

• You must be registered for the NKF 2008 Spring Clinical Meetings toattend this symposium and receive credit.

08-11 Novo Ad 2/22/08 1:10 PM Page 1

Target AudienceNephrology professionals

How Will You Learn?This CME activity will be a live symposium consisting of three lectures and a question and answer session.

Activity PurposeThis symposium will educate nephrology professionals and PCPs on proper management of chronic kidney disease (CKD) and will focus on raising awareness of social and medical issues related to CKD in elderly patients.

Learning ObjectivesAt the conclusion of the program, participants should:

6:30 – 6:35 am Welcome and Introductions Ann O’Hare, MD – Program Chair VA Puget Sound Health Care System, Seattle, Washington

6:35 – 7:00 am Natural History and Epidemiology of CKD in the Elderly Brenda R. Hemmelgarn, MD

7:00 – 7:25 am Assessment of Kidney Function in the Elderly Lesley A. Stevens, MD, MS, FRCP Tufts-New England Medical Center, Boston, Massachusetts

7:25 – 7:50 am Challenges of Managing CKD in the Elderly Ann O’Hare, MD VA Puget Sound Health Care System, Seattle, Washington

7:50 – 8:00 am Questions and Answers

A symposium to be conducted at the National Kidney Foundation 2008 Spring Clinical Meetings

Trends and Challenges in CKD Progression and Management

in Older Adults

April 3, 20086:00 am – 6:30 am: Breakfast & Registration

6:30 am – 8:00 am: Symposium

Grapevine Ballroom D

Declaration of Disclosure: It is the policy of the

independence, objectivity, and scientific rigor in

activity are required to disclose to the audience any relationship they may have with the commercial supporters of this activity or with any other

may be mentioned in their presentations.

Unlabeled/Investigational Use Declaration: During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

Accreditation Statement: The National Kidney

Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement: The National Kidney

a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

provider of continuing nursing education by the New York State Nurses Association, which is accredited as an approver of continuing nursing education by the American Nurses Credentialing Centers Commission on Accreditation.


Disclaimer: The faculty, National Kidney

recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as

prescribing information for each product for approved indications, contraindications, and warnings.

Please note that spouses, guests, or children are not permitted to attend. This is an educational program for healthcare professionals only.

to attend this symposium and receive credit.

Sponsored by the National Kidney Supported by an educational grant from

Thursday, April 3, 200812:00 PM – 12:30 PM Registration and Lunch12:30 PM – 2:00 PM Symposium

ACTIVITY PURPOSEThe purpose of this symposium is to educate nephrologists, fellows,residents, physician assistants, nurse practitioners, nephrology nurses andtechnicians, and renal and clinical dietitians interested in learning about safeand effective control of phosphorus levels in patients with CKD.

HOW YOU WILL LEARNThe symposium is held in a panel discussion format, incorporatingcase-based presentations, didactic lectures, and audience participation usingthe audience response system (ARS).

TARGET AUDIENCEThis program is designed for nephrologists, fellows, residents, physicianassistants, nurse practitioners, nephrology nurses and technicians, and renaland clinical dietitians.

ACCREDITATION AND CREDIT DESIGNATION STATEMENTSThe National Kidney Foundation is accredited by the Accreditation Council forContinuing Medical Education to provide continuing medical education forphysicians.

The National Kidney Foundation designates this educational activity for amaximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should only claimcredit commensurate with the extent of their participation in the activity.


This program is pending approval by the American Academy of NursePractitioners.

The National Kidney Foundation is a Continuing ProfessionalEducation (CPE) Accredited Provider with the Commission on DieteticRegistration (CDR). Registered dietitians (RDs) and dietetictechnicians, registered (DTRs) will receive 1.5 continuing professionaleducation units (CPEUs) for completion of this program/material.

DECLARATION OF DISCLOSUREIt is the policy of the National Kidney Foundation to ensure balance,independence, objectivity, and scientific rigor in all CME activities. Facultyparticipating in this activity are required to disclose to the audience anyrelationship they may have with the commercial supporters of this activityor with any other commercial organizations whose products or devices maybe mentioned in their presentations.

UNLABELED/INVESTIGATIONAL USE DECLARATIONDuring their presentations, faculty may discuss an unlabeled use or aninvestigational use not approved for a commercial product. Each facultymember is required to disclose this information to the audience whenreferring to an unlabeled or investigational use.

DISCLAIMERThe faculty, National Kidney Foundation, and Shire Pharmaceuticals do notrecommend the use of any pharmaceutical, diagnostic test, or device outsideof the labeled indications as approved by the FDA. Please refer to the officialprescribing information for each product for approved indications, contraindi-cations, and warnings.

Dietary Phosphorus and Outcomes in Patients With CKD

Sponsored by the National Kidney Foundation.

Supported by an unrestricted educationalgrant from Shire Pharmaceuticals.

National Kidney Foundation (NKF) 2008 Spring Clinical Meetings

PROGRAM AGENDA12:00 PM Registration and Lunch

12:30 PM Welcome and Introduction Stuart M. Sprague, DOModerator and Program ChairChief, Division of Nephrology andHypertensionEvanston Northwestern HealthcareProfessor of MedicineFeinberg School of MedicineNorthwestern UniversityChicago, Illinois

12:35 PM Should Phosphorus Be Controlled by Stuart M. Sprague, DODietary Restriction or Phosphate Bindersin Patients With CKD?

1:00 PM PRO: Dietary Phosphorus Control Daniel W. Coyne, MDImproves Survival Professor of Medicine

Renal DivisionWashington University School of MedicineSt. Louis, Missouri

1:25 PM CON: Dietary Phosphorus Control Kamyar Kalantar-Zadeh, MD, PhD, MPHIncreases Survival Associate Professor of Medicine and

PediatricsDavid Geffen School of MedicineUniversity of California, Los AngelesDirector, Dialysis Expansion Programand EpidemiologyHarbor–UCLA Medical CenterLos Angeles, California

1:50 PM Panel Discussion/Q&A

2:00 PM Adjourn

EDUCATIONAL OBJECTIVESUpon completion of this symposium, participants will be able to:• Apply dietary restriction techniques to control phosphorus (P) levels in patients with

chronic kidney disease (CKD)• Evaluate the efficacy of dietary P control and its effect on survival• Assess the risk of malnutrition associated with dietary P control• Appropriately implement the use of phosphate binders in controlling hyperphosphatemia

in patients with CKD

Gaylord Texan Resort and Convention CenterGrapevine Ballroom C1501 Gaylord TrailGrapevine, Texas

REGISTRATIONTo ensure participation, preregistration is strongly recommended by March, 31, 2008.To register for this symposium, please call the Registration Center at 1-866-890-2945.On-site registration will begin at 12:00 PM in Grapevine Ballroom C, Gaylord TexanResort and Convention Center, Grapevine, Texas. Seating priority will be given topreregistered attendees; however, walk-ins are encouraged and will be admitted ona first-come, first-served basis, as space permits.

You must be registered for the NKF 2008 Spring Clinical Meetings to attend thissymposium and receive credit.

• Effectiveness of dietary control• Association of phosphorus with survival

• Limitations of dietary control• Effectiveness of phosphate binders

Shire_NKF AD.rev.qxp:1788 AD 8.5x11 2/20/08 3:55 PM Page 1

Thursday, April 3, 200812:00 PM – 12:30 PM Registration and Lunch12:30 PM – 2:00 PM Symposium

ACTIVITY PURPOSEThe purpose of this symposium is to educate nephrologists, fellows,residents, physician assistants, nurse practitioners, nephrology nurses andtechnicians, and renal and clinical dietitians interested in learning about safeand effective control of phosphorus levels in patients with CKD.

HOW YOU WILL LEARNThe symposium is held in a panel discussion format, incorporatingcase-based presentations, didactic lectures, and audience participation usingthe audience response system (ARS).

TARGET AUDIENCEThis program is designed for nephrologists, fellows, residents, physicianassistants, nurse practitioners, nephrology nurses and technicians, and renaland clinical dietitians.

ACCREDITATION AND CREDIT DESIGNATION STATEMENTSThe National Kidney Foundation is accredited by the Accreditation Council forContinuing Medical Education to provide continuing medical education forphysicians.

The National Kidney Foundation designates this educational activity for amaximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should only claimcredit commensurate with the extent of their participation in the activity.


This program is pending approval by the American Academy of NursePractitioners.

The National Kidney Foundation is a Continuing ProfessionalEducation (CPE) Accredited Provider with the Commission on DieteticRegistration (CDR). Registered dietitians (RDs) and dietetictechnicians, registered (DTRs) will receive 1.5 continuing professionaleducation units (CPEUs) for completion of this program/material.

DECLARATION OF DISCLOSUREIt is the policy of the National Kidney Foundation to ensure balance,independence, objectivity, and scientific rigor in all CME activities. Facultyparticipating in this activity are required to disclose to the audience anyrelationship they may have with the commercial supporters of this activityor with any other commercial organizations whose products or devices maybe mentioned in their presentations.

UNLABELED/INVESTIGATIONAL USE DECLARATIONDuring their presentations, faculty may discuss an unlabeled use or aninvestigational use not approved for a commercial product. Each facultymember is required to disclose this information to the audience whenreferring to an unlabeled or investigational use.

DISCLAIMERThe faculty, National Kidney Foundation, and Shire Pharmaceuticals do notrecommend the use of any pharmaceutical, diagnostic test, or device outsideof the labeled indications as approved by the FDA. Please refer to the officialprescribing information for each product for approved indications, contraindi-cations, and warnings.

Dietary Phosphorus and Outcomes in Patients With CKD


Supported by an unrestricted educationalgrant from Shire Pharmaceuticals.

National Kidney Foundation (NKF) 2008 Spring Clinical Meetings

PROGRAM AGENDA12:00 PM Registration and Lunch

12:30 PM Welcome and Introduction Stuart M. Sprague, DOModerator and Program ChairChief, Division of Nephrology andHypertensionEvanston Northwestern HealthcareProfessor of MedicineFeinberg School of MedicineNorthwestern UniversityChicago, Illinois

12:35 PM Should Phosphorus Be Controlled by Stuart M. Sprague, DODietary Restriction or Phosphate Bindersin Patients With CKD?

1:00 PM PRO: Dietary Phosphorus Control Daniel W. Coyne, MDImproves Survival Professor of Medicine

Renal DivisionWashington University School of MedicineSt. Louis, Missouri

1:25 PM CON: Dietary Phosphorus Control Kamyar Kalantar-Zadeh, MD, PhD, MPHIncreases Survival Associate Professor of Medicine and

PediatricsDavid Geffen School of MedicineUniversity of California, Los AngelesDirector, Dialysis Expansion Programand EpidemiologyHarbor–UCLA Medical CenterLos Angeles, California

1:50 PM Panel Discussion/Q&A

2:00 PM Adjourn

EDUCATIONAL OBJECTIVESUpon completion of this symposium, participants will be able to:• Apply dietary restriction techniques to control phosphorus (P) levels in patients with

chronic kidney disease (CKD)• Evaluate the efficacy of dietary P control and its effect on survival• Assess the risk of malnutrition associated with dietary P control• Appropriately implement the use of phosphate binders in controlling hyperphosphatemia

in patients with CKD


REGISTRATIONTo ensure participation, preregistration is strongly recommended by March, 31, 2008.To register for this symposium, please call the Registration Center at 1-866-890-2945.On-site registration will begin at 12:00 PM in Grapevine Ballroom C, Gaylord TexanResort and Convention Center, Grapevine, Texas. Seating priority will be given topreregistered attendees; however, walk-ins are encouraged and will be admitted ona first-come, first-served basis, as space permits.


• Effectiveness of dietary control• Association of phosphorus with survival

• Limitations of dietary control• Effectiveness of phosphate binders

Shire_NKF AD.rev.qxp:1788 AD 8.5x11 2/20/08 3:55 PM Page 1

Sponsored by the National Kidney Foundation Supported by an educational grant from

PROGRAM PURPOSEHyperphosphatemia has been implicated in a myriad of negative consequences including the pathogenesis ofcardiovascular calcification and is independently associated with increased mortality in patients with stage 5 chronickidney disease (CKD). Therefore adequate control of phosphate is essential in these patients; however the mostappropriate therapy has been a matter of much debate. This symposium will review recently published studies evaluatingphosphate binder and its impact on efficacy, patient outcomes, and pharmacoeconomics, especially as it relates totreatment selection and the attainment of KDOQI guidelines for mineral metabolism disorders in the United States.

Educational MethodThis CME activity will be a live symposium consisting of lectures and panel discussion withaudience participation.

AccreditationThe National Kidney Foundation is accredited by the Accreditation Council for ContinuingMedical Education to provide continuing medical education for physicians.

DesignationThe National Kidney Foundation designates this educational activity for a maximum of 1.5 AMAPRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extentof their participation in the activity.

The National Kidney Foundation is an approved provider of continuing nursing education by theNew York State Nurses Association, which is accredited as an approver of continuing nursingeducation by the American Nurses Credentialing Center's Commission on Accreditation.


Declaration of DisclosureIt is the policy of the National Kidney Foundation to ensure balance, independence, objectivity,and scientific rigor in all CME activities. Faculty participating in this activity are required todisclose to the audience any relationship that they may have with the commercial supporters ofthis activity or with any other commercial organizations whose products or devices may bementioned in their presentations.

Unlabeled/Investigational Use DeclarationDuring their presentations, faculty may discuss an unlabeled use or an investigational use notapproved for a commercial product. Each faculty member is required to disclose thisinformation to the audience when referring to an unlabeled or investigational use.

Disclaimer The faculty, National Kidney Foundation, and Fresenius Medical Care – North America (FMC-NA)do not recommend the use of any pharmaceutical, diagnostic test, or device outside of thelabeled indications as approved by the FDA. Please refer to the official prescribing informationfor each product for approved indications, contraindications, and warnings.

AGENDA AND SPEAKERS:

7:30 p.m. Registration and Dinner

8:00 p.m. Introduction by Program ModeratorVincent W. Dennis, M.D.Senior Medical AdviserAmbulatory Services of AmericaBrentwood, Tennessee

8:10 p.m. A Review of Recent Clinical Studies of Patientswith Stage 5 CKD: Impact on Clinical PracticeLynda Szczech, M.D.Associate Professor of MedicineDuke Clinical Research Institute Duke University Medical CenterDurham, North Carolina

8:40 p.m. Phosphate Binder Choice in the Treatment ofPatients with Stage 5 CKD: Health-EconomicConsiderationsWolfgang C. Winkelmayer, M.D., ScDAssistant Professor of MedicineHarvard Medical School Cambridge Brigham and Women's Hospital Boston, Massachusetts

9:10 p.m. Question and Answer SessionFaculty

9:30 p.m. Closing RemarksVincent W. Dennis, M.D.

SYMPOSIUM REGISTRATION• Pre-registration for this symposium is not required.

We recommend arriving at the symposium early. Seating is limitedand will be available on a first come, first serve basis.

• You must be registered for the NKF 2008 Spring Clinical Meetingsto attend this symposium and receive credit.

TARGET AUDIENCEThis program has been designed to meet the learningobjectives of Physicians, Researchers, Fellows,Residents, and may be beneficial to nurses anddietitians.

PROGRAM OBJECTIVESAt the conclusion of the program, participants will be able to:• Discuss the epidemiology of hyperphosphatemia in

patients with stage 5 CKD• Summarize the salient findings from recent clinical

trials that investigated the outcomes, including mortality rates, among patients with stage 5 CKDwho were treated with various phosphate binders

• Understand the recent pharmacoeconomic data forphosphate binder selection and the impact ofapplying the 2003 KDOQI guidelines for bonemetabolism and disease in the United States

Evidence-Based Review of the Management of Hyperphosphatemiaand its Pharmacoeconomic Impact on Patients with Stage 5 CKD: New Perspectives for Optimal Outcomes in 2008Held During the National Kidney Foundation 2008 Spring Clinical Meetings

Thursday, April 3, 2008, 7:30 p.m. - 9:30 p.m.The Gaylord Texan | Grapevine Ballroom C | Grapevine, Texas

08-07 FMC Ad 2/21/08 1:36 PM Page 1

ACTIVITY PURPOSETo familiarize attendees with the availability of published guidelines forthe management of patients with CKD and to acquire a knowledgebase for implementing these guidelines into clinical practice. As aresult of attending this session, Healthcare First anticipates a changein attitudes regarding the early detection and aggressive primary andsecondary prevention of disease progression in these patients.

TARGET AUDIENCEPhysicians, fellows, residents, physician's assistants, nursepractitioners, and nephrology nurses and technicians interested in orinvolved with the management of CKD.

LEARNING OBJECTIVES• Review Treatment Guidelines (JNC-7, KDOQI) as they relate to

treatment of CKD with hypertension and proteinuria

• Review the relations between urine protein excretion,cardiovascular risk and CKD

• Review the therapeutic approaches to hypertension andproteinuria in CKD

• Develop a conceptual framework for stopping the progressionof CKD: treatment goals for hypertension and proteinuria

AGENDA• Slide Presentation One – Proteinuria and Progression:

Primary and Secondary Prevention- Barry M. Brenner, MD

• Slide Presentation Two – Fabry Nephropathy; ProteinuriaWithout Hypertension: Targets for Therapy

- David G. Warnock, MD

• Slide Presentation Three – Progression FromNormoalbuminuria to Overt Proteinuria and CKD in Type IDiabetes: Role of Nocturnal Hypertension

- Daniel C. Batlle, MD

HOW YOU WILL LEARNThis CME activity will be a live symposia consisting of presentations,panel exchange, and audience participation.

PANELISTSBarry M. Brenner, MDBrigham and Woman's HospitalBoston, Massachusetts

David G. Warnock, MDUniversity of Alabama BirminghamBirmingham, Alabama

Daniel C. Batlle, MDNorthwestern University Medical SchoolChicago, Illinois

ACCREDITATIONThe National Kidney Foundation is accredited by the AccreditationCouncil for Continuing Medical Education to provide continuingmedical education for physicians.

DESIGNATION STATEMENTThe National Kidney Foundation designates this educational activity fora maximum of 1.5 AMA PRA Category 1 Credits.TM Physicians shouldonly claim credit commensurate with the extent of their participation inthe activity.

The National Kidney Foundation is an approved provider of continuingnursing education by the New York State Nurses Association, which isaccredited as an approver of continuing nursing education by theAmerican Nurses Credentialing Center's Commission on Accreditation.

This program is pending approval with the American Academy of NursePractitioners.

DECLARATION OF DISCLOSUREIt is the policy of the National Kidney Foundation to ensure balance,independence, objectivity, and scientific rigor in all CME activities.Faculty participating in this activity are required to disclose to theaudience any relationship they may have with the commercialsupporters of this activity or with any other commercial organizationswhose products or devices may be mentioned in their presentations.

UNLABELED/INVESTIGATIONAL USE DECLARATIONDuring their presentations, faculty may discuss an unlabeled use or aninvestigational use not approved for a commercial product. Eachfaculty member is required to disclose this information to the audiencewhen referring to an unlabeled or investigational use.

DISCLAIMERThe faculty, National Kidney Foundation, and Genzyme do notrecommend the use of any pharmaceutical, diagnostic test, or deviceoutside of the labeled indications as approved by the FDA. Please referto the official prescribing information for each product for approvedindications, contraindications, and warnings.

The National Kidney Foundation and Healthcare First reserve the rightto cancel or modify the activity content, faculty, and activities, ifnecessary.

You must be registered for the NKF 2008 Spring Clinical Meetings toattend this symposia and receive credit.

Supported by an unrestricted medical education grant from

Assessing the Role of Proteinuria in the Progression of Chronic Kidney DiseaseNational Kidney Foundation 2008 Spring Clinical Meetings

Friday April 4, 2008

Gaylord TexanGrapevine Ballroom D1501 Gaylord TrailGrapevine, Texas

Breakfast / Live Clinical Experts Roundtable Program: 6:00 AM

Q & A: . . . . . . . . . . . . . . . . . . . . . .7:45 AM

Adjourn: . . . . . . . . . . . . . . . . . . .8:00 AM


NKF_AdNEW2 3/3/08 4:06 PM Page 1

A dinner symposium to be held at the National Kidney Foundation 2008 Spring Clinical Meetings

Friday, April 4, 20087:00 PM – 9:00 PM

Grapevine Ballroom D, Gaylord Texan Dallas, Texas

Program Agenda

7:00 pm – 7:30 pm Registration and Dinner

7:30 pm – 7:45 pm Chair’s IntroductionMark J. Sarnak, MD, MS

7:45 pm – 8:05 pm Sudden Cardiac Death in Pre-dialysis CKD Patients and in Patients Undergoing DialysisCharles A. Herzog, MDProfessor of Medicine, University of MinnesotaDirector, Cardiovascular Special Studies Center United States Renal Data SystemDirector, Cardiac Ultrasound Lab, HCMC

8:05 pm – 8:25 pm Calcium and Phosphorus as Cardiovascular Risk FactorsDavid A. Bushinsky, MDProfessor of MedicineUniversity of Rochester School of Medicine and DentistryRochester, NY

8:25 pm – 8:45 pm Coronary Artery Disease: Screening and TherapyMark J. Sarnak, MD, MS Associate Professor of MedicineTufts University School of MedicineBoston, MA

8:45 pm – 9:00 pm Questions and Answers

Pre-dialysis and DialysisAccreditation Statement(s)

The National Kidney Foundation is accreditedby the Accreditation Council for ContinuingMedical Education to provide continuingmedical education for physicians.

The National Kidney Foundation designatesthis educational activity for a maximum of 1.5AMA PRA Category 1 Credit(s)TM. Physiciansshould only claim credit commensurate withthe extent of their participation in the activity.

The National Kidney Foundation is anapproved provider of continuing nursingeducation by the New York State NursesAssociation, which is accredited as anapprover of continuing nursing education bythe American Nurses Credentialing CentersCommission on Accreditation.

This program is pending approval with theAmerican Academy of Nurse Practitioners.

You must be registered for the NKF 2008Spring Clinical Meetings to attend thissymposium and receive credit.

Disclaimer:The faculty, NKF, and Genzymedo not recommend the use of anypharmaceutical, diagnostic test, or deviceoutside of the labeled indications asapproved by the FDA. Please refer to theofficial prescribing information for eachproduct for approved indications,contraindications, and warnings.

Declaration of Disclosure: It is the policyof the National Kidney Foundation to ensurebalance, independence, objectivity, andscientific rigor in all CME activities. Facultyparticipating in this activity are required todisclose to the audience any relationship theymay have with the commercial supporters ofthis activity or with any other commercialorganizations whose products or devices maybe mentioned in their presentations.

Unlabeled/Investigational UseDeclaration: During their presentations,faculty may discuss an unlabeled use or aninvestigational use not approved for acommercial product. Each faculty member isrequired to disclose this information to theaudience when referring to an unlabeled orinvestigational use.

Activity Purpose

The purpose of this symposium is to examine the link between elevated phosphorus and calcium levelsand the high incidence of cardiovascular (CV) disorders in patients with chronic kidney disease (CKD)and to discuss how appropriate screening and therapy can help minimize the impact of heart disease inthese patients. CV disorders are a major cause of morbidity and mortality in patients with CKD, andsudden death is the leading cause of CV mortality in dialysis patients. Early intervention is important toprolong survival in patients on hemodialysis. Elevated serum phosphorus and calcium concentrationsare associated with increased risk of CV events and death in patients with end-stage renal disease.Recently published data comparing mortality among CKD patients treated with phosphate binders is ofgreat interest to practicing nephrologists and renal dietitians. In addition, recent evidence suggests thatroutine screening of new dialysis patients for vascular calcification may allow early identification ofthose at risk for progressive coronary artery disease (CAD) who would benefit from non-calciumcontaining phosphate binders as suggested by the KDOQI guidelines.

This symposium will also explore such issues as the epidemiology of sudden death in dialysis patients,how different phosphate binders may affect mortality, the proper role of screening for CAD inasymptomatic CKD patients, and the most appropriate therapy for established CAD in dialysis patients.

Target Audience

Physicians, pharmacists, physician assistants, nephrology nurses, nurse practitioners, dietitians,nephrology social workers.

How You Will Learn

This CME activity will be a live symposium consisting of lectures with a question-and-answersession for the audiences.

Learning Objectives

• Learn about the epidemiology of sudden death and possible interventions in dialysis patients

• Learn about the cardiovascular effects of calcium and phosphorus

• Learn about the controversies on coronary artery screening and therapy in CKD

• Learn about the controversies on peripheral vascular disease in dialysis patientsSponsored by the National Kidney Foundation Supported by an educational grant from Genzyme

advert 21/2/08 15:44 Page 1

Optimal Patient Outcomes:Identification and Treatment of Iron Deficiency

Anemia in Early Chronic Kidney Disease

NKF 2008 SPRING CLINICAL MEETINGS

Activity PurposeThe purpose of this symposium is to educate nephrologists, fellows,residents, physician assistants, nurse practitioners, nephrology nursesand technicians, and renal and clinical dietitians interested in learningabout the identification and treatment of iron deficiency in patientswith CKD.

How You Will LearnThe symposium is held in a panel discussion format, incorporatingcase-based presentations, didactic lectures, and audience participationusing the audience response system (ARS).

Target AudienceThis program is designed for nephrologists, fellows, residents,physician assistants, nurse practitioners, nephrology nurses andtechnicians, and renal and clinical dietitians.

Accreditation and Credit Designation StatementsThe National Kidney Foundation is accredited by the AccreditationCouncil for Continuing Medical Education (ACCME) to providecontinuing medical education for physicians.

The National Kidney Foundation designates this educational activity fora maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should onlyclaim credit commensurate with the extent of their participation in theactivity.

The National Kidney Foundation is an approved provider of continuingnursing education by the New York State Nurses Association, which isaccredited as an approver of continuing nursing education by theAmerican Nurses Credentialing Center’s Commission on Accreditation.

This program is pending approval with the American Academyof Nurse Practitioners.

The National Kidney Foundation is a Continuing ProfessionalEducation (CPE) Accredited Provider with the Commission onDietetic Registration (CDR). Registered dietitians (RDs) anddietetic technicians, registered (DTRs) will receive 1.5continuing professional education units (CPEUs) forcompletion of this program/material.

Declaration of DisclosureIt is the policy of the National Kidney Foundation to ensure balance,independence, objectivity, and scientific rigor in all CME activities.Faculty participating in this activity are required to disclose to the audi-ence any relationship they may have with the commercial supportersof this activity or with any other commercial organizations whoseproducts or devices may be mentioned in their presentations.

Unlabeled/Investigational Use DeclarationDuring their presentations, faculty may discuss an unlabeled use or aninvestigational use not approved for a commercial product. Each facultymember is required to disclose this information to the audience whenreferring to an unlabeled or investigational use.

DisclaimerThe faculty, National Kidney Foundation, and AMAG Pharmaceuticals,Inc. do not recommend the use of any pharmaceutical, diagnostic test,or device outside of the labeled indications as approved by the FDA.Please refer to the official prescribing information for each productfor approved indications, contraindications, and warnings.

Educational ObjectivesUpon completion of this symposium, participants will be able to:

• Discuss the prevalence of iron deficiency anemia in CKD and

associated complications

• Outline current clinical practice guidelines and examine recent clinical data

regarding patient identification, testing, and treatment goals

• Review current and future therapeutic approaches to the management of

iron deficiency anemia in CKD

RegistrationTo ensure participation, preregistration is strongly recommended by March 31, 2008.To register for this symposium, please call the Registration Center at 1-866-324-9148.On-site registration will begin at 7:00 PM in Grapevine Ballroom C, Gaylord TexanResort and Convention Center, Grapevine, Texas. Seating priority will be given topreregistered attendees; however, walk-ins are encouraged and will be admittedon a first-come, first-served basis, as space permits.


Supported by an unrestricted educationalgrant from AMAG Pharmaceuticals, Inc.


Friday, April 4, 2008 7:00 PM – 9:00 PM


Program Agenda7:00 PM Registration and Dinner

7:30 PM Welcome and IntroductionAnatole Besarab, MDModerator and Program Chair

7:40 PM Prevalence and Diagnosis of Anemia in Patients With CKDAllen R. Nissenson, MD

8:05 PM State of the Art in Treatment of Iron Deficiency Anemia:Current and Future DirectionsAjay K. Singh, MB, MRCP

8:30 PM Case Review and Panel DiscussionAnatole Besarab, MD

8:50 PM Questions and Answers

9:00 PM Adjourn

AMAG_NKF AD.rev.qxp:1788 AD 8.5x11 3/5/08 9:06 AM Page 1

Optimal Patient Outcomes:Identification and Treatment of Iron Deficiency

Anemia in Early Chronic Kidney Disease

NKF 2008 SPRING CLINICAL MEETINGS

Activity PurposeThe purpose of this symposium is to educate nephrologists, fellows,residents, physician assistants, nurse practitioners, nephrology nursesand technicians, and renal and clinical dietitians interested in learningabout the identification and treatment of iron deficiency in patientswith CKD.

How You Will LearnThe symposium is held in a panel discussion format, incorporatingcase-based presentations, didactic lectures, and audience participationusing the audience response system (ARS).

Target AudienceThis program is designed for nephrologists, fellows, residents,physician assistants, nurse practitioners, nephrology nurses andtechnicians, and renal and clinical dietitians.

Accreditation and Credit Designation StatementsThe National Kidney Foundation is accredited by the AccreditationCouncil for Continuing Medical Education (ACCME) to providecontinuing medical education for physicians.

The National Kidney Foundation designates this educational activity fora maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should onlyclaim credit commensurate with the extent of their participation in theactivity.


This program is pending approval with the American Academyof Nurse Practitioners.

The National Kidney Foundation is a Continuing ProfessionalEducation (CPE) Accredited Provider with the Commission onDietetic Registration (CDR). Registered dietitians (RDs) anddietetic technicians, registered (DTRs) will receive 1.5continuing professional education units (CPEUs) forcompletion of this program/material.

Declaration of DisclosureIt is the policy of the National Kidney Foundation to ensure balance,independence, objectivity, and scientific rigor in all CME activities.Faculty participating in this activity are required to disclose to the audi-ence any relationship they may have with the commercial supportersof this activity or with any other commercial organizations whoseproducts or devices may be mentioned in their presentations.

Unlabeled/Investigational Use DeclarationDuring their presentations, faculty may discuss an unlabeled use or aninvestigational use not approved for a commercial product. Each facultymember is required to disclose this information to the audience whenreferring to an unlabeled or investigational use.

DisclaimerThe faculty, National Kidney Foundation, and AMAG Pharmaceuticals,Inc. do not recommend the use of any pharmaceutical, diagnostic test,or device outside of the labeled indications as approved by the FDA.Please refer to the official prescribing information for each productfor approved indications, contraindications, and warnings.

Educational ObjectivesUpon completion of this symposium, participants will be able to:

• Discuss the prevalence of iron deficiency anemia in CKD and

associated complications

• Outline current clinical practice guidelines and examine recent clinical data

regarding patient identification, testing, and treatment goals

• Review current and future therapeutic approaches to the management of

iron deficiency anemia in CKD

RegistrationTo ensure participation, preregistration is strongly recommended by March 31, 2008.To register for this symposium, please call the Registration Center at 1-866-324-9148.On-site registration will begin at 7:00 PM in Grapevine Ballroom C, Gaylord TexanResort and Convention Center, Grapevine, Texas. Seating priority will be given topreregistered attendees; however, walk-ins are encouraged and will be admittedon a first-come, first-served basis, as space permits.


Supported by an unrestricted educationalgrant from AMAG Pharmaceuticals, Inc.


Friday, April 4, 2008 7:00 PM – 9:00 PM


Program Agenda7:00 PM Registration and Dinner

7:30 PM Welcome and IntroductionAnatole Besarab, MDModerator and Program Chair

7:40 PM Prevalence and Diagnosis of Anemia in Patients With CKDAllen R. Nissenson, MD

8:05 PM State of the Art in Treatment of Iron Deficiency Anemia:Current and Future DirectionsAjay K. Singh, MB, MRCP

8:30 PM Case Review and Panel DiscussionAnatole Besarab, MD

8:50 PM Questions and Answers

9:00 PM Adjourn

AMAG_NKF AD.rev.qxp:1788 AD 8.5x11 3/5/08 9:06 AM Page 1

Exploring the Link BetweenChronic Kidney Disease andCardiovascular Disease

A CME-CERTIFIED SYMPOSIUM at the NKF 2008 Spring Clinical Meetings

Sponsored by theNational Kidney

Foundation

Gaylord TexanDallas, TexasGrapevine Ballroom D

Supported by an unrestrictedmedical educationalgrant from Abbott.

PROGRAM OVERVIEWThis symposium examines the association of cardiovascular disease in patientswith chronic kidney disease. Recent data indicates a much higher incidence ofcardiovascular disease and mortality linked to cardiovascular risk factorsobserved in chronic kidney disease patients. The session highlights currentepidemiologic data, mechanisms contributing to pathophysiological processesand cardiovascular risk factors, and therapies that can reduce risk and improvesurvival in chronic kidney disease patients. This symposium will review currenttherapies for attenuating vascular calcification and bone resorption, provideinsight into classical and non-classical actions of vitamin D analogs, andmanagement strategies for reducing cardiovascular risk factors associated withchronic kidney disease.

LEARNING OBJECTIVES• Identify cardiovascular risk factors associated with chronic kidney disease.

• Understand the mechanisms that contribute to pathophysiologic processesand risk factors for chronic kidney disease patients.

• Review current management strategies to reduce vascular calcification andbone resorption in chronic kidney disease patients.

TARGET AUDIENCE: This CME-certified symposium is directed towardsnephrologists and clinicians who treat patients with chronic kidney disease.

HOW YOU WILL LEARN: This CME activity will be a live symposium consistingof lectures with panel audience participation

ACCREDITATION STATEMENT: The National Kidney Foundation is accreditedby the Accreditation Council for Continuing Medical Education to providecontinuing medical education for physicians.

DESIGNATION STATEMENT: The National Kidney Foundation designates thiseducational activity for a maximum of 1.5 AMA PRA Category 1 Credit TM.Physicians should only claim credit commensurate with the extent of theirparticipation in the activity.



DECLARATION OF DISCLOSURE: It is the policy of the National KidneyFoundation to ensure balance, independence, objectivity, and scientific rigor inall CME activities. Faculty participating in this activity are required to discloseto the audience any relationship they may have with the commercial supportersof this activity or with any other commercial organizations whose products ordevices may be mentioned in their presentations.

UNLABELED / INVESTIGATIONAL USE DECLARATION: During theirpresentations, faculty may discuss an unlabeled use or an investigational usenot approved for a commercial product. Each faculty member is required todisclose this information to the audience when referring to an unlabeled orinvestigational use.

AGENDA

Saturday, April 5, 2008

6:00 AM Registration

6:30 AM Welcome and IntroductionLouisa Tammy Ho, MD

6:35 AM “Exploring the Association Between CardiovascularDisease and Chronic Kidney Disease”Louisa Tammy Ho, MD

7:00 AM “Mechanisms that Contribute to Altered CardiovascularRegulation in Chronic Kidney Disease”Ravi Thadhani, MD

7:25 AM “Management Strategies for Reducing Cardiovascular RiskFactors in Chronic Kidney Disease”Kamyar Kalantar-Zadeh, MD

7:50 AM Q&A/Discussion

REGISTRATION: You must be registered for the NKF 2008 Spring ClinicalMeetings to attend this symposia and receive credit.

DISCLAIMER: The faculty, National Kidney Foundation, and Abbott do notrecommend the use of any pharmaceutical, diagnostic test, or device outside of thelabeled indications as approved by the FDA. Please refer to the official prescribinginformation for each product for approved indications, contraindications, andwarnings.

Saturday, April 5, 20086:00 AM – 8:00 AM

FACULTYLouisa Tammy Ho, MDAssistant Professor of MedicineDivision of Nephrology andHypertensionNorthwestern UniversityEvanston, Illinois

Ravi I. Thadhani, MD, MPHDirector of Clinical Research inNephrologyMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, Massachusetts

KamyarKalantar-Zadeh,MD,PhDAssociate Professor of Medicine andPediatricsDivision of Nephrology andHypertensionLos Angeles Biomedical ResearchInstituteAt Harbor–UCLA Medical CenterTorrance, California

545-074-02-08-SC-NKF-2-Program-Ad-v7:NKF-1 Advertisement 2/27/08 4:10 PM Page 1

Sponsored by the National Kidney Foundation Supported by an educational grant from AMGEN

OptimizingEvidence-Based Best Practices

for the Hemodialysis Team

Symposium Registration: You must be registered for the NKF 2008Spring Clinical Meetings to attend this symposium and receive credit. Toregister for this symposium, please e-mail your name and e-mail addressor fax number to [email protected]. Onsite registration will beavailable just prior to the symposium at our registration desk outside ofGrapevine Ballroom C, starting at 6:00 AM on Friday, April 4, 2008.

How You Will Learn: This CME/CE symposium will incorporate aninteractive multi-disciplinary panel discussion of patient cases as well asan audience response system (ARS) to include audience participation inthe panel discussion.

Accreditation Statement: The National Kidney Foundation is accreditedby the Accreditation Council for Continuing Medical Education to providecontinuing medical education for physicians.

Designation Statement: The National Kidney Foundation designatesthis educational activity for a maximum of 1.5 AMA PRA Category 1Credit(s)™. Physicians should only claim credit commensurate with theextent of their participation in the activity.


This program is pending approval with the American Academy ofNurse Practitioners.

The National Kidney Foundation is a Continuing ProfessionalEducation (CPE) Accredited Provider with the Commission onDietetic Registration (CDR). Registered dietitians (RDs) anddietetic technicians, registered (DTRs) will receive 1.5 con-tinuing professional education units (CPEUs) for completionof this program/material.

Declaration of Disclosure: It is the policy of the National KidneyFoundation to ensure balance, independence, objectivity, and scientificrigor in all CME activities. Faculty participating in this activity are requiredto disclose to the audience any relationship they may have with the com-mercial supporters of this activity or with any other commercial organiza-tions whose products or devices may be mentioned in their presentations.

Unlabeled/Investigational Use Declaration: During their presentations,faculty may discuss an unlabeled use or an investigational use notapproved for a commercial product. Each faculty member is required todisclose this information to the audience when referring to an unlabeledor investigational use.

Disclaimer: The faculty, National Kidney Foundation, and Amgen do notrecommend the use of any pharmaceutical, diagnostic test, or deviceoutside of the labeled indications as approved by the FDA. Please refer tothe official prescribing information for each product for approved indica-tions, contraindications, and warnings.

6:00 AM – 6:25 AM Registration and Buffet Breakfast Available

6:25 AM – 6:30 AM Welcome and IntroductionsBruce Robinson, MD, MSCE – ModeratorVice President – ResearchArbor Research Collaborative for Health, Ann Arbor, Michigan

6:30 AM – 7:00 AM Improving Delivery of Pre-ESRD Care,Case DiscussionRonald Pisoni, PhD, MSDirector of Analytical Support – DOPPSArbor Research Collaborative for Health, Ann Arbor, Michigan

7:00 AM – 7:30 AM Has Catheter Use Increased Due toFistula First? No! Case DiscussionLawrence Spergel, MD, FACSClinical Chair, Fistula First National Breakthrough InitiativeDirector, Dialysis Management Medical GroupSan Francisco, California

7:30 AM – 8:00 AM Managing Multiple Targets for Best PatientOutcomes, Case DiscussionDavid Mendelssohn, MD, FRCPCChief and Physician Director, Department of NephrologyHumber River Regional Hospital and University of TorontoToronto, Canada

Activity PurposeThis interactive learning activity is designed toenhance the performance of dialysis health-care providers in the use of evidence-basedclinical strategies and best practices toimprove the health and quality of life ofpatients on hemodialysis.

Target AudienceThe live symposium is designed for nephrol-ogy nurses, renal and clinical dietitians, andnephrology social workers.

Program Objectives� List two factors that have been

demonstrated to contribute to high first-year mortality among incident End-StageRenal Disease (ESRD) patients and may bemodifiable through optimal pre-ESRD care.

� Describe the relationship between theFistula First initiative and hemodialysiscentral venous catheter use in theUnited States.

� Explain the technique for assessingmultiple outcomes targets simultaneouslyto improve dialysis patient outcomes.

A Breakfast Symposium during theNational Kidney Foundation

2008 Spring Clinical Meetings

Friday, April 4th, 20086:00 AM – 8:00 AM � Gaylord Texan � Grapevine Ballroom C

Pro

gra

mA

ge

nd

a

168 Ad.qxd:168 Ad 3/6/08 9:05 AM Page 1

Sponsored by the National Kidney Foundation Supported by an educational grant from AMGEN

OptimizingEvidence-Based Best Practices

for the Hemodialysis Team

Symposium Registration: You must be registered for the NKF 2008Spring Clinical Meetings to attend this symposium and receive credit. Toregister for this symposium, please e-mail your name and e-mail addressor fax number to [email protected]. Onsite registration will beavailable just prior to the symposium at our registration desk outside ofGrapevine Ballroom C, starting at 6:00 AM on Friday, April 4, 2008.

How You Will Learn: This CME/CE symposium will incorporate aninteractive multi-disciplinary panel discussion of patient cases as well asan audience response system (ARS) to include audience participation inthe panel discussion.

Accreditation Statement: The National Kidney Foundation is accreditedby the Accreditation Council for Continuing Medical Education to providecontinuing medical education for physicians.

Designation Statement: The National Kidney Foundation designatesthis educational activity for a maximum of 1.5 AMA PRA Category 1Credit(s)™. Physicians should only claim credit commensurate with theextent of their participation in the activity.


This program is pending approval with the American Academy ofNurse Practitioners.

The National Kidney Foundation is a Continuing ProfessionalEducation (CPE) Accredited Provider with the Commission onDietetic Registration (CDR). Registered dietitians (RDs) anddietetic technicians, registered (DTRs) will receive 1.5 con-tinuing professional education units (CPEUs) for completionof this program/material.

Declaration of Disclosure: It is the policy of the National KidneyFoundation to ensure balance, independence, objectivity, and scientificrigor in all CME activities. Faculty participating in this activity are requiredto disclose to the audience any relationship they may have with the com-mercial supporters of this activity or with any other commercial organiza-tions whose products or devices may be mentioned in their presentations.

Unlabeled/Investigational Use Declaration: During their presentations,faculty may discuss an unlabeled use or an investigational use notapproved for a commercial product. Each faculty member is required todisclose this information to the audience when referring to an unlabeledor investigational use.

Disclaimer: The faculty, National Kidney Foundation, and Amgen do notrecommend the use of any pharmaceutical, diagnostic test, or deviceoutside of the labeled indications as approved by the FDA. Please refer tothe official prescribing information for each product for approved indica-tions, contraindications, and warnings.

6:00 AM – 6:25 AM Registration and Buffet Breakfast Available

6:25 AM – 6:30 AM Welcome and IntroductionsBruce Robinson, MD, MSCE – ModeratorVice President – ResearchArbor Research Collaborative for Health, Ann Arbor, Michigan

6:30 AM – 7:00 AM Improving Delivery of Pre-ESRD Care,Case DiscussionRonald Pisoni, PhD, MSDirector of Analytical Support – DOPPSArbor Research Collaborative for Health, Ann Arbor, Michigan

7:00 AM – 7:30 AM Has Catheter Use Increased Due toFistula First? No! Case DiscussionLawrence Spergel, MD, FACSClinical Chair, Fistula First National Breakthrough InitiativeDirector, Dialysis Management Medical GroupSan Francisco, California

7:30 AM – 8:00 AM Managing Multiple Targets for Best PatientOutcomes, Case DiscussionDavid Mendelssohn, MD, FRCPCChief and Physician Director, Department of NephrologyHumber River Regional Hospital and University of TorontoToronto, Canada

Activity PurposeThis interactive learning activity is designed toenhance the performance of dialysis health-care providers in the use of evidence-basedclinical strategies and best practices toimprove the health and quality of life ofpatients on hemodialysis.

Target AudienceThe live symposium is designed for nephrol-ogy nurses, renal and clinical dietitians, andnephrology social workers.

Program Objectives� List two factors that have been

demonstrated to contribute to high first-year mortality among incident End-StageRenal Disease (ESRD) patients and may bemodifiable through optimal pre-ESRD care.

� Describe the relationship between theFistula First initiative and hemodialysiscentral venous catheter use in theUnited States.

� Explain the technique for assessingmultiple outcomes targets simultaneouslyto improve dialysis patient outcomes.

A Breakfast Symposium during theNational Kidney Foundation

2008 Spring Clinical Meetings

Friday, April 4th, 20086:00 AM – 8:00 AM � Gaylord Texan � Grapevine Ballroom C

Pro

gra

mA

ge

nd

a

168 Ad.qxd:168 Ad 3/6/08 9:05 AM Page 1

KEEP is supported by

Primary Sponsor

Associate Sponsors

Contributing Sponsors

Additional support provided by

I. KEEP overview and social conceptions of kidney disease: myths vs. realities

II. Glycemic control in kidney disease

III. Interventions and CVD interactions in diabetics with proteinuria

IV. Impact of blood pressure control in CKD

02-35-284A

Join Us for a Breakfast SymposiumSaturday, April 5, 2008 from 6:00 am–8:00 am in Grapevine C.

HOW YOU WILL LEARN: This CME activity will be a live symposium consisting of lectures with panel audience participation.

ACCREDITATION STATEMENT: The National Kidney Foundation is accredited by the Ac-creditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT: The National Kidney Foundation designates this educational activity for a maximum of

Physicians should only claim credit commensurate with the extent of their participation in the activity.

DECLARATION OF DISCLOSURE: It is the policy of the National Kidney Foundation to ensure balance, independence, objectivity, and scientifi c rigor in all CME activities. Faculty participating in this activity are required to disclose to the audience any relationship they may have with the commercial supporters of this activity or with any other commercial organizations whose products or devices may be mentioned in their presentations.

UNLABELED/INVESTIGATIONAL USE DEC�LARATION: During their presentations, faculty may discuss an unlabeled use or an investi-gational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

DISCLAIMER: The faculty and National Kidney Foundation do not recommend the use of any pharmaceutical, diagnostic test, or device out-side of the labeled indications as approved by the FDA. Please refer to the offi cial prescribing information for each product for approved indications, contraindications, and warnings.

Allan J. Collins, MD, FACPPresident, National Kidney Foundation Professor of MedicineUniversity of Minnesota Minneapolis, MN

Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCPVice Chair, NKF KEEP Steering CommitteeConsulting Cardiologist and ChiefDivision of Nutrition and Preventive Medicine William Beaumont Hospital Health CenterRoyal Oak, MI

Samy I. McFarlane, MD, MPH, FACP, FACEProfessor of Medicine Chief, Division of Endocrinology, Diabetes and Hypertension State University of New York Health Science Center at Brooklyn Brooklyn, NY

George Bakris, MDChair, NKF KEEP Steering CommitteeProfessor of Medicine Director, Hypertensive Diseases CenterSection of Endocrinology, Diabetes & Metabolism University of Chicago – Pritzker School of MedicineChicago, IL

Sponsored by

© 2008 N

ational Kidney Foundation, Inc. All R

ights Reserved.

Faculty:

Chronic Kidney Disease Interventions:IMPROVING CKD AND CVD OUTCOMES

1. Provide update on the NKF’s Kidney Early Evaluation Program (KEEP), a community-based screening initiative to identify those at increased risk for kidney disease.

2. Present current views and miscon-ceptions regarding the management and treatment of kidney disease.

3. Poor glycemic control and blood pres-sure are the leading causes of kidney failure and signifi cantly contribute to

heart disease. Best practice recom-mendations impact both CKD and CVD outcomes.

4. Decribe how global risk reduction can be applied to both renal and cardio-vascular systems.

5. Utilize NKF’s KEEP cohort and other cohorts to demonstrate opportunities for improvement in the detection and management of CKD.

Welcome to the NKF 2008 Spring Clinical Meetings!

On behalf of the National Kidney Foundation and the Program Committee, it is our pleasure to welcome you to the NKF 2008 Spring Clinical Meetings. This year’s conference was designed to provide a balanced curriculum that will meet the needs of the kidney healthcare team to stay current in advances in renal disease.

We hope you find that the next few days provide you with stimulating and useful updates. Please be sure to complete the evaluations so we can continue to improve the meeting.

Have a great meeting!

Micheal Allon, MD Beth Piraino, MD

Program Chair Program Co-Chair CM08 CM08

Dear COlleague

Spring Clinical Meetings ’08

NaTiONal KiDNey FOuNDaTiON CONTiNuiNg MeDiCal eDuCaTiON (CMe) PrOgraM MiSSiON STaTeMeNT

The mission of the National Kidney Foundation (NKF) Continuing Medical education Program is to provide education for academic as well as private practitioners in nephrology and related disciplines. These education activities are offered to regional, national and international audiences.

PurPOSe:To provide all members of the kidney healthcare community with current, state-of-the-art science information on prevention, diagnosis and treatment of kidney and urinary tract diseases in order to improve the care of individuals with chronic kidney disease (CKD) and those at risk for developing it.

CONTeNT area:Topics are selected based on physician gaps in knowledge regarding the care and treatment of individuals with kidney disease. KDOQi evidence-based guidelines and the latest peer-reviewed clinical science provide the foundation for developing much of the content as well as professional interests, expert opinions, literature reviews and needs assessment data from patients and caregivers that identify gaps in quality of care relative to physician implementation of the science.

TargeT auDieNCeS:Practicing physicians, residents, and fellows in nephrology, internal medicine, cardiology, endocrinology, family practice, physician assistants, nurse practitioners and other specialties who care for individuals who are at increased risk for, or affected by, CKD.

TyPeS OF aCTiviTieS:live activities include conferences, symposia, courses, hands-on workshops, audience response sessions, and debates. enduring materials include monographs, videotapes, CD-rOM, web-based, PDa/Pocket PC software and audiotape. adult learning principles and critical thinking strategies are incorporated into all education activities by ensuring that participants are given an opportunity to explore new applications and or strategies.

exPeCTeD reSulTS:improve physician practice patterns in order to maximize the quality of care given to patients and improve patient outcomes. This will be accomplished by providing comprehensive educational activities that are current, largely based on evidence-based practice guidelines and expert opinion and by offer-ing a variety of learning formats to meet the diverse needs of our participants. results will be evidenced by post testing and reviewing responses from activity evaluations that ask if participants plan to make any changes in their practice as a result of this activity and to identify these changes. Follow-ing our annual Spring Clinical Meeting, participants will be sent additional web-based evaluation questions which include if they are willing to provide contact information for follow-up. Telephone surveys will then be conducted three to six months following an activity with those who have agreed to follow-up contact.

KEEP is supported by

Primary Sponsor

Associate Sponsors

Contributing Sponsors

Additional support provided by

I. KEEP overview and social conceptions of kidney disease: myths vs. realities

II. Glycemic control in kidney disease

III. Interventions and CVD interactions in diabetics with proteinuria

IV. Impact of blood pressure control in CKD

02-35-284A

Join Us for a Breakfast SymposiumSaturday, April 5, 2008 from 6:00 am–8:00 am in Grapevine C.

HOW YOU WILL LEARN: This CME activity will be a live symposium consisting of lectures with panel audience participation.

ACCREDITATION STATEMENT: The National Kidney Foundation is accredited by the Ac-creditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT: The National Kidney Foundation designates this educational activity for a maximum of

Physicians should only claim credit commensurate with the extent of their participation in the activity.

DECLARATION OF DISCLOSURE: It is the policy of the National Kidney Foundation to ensure balance, independence, objectivity, and scientifi c rigor in all CME activities. Faculty participating in this activity are required to disclose to the audience any relationship they may have with the commercial supporters of this activity or with any other commercial organizations whose products or devices may be mentioned in their presentations.

UNLABELED/INVESTIGATIONAL USE DEC�LARATION: During their presentations, faculty may discuss an unlabeled use or an investi-gational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

DISCLAIMER: The faculty and National Kidney Foundation do not recommend the use of any pharmaceutical, diagnostic test, or device out-side of the labeled indications as approved by the FDA. Please refer to the offi cial prescribing information for each product for approved indications, contraindications, and warnings.

Allan J. Collins, MD, FACPPresident, National Kidney Foundation Professor of MedicineUniversity of Minnesota Minneapolis, MN

Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCPVice Chair, NKF KEEP Steering CommitteeConsulting Cardiologist and ChiefDivision of Nutrition and Preventive Medicine William Beaumont Hospital Health CenterRoyal Oak, MI

Samy I. McFarlane, MD, MPH, FACP, FACEProfessor of Medicine Chief, Division of Endocrinology, Diabetes and Hypertension State University of New York Health Science Center at Brooklyn Brooklyn, NY

George Bakris, MDChair, NKF KEEP Steering CommitteeProfessor of Medicine Director, Hypertensive Diseases CenterSection of Endocrinology, Diabetes & Metabolism University of Chicago – Pritzker School of MedicineChicago, IL

Sponsored by

© 2008 N

ational Kidney Foundation, Inc. All R

ights Reserved.

Faculty:

Chronic Kidney Disease Interventions:IMPROVING CKD AND CVD OUTCOMES

1. Provide update on the NKF’s Kidney Early Evaluation Program (KEEP), a community-based screening initiative to identify those at increased risk for kidney disease.

2. Present current views and miscon-ceptions regarding the management and treatment of kidney disease.

3. Poor glycemic control and blood pres-sure are the leading causes of kidney failure and signifi cantly contribute to

heart disease. Best practice recom-mendations impact both CKD and CVD outcomes.

4. Decribe how global risk reduction can be applied to both renal and cardio-vascular systems.

5. Utilize NKF’s KEEP cohort and other cohorts to demonstrate opportunities for improvement in the detection and management of CKD.

FPOFPO

What’s Inside…

17 CM08 Program Committee

18 NKF Leadership

19 NKF Distinguished Lectures and Awards

27 NKF Professional Council Awards

28 Contributors

31 Exhibit Hall/Poster Information

32 General Information

32 Program Objectives

34 Corporate Partners

36 Corporate Supported Symposia

37 Disclosure Information

Program Tracks:

42 Physician

63 Advanced Practitioner

72 Nephrology Nurse and Technician

82 Renal and Clinical Dietitian

94 Nephrology Social Worker

100 Clinical Conversations Lunches

102 Exhibit Hall Map and Listings

113 Research Grant Recipients

114 Hotel Map

115 Faculty

National Kidney Foundation

Spring Clinical Meetings ’08 p.17

MichaelAllon,MDProgram Chair

university of alabama Birmingham, al

BethPiraino,MDProgram Co-Chair

university of Pittsburgh Pittsburgh, Pa

SharonAdler,MDuCla Medical Center Torrance, Ca

CarolynAtkins,RN,BS,CCTCNephrology Nurse and Technician

Program Chair

Children’s Medical Center Dallas, Tx

JoanneM.Bargman,MD,FRCPCToronto general Hospital Toronto, Ontario, Canada

SrinivasanBeddhu,MDuniversity of utah Health Sciences Center Salt lake City, uT

LaurieE.Benton,RN,PA-C,BS,MPASAdvanced Practitioner Program Co-Chair

Scott & White Hospital Temple, Tx

JeffreyBerns,MDuniversity of Pennsylvania School of Medicine Philadelphia, Pa

MichaelJ.Choi,MDJohns Hopkins university School of Medicine Baltimore, MD

AndreaDeKam,LMSWNephrology Social Worker Program Co-Chair

university of Michigan Dialysis livonia, Mi

PeterB.DeOreo,MD,FACPCenters For Dialysis Care Shaker Heights, OH

MarrianneHutton,RD,CDERenal & Clinical Dietitian

Program Co-Chair

Fresenius Medical Care North america Santa rosa, Ca

KamyarKalantar-Zadeh,MDHarbor-university of California Torrance, Ca

PamelaS.Kent,MS,RD,CSR,LDRenal & Clinical Dietitian Program Chair

genzyme renal vermilion, OH

BobbieKnotek,RN,BSN,CNN,LPHQNephrology Nurse and Technician

Program Co-Chair

eSrD Network of Texas, inc. Dallas, Tx

JuliaLewis,MDvanderbilt university Medical Center Nashville, TN

CharmaineLok,MDToronto general Hospital Toronto, Ontario, Canada

BarbaraWeisMalone,BSN,RN,CFNPAdvanced Practitioner Program Co-Chair

university of Colorado Health Sciences Center golden, CO

IvanD.Maya,MDuniversity of alabama Birmingham, al

MicheleH.Mokrzycki,MD,MSMontefiore Medical Center albert einstein College of Medicine Bronx, Ny

AnnO’Hare,MDuniversity of Washington Seattle, Wa

MilagrosD.Samaniego,MDuniversity of Wisconsin Madison, Wi

StuartM.Sprague,DONorthwestern university evanston, il

StephanieStewart,LICSWNephrology Social Worker Program Chair

Mayo Clinic rochester, MN

MariaTaylor,PharmDuniversity of alabama Birmingham, al

MiguelVazquez,MDuniversity of Texas-Southwestern Dallas, Tx

Ex-Officio

AllanJ.Collins,MD,FACPJosephVassalotti,MD

PrOgraM COMMiTTee

Over its 58-year history, the NKF has grown to become the preeminent voluntary health care organization dedicated to improving outcomes for people covering the entire spectrum of chronic kidney and urologic diseases.

The Foundation has made tremendous advances in its mission through the visionary leadership of the National Presidents and Chairmen.

The mission of the National Kidney Foundation is to prevent kidney and urinary tract diseases, improve the health and well-being of individuals and families affected by these diseases and increase the availability of all organs for transplantation.

Presidentallan J. Collins, MD, FaCP 2006–2008

Past PresidentsDavid Warnock, MD 2004–2006Brian J.g. Pereira, MD 2002–2004William F. Keane, MD 2000–2002Joel D. Kopple, MD 1998–2000garabed eknoyan, MD 1996–1998alan r. Hull, MD 1994–1996Neil a. Kurtzman, MD 1992–1994Shaul g. Massry, MD 1990–1992Saulo Klahr, MD 1988–1990richard J. glassock, MD 1986–1988robert W. Schrier, MD 1984–1986David a. Ogden, MD 1982–1984richard M. Freeman, MD 1980–1982Stuart a. Kleit, MD 1978–1980arvin Weinstein, MD 1976–1978James C. Hunt, MD 1973–1976e. lovell Becker 1970–1973george e. Schreiner 1968–1970george lingua 1967–1968William J. Jones, MD 1966–1967Wallace W. McCrory, MD 1964–1966Daniel P. richman, MD 1960–1964William a. Wargo 1959–1960Henry Kessler, MD 1954–1959Mrs. John e. Tedford 1952–1954Mrs. ada u. DeBold 1950–1952(Founder)

ChairmanTom McDonough 2008–2010

Past ChairmenCharles B. Fruit 2005–2007Fred l. Brown, MBa, FaCHe 2003–2005andrew Baur 2001–2003Frederick a. Herbert 1999–2001Joseph l. Brand 1997–1999Wendy Brown, MD 1995–1997a. Bruce Bowden 1993–1995Donald r. Wilson 1991–1993Charles e. Westcott 1989–1991William P. Hunter, Jr. 1987–1989The Honorable John N. Kirkendall 1985–1987John Hoag 1983–1985e. Burns Mclindon 1981–1983Oliver W. Porter 1979–1981Harold D. Schwartz 1977–1979Jack C. Kent 1975–1977Jordan e. ringel 1973–1975

The office of Chairman was created in 1973.

leaDerSHiP NaTiONal KiDNey FOuNDaTiON

p.18 National Kidney Foundation

The Shaul G. Massry Distinguished LectureThislectureshipwasestablishedtohonorDr.ShaulG.MassryforhisscientificachievementsandhiscontributionstothekidneyhealthcarecommunityandtheNationalKidneyFoundation.The2008honoredlecturerisTomGreene,PhD.Dr.Greenewillbepresenting“RandomizedandObservationalStudiesinNephrology:HowStrongIstheEvidence?”onThursday,April3rd.

after receiving his PhD in statistics from Cornell, Dr. greene served as an assistant Profes-sor of Statistics at the university of Kentucky from 1985 to 1989. He moved to the Department of Statistics and epidemiology at the Cleveland Clinic Foundation in 1991, where Dr. greene joined the

department’s Data Coordinating Center for multi-center clinical trials. Dr. greene’s close relationship with the field of nephrology began soon thereafter, and in 1993 Dr. greene became the lead statistician for the data analyses of the Modification of Diet in renal Disease Study. This work provided Dr. greene the opportunity to interact closely with many researchers in the field. in subsequent years, Dr. greene and his colleagues at the Cleveland Clinic Foundation coordinated other major clinical trials in nephrology, including the Hemodialysis Study, the african american Study of Kidney Disease, the Dialysis access Consor-tium, the Focal Segmental glomerulosis Study, and the Frequent Dialysis Network. Collaborations in association with these studies led to methodological research into clinical trial designs, outcome measures in kidney disease, kinetic modeling, and estimation of renal function. Dr. greene is continuing his collaborations in nephrology after moving to the university of utah in 2006.

Past Shaul G. Massry Distinguished Lecture Recipients2007 eberhard ritz, MD2006 giuseppe remuzzi, MD, FrCP2005 edmund J. lewis, MD2004 Hans-Henrik Parving, MD, DMSc2003 robert alpern, MD2002 Joseph v. Bonventre, MD, PhD2001 andrzej S. Krolewski, MD, PhD2000 richard J. glassock, MD1999 giuseppe Bianchi, MD1998 Josephine Briggs, MD1997 gary e. Striker, MD1996 alfred Michael, MD

The Donald W. Seldin AwardTheDonaldW.SeldinAwardwasestablishedtorecognizeexcellenceinclinicalnephrologyinthetraditionofoneoftheforemostteachersandresearchersinthefield,Dr.DonaldW.Seldin.The2008awardrecipientisThomasD.DuBose,Jr.,MD.

Dr. DuBose is the Tinsley r. Harrison Professor and Chair of internal Medicine and Professor of Physiology and Pharmacology at Wake Forest university School of Medicine. His training in inter-nal Medicine was accomplished at Parkland Memorial Hospital in Dallas, Texas. a research and

clinical fellowship in Nephrology was completed at the university of Texas Southwestern Medical Center under Drs. Juha P. Kokko and Donald W. Seldin.

Dr. DuBose was initially appointed assistant Professor of Medicine at the university of Texas Health Science Center at Dallas, Southwestern Medical School and was subsequently recruited to the university of Texas Medical Branch, galveston where he became Professor of Medicine and of Physiology and Biophysics, and served as Chief of the Division of Nephrology. From 1991–1999, Dr. DuBose was Professor of internal Medicine and of integrative Biology, Pharmacology, and Physiology and Director of the Division of renal Diseases and Hyper-tension at the university of Texas Medical School–Houston, where he also served as vice Chair of internal Medicine. Prior to being recruited to Wake Forest university School of Medicine, Dr. DuBose served as the Peter T. Bohan Professor and Chair of the Department of internal Medicine at the university of Kansas, School of Medicine.

The overall goal of investigation by his laboratory is to illuminate factors involved in the molecular regulation of tubule transporters responsible for urinary acidification and potassium homeostasis. Several translational studies from this group have explained the pathophysiological basis of classical distal renal tubular acidosis with hypokalemia (Type 1) and the generalized distal nephron defect re-sulting in Type 4 rTa with hyperkalemia. He and his co-workers have advanced a new model of urinary acidification which has placed the regulation of ammonia production and transport as pivotal for acid-base homeostasis and have elucidated the consequences of abnormal potassium balance on acidosis and alkalosis, respectively. Current studies have identified the contribution of the colonic H+, K+-aTPase to the maintenance of metabolic alkalosis. This investigator has been funded continually by the NiH since 1981.


DiSTiNguiSHeD leCTureS aND aWarDS

Tom Greene, PhD

Thomas D. DuBose, Jr., MD

Dr. DuBose served as President of the american Society of Nephrology, 2005–2006 and was an elected member of Council for seven years. at the aSN he was most closely identified with development of the Public Policy Board, and served as Chair of the aSN grants Program. in the latter position, he expanded the scope and size of the awards available for academic career development and innovation among established investigators. The initiative of his presidency was to encourage nephrol-ogists, primary care physicians, and federal funding agencies to work in partnership and to recognize that chronic kidney disease is a public health issue requiring a coordinated response. He helped organize a multi-society task force involving all kidney organizations to be more effective in educating the public and funding agencies on placing chronic kidney disease within existing programs in cardiovascular diseases and diabetes.

Dr. DuBose has held several leadership positions in the american Heart association Council on the Kidney in Cardiovascular Disease and was Chair 2002–2004. in 2005, Dr. DuBose received the Distinguished Science award from the aHa.

DuBose is an author of 147 published papers and chapters in textbooks. along with Dr. lee Hamm, he co-edited the text: Acid-Base and

Electrolyte Disorders. The second edition of this textbook is scheduled to be published in 2008.

Past Donald W. Seldin Award Recipients

2007 l. lee Hamm, MD, FaCP2006 Heine Murer, MD and Bernard rossier, MD2005 roland C. Blantz, MD2004 gerhard H. giebisch, MD2003 William M. Bennett, MD2002 Professor Carl erik Mogensen2001 Friedrich K. Port, MD, MS, FaCP2000 Tilman B. Drüeke, MD1999 Shaul g. Massry, MD1998 alan r. Hull, MD1997 Thomas F. Parker, iii, MD1996 Floyd C. rector, MD1995 Barry M. Brenner, MD1994 Manuel Martinez-Maldonado

David M. Hume Memorial AwardTheDavidM.HumeAwardwascreatedinmemoryofoneoftheNationalKidneyFoundation’smostdistinguishedmembers.TheHumeAwardisthehighesthonorgiventoadistinguishedscientist-clinicianinthefieldofkidneyandurologicdiseases.Itisbestoweduponanindividualwhoexemplifiesthehighidealsofscholarshipandhumanitarianisminanoutstandingmanner.The2008awardrecipientisLawrenceHunsicker,MD.

Dr. Hunsicker is Professor of internal Medicine and Medical Director of Organ Transplantation at the university of iowa, College of Medicine. His research interests include progressive kidney disease, transplantation medicine, the design and performance of clinical trials, and the analysis of large

national medical databases. in 1979 he founded with Dr. edmund lewis the Collaborative Study group (CSg), which has demonstrated a striking benefit from blockade of the renin-angiotensin system in patients with diabetic kidney disease. This group is now studying the efficacy of sulodexide in diabetic kidney disease. Dr. Hunsicker was also one of the Pis in the Modification of Diet in renal Disease Study. Dr. Hunsicker played major roles in the design of the data registries of the united Network for Organ Sharing (uNOS) and the united States renal Data System (uSrDS). He was also the Principal investigator for the economic Special Studies Center of the uSrDS.

Dr. Hunsicker was one of the founders and later President of the american Society of Transplantation and in 2000 was awarded their roche lifetime achievement award. He has been President of the National Kidney Foundation of iowa and regional President of the National Kidney Foundation. He has served as President of uNOS and was also the first Medical advisor to the american Organ Pro-curement Organization. He served from 2001 to 2004 on the initial HHS Secretary’s advisory Committee on Organ Transplantation. He has been a member and chair of many NiH Study Sections and is presently a member of the FDa advisory Committee on antivirals.


Lawrence Hunsicker, MD

Past David M. Hume Memorial Award Recipients

2007 William g. Couser, MD2006 Frank Delmonico, MD2005 roland C. Blantz, MD2004 John Stewart Cameron, MD2003 Franklin H. epstein, MD2002 Barry M. Brenner, MD2001 William e. Mitch, MD2000 [No award]1999 Neil a. Kurtzman, MD1998 Jared J. grantham, MD1997 Thomas e. andreoli, MD1996 edmund g. lowrie, MD1995 Joseph W. eschbach, MD1994 Wadi N. Suki, MD1993 Joel D. Kopple, MD1992 Saulo Klahr, MD1991 Professor august Heidland1990 richard J. glassock, MD1989 Professor Priscilla Kincaid-Smith1988 Shaul g. Massry, MD1987 robert W. Schrier, MD1986 robert Heptinstall, MD1985 Willem J. Jolff, MD1984 Charles r. Kleeman, MD1983 robert W. Berliner, MD1982 Professor Hugh e. de Wardener1981 Donald W. Seldin, MD1980 george e. Schreiner, MD1979 John P. Merrill, MD1978 Thomas e. Starzl, MD1977 Henry l. Barnett, MD1976 Carl. W. gottschalk, MD1975 Belding Scribner, MD1974 robert M. Kark, MD1973 Jean Hamburger, MD

The Garabed Eknoyan AwardTheGarabedEknoyanAwardwascreatedtorecognizeanindividualwhohaspromotedthemissionoftheNationalKidneyFoundationinMakingLivesBetterforpeoplewithkidneydiseasethroughexcep-tionalcontributionstokeyinitiativesofNKFsuchastheKidneyDiseaseOutcomesQualityInitiative(KDOQI)orclinicalresearchinthefieldofkidneydisease.The2008awardrecipientisAdeeraLevin,MD,FRCPC.

Dr. levin is currently a Clinical Professor of Medicine at the university of British Columbia (BC), Co-director of the Clinical investigator Program at uBC. She is the executive Director of the BC Provincial renal agency, an organization which manages and coordinates the care of patients

with kidney disease in the province of BC, and which has developed and maintained the provincial registry for renal patients.

Dr. levin is the Past Chair of the Kidney Foundation of Canada Biomedical Fellowship and Scholarship Committee, and serves as Chair of the Curriculum Committee for a new innovative program for the train-ing of Canadian clinical scientists in kidney disease (KreSCeNT). in addition she is Chair of the NKF KDOQi clinical Practice guideline initiative process, and is on the Board of Directors and executive com-mittee of the newly formed KDigO, an international group providing collaborative structure for outcomes research and guideline develop-ment in CKD.

Her research and clinical activities focus on chronic kidney disease, co-morbidities associated with CKD, mechanisms of disease, and health outcomes research. She is active in mentoring young investigators in kidney-related research, and holds numerous grants for clinical studies.

Dr. levin has over 135 peer-reviewed publications, numerous book chapters, and has been guest editor for sections in Current Opinion in

Nephrology and Hypertension for two consecutive years, as well as serv-ing on the editorial board for NDT, JASN and AJKD. She reviews papers for Circulation, New England Journal of Medicine, Annals of Internal

Medicine, Canadian Family Practice and Kidney International as well.

Dr. levin was recently awarded a team-planning grant from Michael Smith to create an active research team, iNTegraTiON, to develop a research strategy for the study of complex patients; and was also awarded a Provincial Treasury Board administered Health innovation Fund grant to develop and assess novel methods of care


Adeera Levin, MD, FRCPC

delivery for patients with Diabetes, Kidney Disease and Heart Disease in the province of BC.

Past Garabed Eknoyan Award Recipients

2007 Norbert H. lameire, MD2006 Francesco locatelli, MD2005 Nathan W. levin, MD, FaCP2004 Neil r. Powe, MD, MPH, MBa2003 Bertram l. Kasiske, MD2002 andrew S. levey, MD

Joel D. Kopple AwardTheJoelD.KoppleAwardisanannualawardhonoringanindividualwhohasmadesignificantcontributionstothefieldofrenalnutrition.Thisyear’sJoelD.KoppleAwardrecipientisAlisonL.Steiber,PhD,RD,LDwhowillbespeakingon“Dietitian:PowerhouseBehindthePatients.”

alison Steiber is the Director of the Coordinated Dietetic intern-ship/Master’s Degree Program at Case Western reserve univer-sity in Cleveland, Ohio. allison received her Bachelor’s Degree in Dietetics from Mankato State university, followed by her Mas-ter’s Degree from the university

of Kansas Medical Center. She earned her Doctorate in Nutrition from Michigan State university. Her dissertation was on carnitine levels in patients receiving hemodialysis as well as supplementation with carnitine to study the effects on clinical parameters and quality of life. She was the recipient of a CrN National research grant in 2004 to conduct the “North american Subjective global assessment valida-tion Project” which was published recently in the Journal of Renal

Nutrition. Dr. Steiber has published numerous articles, abstracts and CPe modules and has been a phenomenal force in encouraging and fostering renal dietitians in research and excellence in practice.

Past Joel D. Kopple Award Recipients

2007 Kamyar Kalantar-Zadeh, MD, PhD, MPH2006 Mary Pat Kelly, MS, rD, gNP2005 Jerrilynn D. Burrowes, PhD2004 Judith Beto, PhD, rD, FaDa2003 linda M. McCann, rD, lD, CSr2002 linda Moore, rD, lDN

KDOQI Distinguished Service AwardInrecognitionoftheirlongtimededicationandeffectivenessinimprovingclinicalresearchinthefieldsofkidneyandurologicdisease,theNationalKidneyFoundationwishestohonorDr.LawrenceY.C.Agodoa,Dr.PaulW.Eggers,andDr.JohnW.KusekwithaspecialKDOQIDistinguishedServiceAward.Thisawardwasestablishedtorecognizesignificantcontributionsintheareaofchronickidneydiseasehealthcareandresearch.

Dr. agodoa graduated from the Cornell university College of Medicine, New york, Ny in 1971. He completed internship and residency training in internal Medicine at the university of Washington Hospitals in Seattle, Wa, and training in clinical and biomedical research in Nephrology and renal Pathology.

He was appointed Chief of the Nephrology Service at the Madigan army Medical Center, Tacoma, Wa. in 1976. in 1981, he returned to the university of Washington and completed two years of clinical and research training in rheumatology and immunology. in 1983, he was assigned to the Walter reed army Medical Center as assistant Chief of the Nephrology Service and the Nephrology Training Program, and was appointed to the Faculty of Medicine at the uniformed Services university of the Medical Sciences (uSuMS), Bethesda, Maryland. in 1985, he was appointed Director of the Military Medical research Fellowship at the Walter reed army institute of research.

in 1987, Dr. agodoa was appointed Director of the Clinical affairs Pro-gram in the Division of Kidney, urologic, and Hematologic Diseases at the National institute of Diabetes, Digestive and Kidney Diseases of the National institutes of Health (NiH) in Bethesda, Maryland.


Lawrence Y.C. Agodoa, MD, FACP

Alison Steiber, PhD, RD, LD

Presently, he is Professor of Medicine at the uniformed Services uni-versity of the Health Sciences, F. edward Hebert School of Medicine, and Program Director at the National institutes of Health. His current duties include the following:n Director, Office of Minority Health research Coordination at the

National institute of Diabetes and Digestive and Kidney Diseases (NiDDK), National institutes of Health.

n Director of the Minority Health Program in the Division of Kidney, urologic and Hematologic Diseases (DKuHD).

n Program Scientist and Coordinator of the multi-center clinical trial, The african american Study of Kidney Disease and Hypertension (aaSK) Cohort.

n Co-Project Officer of the eSrD renal database, the united States renal Data System (uSrDS).

Dr. eggers is the Program Direc-tor for Kidney and urology epide-miology at the National institute of Diabetes and Digestive and Kidney Diseases. He oversees the united States renal Data System (uSrDS), the urologic Diseases in america (uDa) project, the Boston area Community Health

(BaCH) Study, the Frequent Hemodialysis Network (FHN) Clinical Trial, the NiDDK data repository, and the raND interstitial Cystitis epidemiology (riCe) survey. in addition, he oversees a variety of epi-demiological grants in the area of kidney and urologic diseases.

Prior to joining NiDDK, Dr. eggers was Director of the Division of Beneficiary research in the Office of Strategic Planning at the Health Care Financing administration (HCFa). He worked on research and evaluation studies at HCFa since 1978. He has conducted studies and evaluations of Medicare enrollment in HMOs, the Prospective Pay-ment System, Physician Payment reform, and the hospice benefit. His major area of expertise is the end Stage renal Disease Program. His research on eSrD includes epidemiological studies of mortality and morbidity among eSrD beneficiaries, transplantation studies and cost studies of dialysis and transplantation. He has over 60 publica-tions concerning various issues relating to the Medicare program, and eSrD in particular.

John W. Kusek received his PhD from the university of Michigan. He is currently at the Division of Kidney, urologic and Hematologic Diseases, National institute of Diabetes and Digestive and Kid-ney Diseases (NiDDK), National institutes of Health. Prior to coming to the NiH in 1983 he was

a faculty member in the Department of epidemiology and Biometry, School of Public Health, university of illinois at Chicago. For the past 18 years he has worked on major clinical research studies in chronic kidney disease and urologic diseases. He has served as Project Sci-entist or assistant Project Scientist on the following studies of chronic kidney disease: The Modification of Diet in renal Disease Study, the african american Study of Kidney Disease and Hypertension, the Hemodialysis Study, the Dialysis access Consortium, the Folic acid for vascular reduction in renal Transplants, the Chronic Kidney Disease epidemiology Collaboration and the Chronic renal insufficient Cohort Study. He has also served as Project Scientist for a large number of clinical research studies in urology, including the Medical Therapy of Prostatic Symptoms Trial, the Chronic Prostatitis Collaborative research Network, the interstitial Cystitis Clinical research Network, the urinary incontinence research Network, the Minimally invasive Surgical Therapy Network, the Complementary and alternative Medi-cine for urological Symptoms trial and the Boston area Community Health Survey. He has published over 100 articles on chronic kidney disease and urology, over 200 abstracts, and several book chapters. He has received two NiH Director’s awards, the NiH award of Merit and a special achievement award from the NiDDK. He has reviewed manuscripts for over a dozen leading medical journals.

John W. Kusek is married to Jody, a Senior investigator for Monitoring and evaluation at the World Bank, specializing in Hiv/aiDS in africa. They have two daughters, Jessica, a lawyer currently serving as a clerk for a state of Maryland circuit court judge and Jenna, a high school senior.


Paul W. Eggers, PhD

John W. Kusek, PhD

CM08 International Distinguished Medal RecipientsTheInternationalDistinguishedMedalwasestablishedin1990tohonortheachievementofindividualswhohavemadesignificantcontributionstothefieldofkidneydiseaseandextendedthegoalsoftheNationalKidneyFoundation.TheFoundationPresidentpresentsmedalseachyeartorecognizetheaccomplishmentsofindividualsthroughtheirclinicalwork,rolesinacademia,scientificdiscoveriesorvolunteerworkinorganizationssimilartotheFoundation.

Dr. Charra was born april 19, 1942, in Décazeville, in the central part of France. He spent his early youth in France, then in Morocco.

Dr. Charra’s family took summer vacations at his mother’s home in Coligny near Switzerland, where he met Marie-Jo his wife-to-be. He attended medical school in

Montpellier between 1961 and 1968. He married Marie-Jo in 1966. They lived two years in Seattle where he was a senior fellow in nephrology under B.H.Scribner with their two first children; Claire, an oncologist, and vincent, a professor of history.

The two years spent in Seattle left an indelible impression on Bernard and Marie-Jo. Dr. Charra was strongly influenced in his career by B.H. Scribner who became a close friend over the years and corresponded daily. Dr. Charra joined Dr. laurent in Tassin near lyon in 1979 where he spent the following 26 years as a nephrologist and ultimately as the head of the unit. They had two more children, a son Clément, a general practitioner, and Camille, a designer.

Dr. Charra’s favorite motto in life is taken from reinhold Neibuhr: “god, grant me the serenity to accept the things i cannot change, cour-age to change things i can, and the wisdom to know the difference.”

Dr. Hoy is Professor of Medicine and Director of the Center for Chronic Disease at the university of Queensland, australia. Her work on high-risk populations in the uSa and australia has helped promote expansion of nephrolo-gy’s focus beyond eSrD to early markers of risk and disease,

and the notion of their integration with other chronic diseases. Her research addresses the epidemiology of renal disease, hypertension, type 2 diabetes and cardiovascular disease, and determinants of ac-centuated susceptibility to disease, including intrauterine and early life events, and their structural markers. it also addresses primary and secondary prevention, outcomes research, health services and policy and cost-effectiveness evaluations. She advocates for programs of systematic surveillance and management of chronic kidney disease in high risk groups, and has modeled their success in australian aboriginal groups. She advocates for a needs-based system of health care delivery at the community level, and, working on protocols for primary pharmacologic prevention. Her awards include: austin Doyle award, High Blood Pressure research Council of australia, 1997; Wyeth award, Best manuscript in MJA, australian Medical association, 2000; Wyeth award, Best manuscript in MJA, australian Medical association, 2002; australian Kidney Foundation Clinical Nephrology award: 2002. Best oral presentation 38th annual Meeting of the aNZSN, 2002; australian Kidney Foundation Clinical Nephrology award: 2004. Best oral presentation 40th annual Meeting of the aNaSN, 2004; Barry M. Brenner endowed lectureship: american Society of Nephrology, 2006.


Bernard Charra, MD

Wendy Hoy, MD

Professor Michel Jadoul, born in 1958, is married and has three children, aged 22, 19 and 15. He completed his medical studies in 1983 at the université Catholique de louvain, Brussels, Belgium. He trained in internal medicine and nephrology with Professor Charles van ypersele de Strihou

as his mentor and spent a year in the academic Hospital in utrecht (Professors Dorhout Mees and Koomans) in the Netherlands.

He is the head of the Department of Nephrology of the Cliniques universitaires Saint luc since 2003 and Clinical Professor at the université Catholique de louvain. His main clinical research interests relate to Beta2microglobulin-amyloidosis, hepatitis C in dialysis and, more recently, falls and bone fractures in hemodialysis patients and cardiovascular complications in kidney transplant recipients. He is an associate editor of the American Journal of Kidney Diseases and a member of the editorial Board of Nephrology Dialysis Transplantation and Clinical Nephrology. Professor Jadoul is country investigator with Professor Norbert lameire for DOPPS in Belgium and cochair with Professor David roth of the Kidney Disease improving global Outcomes Hepatitis C in CKD Clinical Practice guideline Work group.

yves vanrenterghem, MD, PhD, re-ceived his MD degree in 1973 from the Catholic university of leuven, Belgium. He then undertook a research Fellowship at the Queen elisabeth Foundation for Medical research in Brussels, Belgium. at present he is affiliated with the university Hospital gasthuisberg

in leuven, Belgium, where he is Chairman of the Department of Nephrology and Professor of Medicine. Since 1993 he is a member of the Board of eurotransplant international of which he was the President between 1996 and 2005. Previously he was Treasurer of the european Society for Organ Transplantation and a member of the Scientific Committee of the eDTa registry. Professor vanrenterghem is Subject editor of Nephrology Dialysis and Transplantation (NDT), associate editor of the American Journal of Transplantation and a member of the editorial Board of Transplantation. recently he was elected as the

european representative of the Council of the Transplantation Soci-ety. Dr. vanrenterghem is the vice-Chairman of the global alliance for Transplantation. Since 2005 he is a Member of the KDigO Board. He has been the principal investigator of several international multi-center trials on new immunosuppressive agents after kidney transplantation. in 1987 he was the winner of the 20th eurotransplant anniversary award. From 1996 till 2001 he was the holder of the Baxter Chair for renal Transplantation.

Past International Distinguished Medal Recipients

2007Mona al-rukhaimi, MD, Dubai, united arab emiratesDick de Zeeuw, MD, PhD, groningen, The NetherlandsSayyid ali Jaffer Naqvi, MD, Karachi, PakistanSusumu Takahashi, MD, PhD, Tokyo, JapanChristoph Wanner, MD, Wurzburg, germany

2006Jorge Cannata-andia, MD, Oviedo, SpainPrakesh Keshaviah, MD, Dehradun, uttaranchal, indiagabriel Mircescu, MD, Bucharest, romaniayusuke Tsukamoto, MD, Tokyo, JapanHaiyan Wang, MD, Beijing, China

2005John Dirks, MD, Toronto, Ontario, CanadaSaraladevi Naicker, MD, Johannesburg, South africaluis revert, MD, Barcelona, SpainWu Chang yang, MD, Taiwan, China

2004Peter g. Blake, MB, FrCP, Toronto, Canada Kai-uwe eckardt, MD, Berlin, germanyS. adibul Hasan rizvi, MBBS, FrCS, FrCSe, FCPS, FrCP, Karachi, Pakistan Bernardo rodriguez-iturbe, MD, Maracaibo, venezuelaClaudio ronco, MD, vicenza, italy

2003georgi abraham, MD, Chennai, indiaShanyan lin, MD, Shanghai, ChinaNester Schor, MD, PhD, São Paolo, BrazilCarmine Zoccali, MD, reggio, italy


Michel Jadoul, MD

Yves Vanrenterghem, MD, PhD

Past International Distinguished Medal Recipients (continued)

2002gavin Becker, MD, victoria, australiaFrancesco locatelli, MD, lecco, italySergio Mezzano, MD, valdivia, Chilegiuseppe Piccoli, MD, Torino, italyWladyslaw Sulowica, MD, PhD, Kracow, Poland

2001elvira emilia arrizurieta, MD, Buenos aires, argentinaHans-Henrick Parving, MD, DMSC, Copenhagen, Denmarkyahya Sagliker, MD, adana, TurkeyFernando valderrababo, MD, PhD, Madrid, Spain

2000vittorio andreucci, MD, PhD, Naples, italyNorbert lameire, MD, PhD, ghent, BelgiumFlorian lang, MD, PhD, Tubingen, germany

1999Jonas Bergstrom, MD, PhD, Huddinge, SwedenWalter H. Hörl, MD, PhD, vienna, austriavincenzo Savica, MD, Messina, italygianfranco guarnieri, MD, Trieste, italy

1998Professor rosario Maiorca, Brescia, italyJohn Walls, MD, leicester, englandShaul M. Shasha, MD, Nahariya, israelProfessor Jean-Pierre grunfeld, Paris, France

1997Professor guido Bellinghieri, Sicily, italyProfessor Hirotoshi Morii, Osaka, JapanProfessor Momir H. Polenakovic, Skopje, MacedoniaProfessor Boleslaw rutkowski, gdansk, Poland

1996Professor Judit Nagy, Pecs, HungaryProfessor Karel Opatrny, Pizen, Czech republicMiguel C. riella, MD, Curitba, Brazil

1995Maurice Slapak, MD, Hampshire, englandguy laurent, MD, Tassin, FranceDavid N. Kerr, MD, london, englandalexander P. Disney, MD, adelaide, South australiaandrzej Ksiazek, MD, lublin, Poland

1994Stefan angielsi, MD, gdansk, PolandNatale g. De Santo, MD, Naples, italyProfessor Miroslaw Mydilk, Kosice, Slovac republic

1993Jamie Herrera-acosta, MD, Mexico City, MexicoJose l. rodicio, MD, Madrid, SpainProfessor Sandor, Sonkodi, Hungaryvisith Sitprija, MD, Bangkok, Thailand

1992Professor albert valek, CzechoslovakiaProfessor Mary g. Mcgeown, Belfast, irelandProfessor Ori Better, Haifa, israelProfessor rashad Barsoum, Cairo, egyptProfessor Karl M. Koch, Hannover, germanyM. Derome Tremblay, France

1991Professor Nobuhiro Sugino, Tokyo, JapanProfessor K.S. Chugh, Mumbai, indiaProfessor renee Habib, Paris, FranceProfessor Franciszek Kokot, PolandProfessor Sevrin ringoir, ghent, Belgium

1990Professor Kazimierz Baczyk, Poznan, PolandProfessor vittorio Bonomini, Bologna, italyProfessor J. Stewart Cameron, london, englandT.T. Durai, MD, SingaporeProfessor Henri Jahn, Strasbourgh-Cedex, FranceProfessor eberhard ritz, Heidelberg, germany



each year, NKF Professional Councils recognize individuals who have made outstanding contributions in the field of renal health. it is an honor to announce some of those individuals who will be formally recognized at this year’s meeting.

COuNCil OF NePHrOlOgy SOCial WOrKerS (CNSW)

CNSW Lifetime Achievement AwardPatriciaMcKevitt,ACSW,LCSW

Patricia McKevitt is celebrating 35 years in renal health. She began her career in 1973 — just as Medicare made dialysis available on a broad scale. Since 1981 she has been the Director of Social Work at Chromalloy american Kidney Center and a research associate in Medicine, Washington university School of Medicine. She is truly one of the founders of CNSW, having served as its third Chair as well as many other positions. She has also been continually active with NKF and her local Chapter as well as the Network Coordinating Council. She serves on the editorial boards of five journals/magazines. She also contrib-uted heavily to the CNSW CQi Manual. She has been a leader in renal social work through presentations and publications from the beginning of her career. She has served on the National advisory Board of the longitudinal, international National Dialysis Outcomes and Practice Patterns Study (DOPPS). Pat’s career is certainly exemplary.

The 2008 CNSW Merit AwardJudyCaldwell,LMSW,ACSW,DaVitaGardenWest,Westland,MIJudy has been a leader for the Michigan CNSW Chapter and has served on the Program Committee as Chair and Co-Chair for the annual Symposium. She has worked with the Discharge Planners Outreach Program Committee, a special program to increase the communication between hospitals and the dialysis units. She is also sharing her skills through mentoring new social workers and those wishing to become involved in the Michigan NKF and CNSW.

DianePerry,LISW,EdinaDialysisofDaVita,Edina,MNDiane has been an active member of the upper Midwest NKF gift of life program promoting and educating patients, families, and staff about organ donation and transplantation. She has also helped coordi-nate the local KeeP program, which promotes early detection of CKD. Diane worked with State Services for the Blind to implement a books-on-tape program for blind patients.

COuNCil ON reNal NuTriTiON (CrN)

Joel D. Kopple AwardAlisonL.Steiber,PhD,RD,LD

Please see page 22 for biographical information.

Susan Knapp Excellence in Education AwardJaneGreene,MS,RD,CSR,LDN

Jane greene is the education Coordinator for the renal Clinic and is a renal Dietitian at vanderbilt university Medical Center. in addition, Jane is a Preceptor for the Dietetic internship at vanderbilt university Medical Center for the past 18 years. She is also involved in the education of her peers and other health care professionals including a preceptor for the adult acute Care Nurse Practitioner Program and the Nephrology Fellowship program. additionally, Jane participates in community outreach by providing classes and overseeing educational materials and care plans for CKD patients through the vanderbilt Nephrology Clinic. Jane has been an invited speaker at over 40 local, state and national meetings in addition to publishing over a dozen peer-reviewed journal articles. She is active with local and national CrN activities serving as regional representative for region 2. Jane is truly passionate about education and the patients she cares for.

Recognized Renal DietitianMarianneVennegoor,RD,HPC

Marianne vennegoor is the first dietitian to receive this award outside of the united States. She studied and earned her degree in Nutrition and Dietetics in the Netherlands. She also completed a middle man-agement course at guy’s and St. Thomas’ Hospital where she worked for 31 years. She has traveled the world as an ambassador for renal dietitians and has shared her expertise in the united Kingdom, austria, France, Czech republic, greece, germany, italy, israel, Japan, Mexico, Philippines, russia, estonia, Spain and Sweden. Marianne has been the contact for the european CrN for the past 14 years. additionally, she remains active with the international Society of renal Nutrition and Metabolism, the international Congress of Dietetics and the interna-tional Society for Peritoneal Dialysis. She is a founding member and Chair of the Dietetic Subgroup of the european Dialysis and Transplant Nurses association european renal Care (eDTNa/erCa). She is also Chair of the education Committee of the international Federation of Kidney Foundations. Marianne has also been a member of the

CM08 NKF PrOFeSSiONal COuNCil aWarDS

CM08 Contributors

Primary Contributors:Corporate Supported Symposia

abbott

aMag Pharmaceuticals, inc.

amgen

Fresenius Medical Care

genzyme

Novo Nordisk

Ortho Biotech Products, l.P.

Shire Pharmaceuticals

Meeting Contributors:additional Conference Materials and events

abbott

amgen

astellas Pharma uS, inc.

Bard

Baxter Healthcare

Boehringer ingelheim

genzyme

Keryx Biopharmaceuticals, inc.

MedComp

Merck

Omron



Watson Pharma, inc.


editorial Board for Advances in Renal Replacement Therapy, the Journal of Renal Nutrition and the Journal of the EDTNA/ERCA.

COuNCil OF NePHrOlOgy NurSeS aND TeCHNiCiaNS (CNNT)

The 2008 CNNT Distinguished Service AwardDadiDing,RN,CNN

Dadi has been on the CNNT executive Committee for two terms as region 3 Chair. She has worked very closely with our two councils (illinois and iowa) to assist with recertifi cation and communication. in addition, she and Kay Hall, outgoing region 2 Chair, developed

and completed the new orientation manual for new executiveCommittee Members.

2008 CNNT Distinguished Service AwardKayHall,RN,CNN,BSN

Kay has served as Chair for region 2 for the past four years. in addi-tion to her normal duties as Chair, she has written numerous articles for RenaLink in regulatory issues and helped the council with issues related to CMS and survey regulations. She has also co-authored the orientation manual for new Council Members with Dadi Ding.

TheNationalKidneyFoundationgratefullyacknowledgesthesupportofthefollowingorganizationswhohelpedmaketheNKF2008SpringClinicalMeetingspossible:

What’s In store?

A Curriculum for CKD Risk Reduction and Care

store hours:Thursday

8:00 a.m. – 6:30 p.m.

Friday

7:00 a.m. – 6:00 p.m.

Saturday

7:00 a.m. – 5:00 p.m.

Store is located at Ballroom Foyer in the NKF Registration Area.

02-10-491A© 2008 National Kidney Foundation, Inc. All rights reserved.

April 3 April 4 April 5

Use YoUr coUpon to save

FIve Dollars on pUrchases oF $25 or moreOne COupOn per purChase

Be a part oF oUr

raFFleDraWIngs

everY DaY


Poster PresentationsCMO8 provides an opportunity to meet with over 300 authors to discuss their research experiences and significant areas of development in chronic kidney disease. all participants will have an opportunity to view a stimulating selection of poster presentations in the exhibit Hall,

starting Thursday, April 3 at 6:00pm and ending Saturday, April 5 at 1:00pm.

Authors available for questions at the Exhibit Hall Opening and Networking Reception

on Thursday.

exHiBiTHall

2008 Exhibit Hall and Poster Presentation Hours

Thursday, April 3 6:00pm–7:30pm Opening Ceremonies and Faculty Reception –

Visit Posters/Exhibits

Friday, April 4 7:00am–8:00am Posters/Exhibits and Continental Breakfast

10:00am–2:00pm Posters/Exhibits and Lunch

5:30pm–7:00pm Networking Reception – Posters/Exhibits

Saturday, April 5 9:00am–1:00pm Posters/Exhibits and Brunch

Meeting ObjectivesParticipants will learn about new and evolving concepts related to kidney disease through workshops, debates, interactive courses and traditional didactic sessions. The meet-ings’ learning objectives are to increase the participants’ understanding, knowledge and competency regarding improving patient care in the following areas:n Methods to preserve hemodialysis access

and prevent infectious complicationsn acute kidney injury, long-term impact, and

strategies for preventing aKin Causes of secondary hypertensionn What’s new on nephrogenic systemic fibrosisn understanding the controversies regarding

living donors for kidney transplantationn The controversy over the target hemoglobin

in CKD.

NKF’s Expectation of PresentersThrough the National Kidney Foundation Spring Clinical Meetings and continuing edu-cation programs, NKF promotes excellence in kidney health care education. NKF expects that all presenters affiliated with the NKF 2008 Spring Clinical Meetings will provide informa-tive and fully accurate content that reflects the highest level of scientific rigor and integrity.

Target AudienceThe National Kidney Foundation 2008 Spring Clinical Meetings are designed for kidney doc-tors in the private sector and academia, fellows and residents with a special interest in kidney disease, general internists, pharmacists, physi-cian assistants, nephrology nurses and techni-cians, nurse practitioners, nephrology social workers, renal and clinical dietitians, and any other clinician involved in the care and treat-ment of individuals with kidney disease.

CME/CEUinformation pertaining to CMes or Ceus can be found at the beginning of each program track.

CME & CEU Session TrackingNKF offers an online system for tracking your CMe/Ceus. With an easy swipe of a badge, attendance at sessions will automatically be recorded—no more forms to complete! CMe and Ceu credit information will be uploaded instantaneously to a web site for easy viewing. you are able to print a certificate of attendance at your own convenience and without any hassle! access this system conveniently by visiting www.expobadge.com/certification/nkf2008

The online service is available through July 4, 2008.

NKF Registration, Ticket Sales and Informationlocated in the Foyer, Ballroom level.

registration Hours are:Tuesday 3:00pm–8:00pm Wednesday 7:00am–6:00pm Thursday 5:30am–6:00pm Friday 7:00am–5:00pm Saturday 7:00am–5:00pm Sunday 7:00am–1:00pm (information only)

Tickets for activities requiring separate registration and/or a separate fee are available at the Ticket Sales Booth in the registration area. Staff are available at the Meeting infor-mation Booth to answer any questions that you may have.

BadgesPlease wear your registration badge for admission to all meeting activities. There is a $25.00 replacement fee for lost badges.

Poster PresentationsOver 300 abstracts will be presented as poster presentations. Posters are available for view-ing in the exhibit Hall during exhibit hours noted on page 31.

CM08 Evaluations – Your Feedback Really Mattersevaluations will be distributed at the begin-ning of each session and collected at the end. There will also be evaluation drop-off locations around the meeting area. evaluations are very important to all of us. The planning and execu-tion of useful and sound continuing education programs are largely guided by input provided by program participants. your responses will help ensure that future programs are informa-tive and meet your educational needs. Please take a few minutes to let us know what you think, because your feedback really matters!

geNeral iNFOrMaTiON


National Young Investigator’s ForumWednesday, april 2

Participationbyinvitationonly.

The National Kidney Foundation is pleased to host the Third National young investigators Forum chaired by Paul Sanders, MD and robert Toto, MD. Participants include the win-ners of the five regional young investigators Forums held in the first quarter of 2008 as well as those from the 2007 Forums. Presenters will compete in the Clinical research or Basic research categories. a panel of faculty judges will select the award winners in each category.

NKF gratefully acknowledges the support of amgen who has made this program possible.

Internal Medicine and Pediatric Trainees ProgramWe are pleased to welcome internal Medicine and Pediatric Trainees to CM08. This special program encourages highly-qualified and interested individuals to enter the field of kidney disease. The program provides internal Medicine and Pediatric trainees concentrated exposure to cutting-edge clinical and experi-mental Nephrology in the stimulating learning environment. The goals of the program are to shed light on the broader aspects of the subspecialty than what house staff experience on the wards in their daily routine.

Fellows Event: Career Choices in Nephrology/Fellows ReceptionHeld in association with Women in Nephrology

Participationbyinvitationonly.

Saturday, april 5, 5:30pm–7:00pm

Coordinators: Sharon Moe, MD, and Milagros D. Samaniego, MD

Panelists: Sharon adler, MD, Sumit Kumar, MD, Chris lu, MD, lauren McDonald, MD, Jose Menoya, MD, robert Toto, MD, and Miguel vazquez, MD

Have you ever wondered what you are going to do when you finish your Nephrology train-ing? “Career Choices in Nephrology” is your opportunity to hear from individuals who work in all aspects of Nephrology. The session is for fellows and residents who are trying to decide what career path to choose in nephrology, and how to go about getting there. The session will begin with a panel discussion by individu-als currently active in academic medicine as educators and researchers, private practice, interventional nephrology, and industry. learn why these Nephrologists decided on their career paths, their backgrounds, what they did to secure their jobs, and if (and how) they would do it again if they were starting over. after the panel discussion, there will be time for questions and answers followed by a beer/wine reception and hors d’oeuvres. This is a great time to network.

National Kidney Foundation Kidney Learning System (KLS) StoreCenter Foyer, Ballroom level

The NKF KlS store has many items for pro-fessional and patient education and public awareness. Please stop by to pick up single, complimentary copies of KlS brochures, to see newly available materials and to browse and purchase resources related to CKD care.

The (KlS) store hours are: Thursday 8:00am–6:30pm Friday 7:00am–6:00pm Saturday 7:00am–6:00pm

Exhibit Hall Informationexhibits and posters are located in the exhibit Hall. exhibitors are a vital part of the NKF Spring Clinical Meetings. The NKF thanks our exhibitors for their continued support of our educational programs, and cordially invites attendees to the following receptions:n Thursday, april 3, for the exhibit Hall Open-

ing reception which will be held at 6:00pm in the exhibit Hall. Posters will also be on

display with authors present. Top poster presenters announced.

n Friday, april 4, for a Networking reception held in the exhibit Hall from 5:30pm–7:00pm. Meet colleagues for cocktails and hors d’oeuvres in a relaxed atmosphere before you attend one of the dinner symposia.

Membership Questions?NKF professional membership provides numerous benefits for physicians, pharma-cists, advanced practitioners, nurses, techni-cians, dietitians and social workers. Stop by the Membership Booth located in the NKF registration area to learn more about how to become an NKF member.

The Learning ContinuesRecordingsMost sessions will be audio taped.* Tapes and MP3 audio CD-rOMs will be sold in the registration area at the “Conference Copy, inc.” table will be available following the meeting. Please refer to the topic list included in your tote bag for more information or you can check the NKF web site for this information.

* Speaker permission must be granted in order to tape a session or a particular speaker.

FacultySlidePresentationsFinal slide presentations* will be posted on the NKF web site at the conclusion of the meeting and will be made available to registrants of CM08.

* Presentations available with faculty permission only.


TheNationalKidneyFoundationgratefullyacknowledgesourcorporatepartnerswhohavesupportedtheFoundationandenabledustoworktowardsitsmissionofpreventingkidneyandurinarytractdiseases,improvingthehealthandwell-beingofindividualsandfamiliesaffectedbythesediseases,andincreasingtheavailabilityofallorgansfortransplantation.ApercentageoffundsraisedarealsodirectedtowardtheFoundation’sresearchprogram.InterestedcorporationsmaycallGeraldineC.Connorsat800.662.9010x215forinformation.

TheNKFwishestorecognizeandthankthefollowingcorporatepartners:

CM08 COrPOraTe ParTNerS


Platinumabbott

amgen

genzyme

roche

Wyeth Pharmaceuticals

DiamondMerck & Co., inc.

Goldembassy of the

united arab emirates

Silverastellas Pharma

uS, inc.

Boehringer ingelheim Pharmaceuticals, inc

CB richard ellis

glaxoSmithKline


Novartis Pharmaceu-ticals Corporation

BronzeC O r e (Center

for Organ recovery & education)

Fresenius Medical Care

Keryx Biopharmaceu-ticals

Musculoskeletal Transplant Foundation (MTF)

NCCC-Charity

Pfizer, inc.

Quest Diagnostics

abbott Nutrition

Schwarz Pharma, inc

The Coca-Cola Company

Watson laboratories, inc.

ContributorBristol-Myers Squibb

Company

Strides for Nephropathy

Takeda Pharmaceuti-cals North america, inc

SupporterPiNg

Friendaffymax inc.

Bard Peripheral vascular

Davita

golf Digest

gSW Worldwide

lockheed Martin

Satellite laboratory Services

Sigma-Tau Pharma-ceuticals

The Binding Site, inc.

Tourneau

united Healthcare

WHERE THERE’S A

THERE’S A

WAYTO SAVE A LIFE!

You can give the gift of life... even when yours is over... through the National Kidney Foundation’s Planned Giving Program. Your financial contribution to fight kidney disease can come by way of your will... life insurance... real estate or gifts of securities, and your estate can even enjoy a tax break! For more information contact the National Kidney Foundation.

1.800.622.9010 www.kidney.org

Wednesday, April 27:30pm–9:30pm

AssociationofMineralMetabolism,VitaminDTherapy,andCalcimimetricsonChronicKidneyDiseasePatientSurvivalSupported by an educational grant from abbott

Thursday, April 36:00am–8:00am

EffectsofGlycemicControlonOutcomesinDiabeticswithChronicKidneyDiseaseSupported by an educational grant from Novo Nordisk

6:00am–8:00am

TrendsandChallengesinCKDProgressionandManagementinOlderAdultsSupported by an educational grant from Ortho Biotech Products, l.P.

12:00pm–2:00pm

DietaryPhosphorusandOutcomesinPatientswithCKDSupported by an educational grant from Shire Pharmaceuticals

7:30pm–9:30pm

AnEvidence-BasedReviewoftheManagementofHyperphosphatemiaanditsPharmacoeconomicImpactonPatientswithStage5CKD:NewPerspectivesforOptimalOutcomesin2008Supported by an educational grant from Fresenius Medical Care – North america

Friday, April 46:00am–8:00am

AssessingtheRoleofProteinuriaintheProgressionofChronicKidneyDiseaseSupported by an educational grant from genzyme

6:00am–8:00am

NewDOPPSFindingsonOptimizingPracticesfortheHemodialysisTeamSupported by an educational grant from amgen

7:00pm–9:00pm

CardiovascularDiseaseinCKDPatientsPre-DialysisandonDialysisSupported by an educational grant from genzyme

7:00pm–9:00pm

OptimalPatientOutcomes:IdentificationandTreatmentofIronDeficiencyAnemiainEarlyCKDSupported by an educational grant from aMag Pharmaceuticals, inc.

Saturday, April 56:00am–8:00am

ChronicKidneyDiseaseInterventions:ImprovingCKDandCVDOutcomes

6:00am–8:00am

ExploringtheLinkBetweenChronicKidneyDiseaseandCardiovascularDisease:ReducingMortalitySupported by an educational grant from abbott

BreaKFaST, luNCH aND DiNNer SyMPOSia


The National Kidney Foundation is required by the accreditation Council for Continuing Medical education to disclose significant support or sub-stantial financial relationships between planners, presenters and com-mercial entities for all Continuing Medical education (CMe) activities.

NKF sent a “Faculty Disclosure Form” to the faculty participating in the 2008 Spring Clinical Meetings (april 2–6, 2008, in Dallas, Texas). all faculty members participating in a NKF-sponsored activity are expected to disclose to the participants prior to the educational activity the existence of any significant financial or other relationships held by themselves, and/or family members, with the manufacturer(s) of any commercial product(s) or provider(s) of any commercial service(s) discussed in an educational presentation.

The faculty member is also required to disclose to the activity audience when an unlabeled use of a commercial product, or an investigational use not yet approved for any purpose, is discussed during an educa-tional activity. The intent of this disclosure is to provide attendees with information prior to their participation in the educational activity.

all invited speakers for the National Kidney Foundation 2008 Spring Clinical Meetings are expected to complete a “Faculty Disclosure Form.” Speakers who did respond, but have nothing to disclose, are listed with no information next to their name. Speakers who did not complete a disclosure form prior to presentation are not allowed to present as per the Foundation’s Disclosure Policy. Meeting participants may also refer to the Session Chair introductory remarks for each session for final listings of disclosures and off-label or unapproved usages of a product.

DiSClOSure OF PlaNNerS aND FaCulTy COMMerCial relaTiONSHiPS


FaCulTy DiSClOSure liSTiNg

KaraAbbas

MartinAbrahamsongrant/research support: Pfizer; Speaker’s bureau: eli lilly, glaxoSmithKline, Merck, Novo Nordisk, Novartis, Pfizer, Sanofi- aventis, Takeda

KennethAbreo

BethAdams

SharonAdlergrant/research support: aspreva, genzyme, genentech

AnilAgarwal

ZalmanAgus

MichaelAllon

GeraldAppelgrant/research support: Merck, Pfizer, aspreva; Consultant/scientific advisor: Merck, Pfizer, astra Zeneca, aspreva, genentech; Speaker’s bureau: Merck, Pfizer, astra; Zeneca, aspreva, genentech

GeorgeAronoff

StephenAshOfficer/director or holder of more: ash access Technologies

ArifAsif

CassandraAspinall

JohnAsplinFull/Part time employment: litholink Cor-poration; Consultant/scientific advisor: altus Pharmaceuticals

CarolynAtkins

MaryAnnBaily

GeorgeBakrisgrant/research support: NiH (NiDDK/NHlBi) glaxo-Smith Kline, Forest; Consultant/ scientific advisor: abbott, Boerhinger- ingelheim, BMS/Sanofi-aventis, Forest, glaxo-Smith Kline, Merck, Novartis, Walgreens, gileada, Sankyo; Speaker’s bureau: abbott, Boerhinger-ingelheim, BMS/Sanofi-aventis, Forest, glaxo-Smith Kline, Merck, Novartis, Walgreens, gileada, Sankyo

LyndaBall

JulieBarboza

JoanneBargman

LoisBates

DanielBatlle

GeraldBeck

SrinivasanBeddhu

AnnBeemerCotton

FilitsaBender

LaurieBenton

SuzanneBergman

TomasBerl

JeffreyBerns

AnatoleBesarabConsultant/scientific advisor: vascalert

JudithBetoConsultant/scientific advisor: amgen; Speaker’s bureau: amgen, Shire

PeterBlake

MaryEllenBrabecSpeaker’s bureau: Shire Pharmaceuticals

KathleenBradySpeaker’s bureau: abbott

EmmauelBravo



BarryBrennerConsultant/scientific advisor: genzyme, Novartis

K.BridgetBrosnihan

TeriBrowne

JohnBurkartgrant/research support: Baxter, genzyme, abbott, Watson, NxStage; Consultant/ scientific advisor: Baxter, genzyme, NxStage; Speaker’s bureau: Baxter

DavidBushinskyConsultant/scientific advisor: amgen, genzyme, Shire, ilypso, relypsz; Speaker’s bureau: amgen, genzyme, Shire, ilypso, relypsz; Officer/director or holder of more: amgen

JessicaCabness

MaryBethCallahan

DonnaCalvin

EllenCase

ClaireCasselman

LeeCauble

SheldonChaffer

ChristopherChan

AlfredCheung

DolphChianchiano

MichaelChoi

LouiseClement

CarolynCochran

JeanColaneriSpeaker’s bureau: amgen

AllanCollinsgrant/research support: amgen, roche, NxStage, Baxter; Consultant/scientific advisor: amgen, roche, NxStage

DaniloConcepcion

BonnieConrad

GabrielContreras

SandraCoorough

DanielCoynegrant/research support: abbott, amgen, roche, Watson; Consultant/scientific advisor:

abbott, roche, iNeOS, Watson; Speaker’s bureau: abbott, amgen, Watson

RonaldCrossnoFull/Part time employment: vistaCare

JohnCrouch

JimCurtisOther financial or material support: Home Dialysis Plus

KirstendeGrootConsultant/scientific advisor: aspreva; Speaker’s bureau: roche

JanDeane

AndreaDeKam

FrancisDelmonicoSpeaker’s bureau: astellas, roche; Other financial or material support: Wyeth; Full/Part time employment: New england Organ Bank, The Transplantation Society

LauraDembergrant/research support: Neurochem, inc.

VincentDennisConsultant/scientific advisor: Fresenius Medical Corporation

PeterDeOreo

ThomasDepner

DavidDeWalch

LesleyDinwiddieConsultant/scientific advisor: arrow interna-tional, graftcath, inc., excelsior; Speaker’s bureau: Hoffmann la roche of Canada

BradleyDixonConsultant/scientific advisor: Proteon Therapeutics, Pervasis Therapeutics

BartDolmatchConsultant/scientific advisor: edwards lifesciences, Bard

MaryAnnDooleyConsultant/scientific advisor: aspreva, Teva, genentech, amgen, Human genome Sciences, roche, iDeC, uCB

TilmanDruekegrant/research support: amgen, genzyme, Shire; Consultant/scientific advisor: amgen,

genzyme, ineos, Mitsubishi; Speaker’s bureau: amgen, genzyme, Mitsubishi

RobertDuncan

PaulEggers

KarenEgloso

RichardEisenstaedtSpeaker’s bureau: Ortho Biotech

GarabedEknoyan

KimberlyEnglish

JessicaFarrell

DanielFeigSpeaker’s bureau: TaP Pharmaceticals

HarveyFeldman

HaroldFeldman

FredricFinkelstein

MichaelFlessner

CharlesFoulksSpeaker’s bureau: amgen

StanleyFranklinConsultant/scientific advisor: atCor Medical, Bristol-Myers Squibb, Merck, Pfizer; Speak-er’s bureau: Merck, Bristol Myers Squibb, Boehringer ingelheim

AllonFriedman

BarbaraFromm

JoelGlickman

DeborahGliddenSpeaker’s bureau: amgen, abbott

ElaineGo

DavidGoldfarbConsultant/scientific advisor: altus Pharmaceuticals, OxThera, TaP Pharmaceuticals

ThomasGolperConsultant/scientific advisor: Baxter

ThomasGonwagrant/research support: Wyeth, genzyme

JanelleGonyea

JohnGowan

MichaelGrassoConsultant/scientific advisor: Karl Storz, Boston Scientific, Cook urological



TomGreenegrant/research support: Keryx Corporation

LoicGuillevin

KayHallFull/Part time employment: Davita

LisaHall

LeeHamm

HaewookHan

JeffHarder

JohnHartman

JeanetteHasse

MaryHastingsHagar

RebeccaHays

MikhaelleHeald

DavidHellmann

BrendaHemmelgarngrant/research support: amgen, Merck

ElizabethHenery

JohannHerberthConsultant/scientific advisor: amgen

CharlesHerzoggrant/research support: amgen, Medtronic, astra Zeneca, NiH; Consultant/scientific advisor: amgen, Medtronic, roche, Ortho BioTech, guidant, CorMedix; Other financial or material support: roFar

JonathanHimmelfarb

DeborahHinnenConsultant/scientific advisor: lilly, aventis, intuity; Speaker’s bureau: lilly, aventis, roche, aPha, aaDe

L.TammyHoConsultant/scientific advisor: abbott; Speaker’s bureau: Orthobiotec

KimberlyHodgeConsultant/scientific advisor: NxSTage Medical

R.MichaelHofmann

RonaldHogggrant/research support: Pronova Biocare, Merck, roche

JeffreyHoggard

PriscillaHollanderConsultant/scientific advisor: Pfizer, Novo Nordisk, Sanofi aventis; Speaker’s bureau: Pfizer

NormanHollenberg

JeanHolley

TriciaHoward

KirkHughes

LawrenceHunsickergrant/research support: Keryx, Sanofi-aventis; Consultant/scientific advisor: Keryx, Pfizer, Sanofi-aventis, isotechnika, Teijin group, CorMedix Pharmaceuticals; Speaker’s bureau: Bristol-Myers Squibb, Sanofi-aventis

MarianneHuttonConsultant/scientific advisor: Shire; Speaker’s bureau: Shire

AjayIsranigrant/research support: roche, amgen, Bristol Myers Squibb

BertrandJaberConsultant/scientific advisor: NxStage Medical, inc., advanced Magnetic, inc.

AimeeJaremowicz

StephanieJohnstone

SheilaJowsey

PeterJuergensen

KamyarKalantar-Zadehgrant/research support: abbott, amgen, Shire, Watson, genzyme; Speaker’s bureau: abbott, amgen, Shire, Watson, genzyme

MarciaKalistaRichards

JudithKari

PamelaKentFull/Part time employment: genzyme

Rita-AnKiely

PaulKimmelConsultant/Scientific advisor: Pfizer, Fresenius; Stockholder: Johnson & Johnson, amgen, Merck, lilly, Pfizer, Fresenius

LisaKindy

AlanKliger

BobbieKnotek

NormaKnowles

StephenKorbet

AndreaKostick

CsabaKovesdy

SumitKumar

DanaKumjian

WarrenKupin

KristinLarson

ThuLe

NathanLevingrant/research support: roche; Consultant/scientific advisor: Fresenius, roche

EdmundLewisOther financial or material support: Keryx

KirstieLewis

JuliaLewisgrant/research support: Keryx Biopharma-ceuticals, Novartis

AnneLiles

RobertLindsay

RobertLockridgeConsultant/scientific advisor: renal Solutions, inc.

CharmaineLok

CynthiaLord

ElenaLucio

CathiMartinConsultant/scientific advisor: Shire; Speaker’s bureau: amgen, Shire

ArthurMatas

IvanMaya

MaureenMcCarthy

WilliamMcClellanConsultant/scientific advisor: amgen, roche

PeterMcCullough

LaurenMcDonaldOfficer/director or holder of more: Fresenius Medical Care

SamyMcFarlane

JenniferMcGuoirkFull/Part time employment: abbott laboratories



StephanieMcIntyre

DianneMcKay

PatMcKevitt

BethMcQuiston

RajnishMehrotraSpeaker’s bureau: Baxter Health Care

RavindraMehta

MarkMeier

DavidMendelssohn

JoeMerighi

JefferyMetzger

MiriamMichael

CindyMiller

MeredithMiller

RonaldMiller

RichardMishler

OrsonMoe

SharonMoegrant/research support: genzyme; Consultant/scientific advisor: genzyme, amgen, ineos; Speaker’s bureau: genzyme

MicheleMokrzycki

AnneMooreSpeaker’s bureau: gundersen lutheran Medical Foundation

BruceMorgensternOther financial or material support: astra-Zeneca

DonnaMortondeSouzaFull/Part time employment: genzyme

AlvinMoss

SalimMujais

MaryMurphy

PatrickMurraygrant/research support: NxStage Medical, inc.; Consultant/scientific advisor: Scios, inc., NxStage Medical, inc.; Speaker’s bureau: Scios, inc., NxStage Medical, inc.

MohanramNarayanan

AndrewNarva

IraNemeth

MarianneNeumann

AllenNissensongrant/research support: amgen, Hoffman- la roche, NiH; Consultant/scientific advisor: advanced Magnetics, affymax, Davita OCMO, amgen, Hoffman-la roche; Speaker’s bureau: Watson Pharma

AnnO’Hare

EdmondO’Riordan

EmilPaganinigrant/research support: Quark Pharmaceuti-cals, Biosite, inc., amgen; Consultant/scien-tific advisor: NxStage Medical, Quark Phar-maceuticals, Biosite, inc., amgen; Speaker’s bureau: Watson Pharmaceuticals

RobertPageSpeaker’s bureau: Pfizer, astra-Zeneca

JoniPagenkemper

PaulPalevsky

JessiePavlinac

MarcPenngrant/research support: athersys; Other financial or material support: acellerx Therapeutics

MarkPerazella

BethPiraino

MarcPohl

MeganPrescott

PatPrestonConsultant/scientific advisor: Johnson & Johnson, Ortho-McNeil

WajehQunibigrant/research support: NaBi Biopharma-ceutical, Fresenius

JaiRadhakrishnanConsultant/scientific advisor: genentech

PandurangaRao

RobertReilly

CleoRichard

MarkRobertsgrant/research support: archimedes, inc.; Consultant/scientific advisor: archimedes, inc.

BruceRobinson

MichaelRocco

RogerRodby

JamesRodrigue

CarolRoe

ArturoRollaSpeaker’s bureau: lilly, Novo Nordisk, glaxoSmithKline, roche

JamieRoss

PrabirRoy-Chaudhury

BharatSachdeva

AntoineSamaha

MilagrosSamaniegoSpeaker’s bureau: genzyme

EduardoSanchezSpeaker’s bureau: Sanofi aventis

PaulSanders

GailSansiverogrant/research support: elcam Medical; Consultant/scientific advisor: angioDynam-ics, Boston Scientific, genentech, elcam Medical

MarkSarnakgrant/research support: amgen

MarySchira

KathySchiroHarvey

DonaldSchonConsultant/scientific advisor: Bard; Speak-er’s bureau: Bard; Other financial or material support: MedComp, angioDynamics

AntonSchoolwerthgrant/research support: amgen; Consul-tant/scientific advisor: OrthoBiotech, inc.; Speaker’s bureau: amgen

DonnaSecker

MaryAnnSevick

EdwardSiew

EdwardSilverhardtFull/Part time employment: Center for applied Behavioral Sciences, Davita Sparks Dialysis

BeverlySneedFull/Part time employment: abbott laboratories renal Care Division

Mi-KyungSong



LawrenceSpergel

StuartSpragueConsultant/scientific advisor: abbott; Speaker’s bureau: abbott

GlenStanbaugh

AlisonSteibergrant/research support: Sigma Tau Pharmaceuticals, inc.; Speaker’s bureau: Sigma Tau Pharmaceuticals, inc., genzyme, abbott

LesleyStevens Speaker's bureau: Quest Diagnostics

StephanieStewart

KristinStockard

DanaSturtevant

WadiSukigrant/research support: genzyme; Consultant/scientific advisor: genzyme; Speaker’s bureau: genzyme

MarySundell

DuaneSunwold

LyndaSzczechgrant/research support: Ortho Biotech

PaulSzczybor

HaroldSzerlip

MichaelTalamantes

MariaTaylor

StephenTextor

RaviThadhanigrant/research support: abbott; Speaker’s bureau: abbott, genzyme

CharlieThomas

CherylThomasgrant/research support: Waterpik, Sonicare, Biotene; Other financial or material support: Proctor and gamble

KathrynThurber-Smith

TrentTipple

AshitaTolwaniSpeaker’s bureau: gambro renal Products

FaithTootell

JosephTorrealba

RobertTotogrant/research support: Novartis; Consultant/scientific advisor: Merck, amgen; Speaker’s bureau: Merck, amgen, Novartis

MandyTrolinger

LaraTushla

TraceyTyus-Bailey

MarkUnruhgrant/research support: Baxter

ArisUrbanes

TusharVachharajani

RamiroValdez

JosephVandeGriend

JosephVassalotti

MiguelVazquez

JoyceVergiliSpeaker’s bureau: Shire Pharmaceutical

ThomasVeselyConsultant/scientific advisor: W.l. gore, Pervasis Therapeutics, elcam, inc.

RonaldVictor

TheodôrVogels

BradleyWaradySpeaker’s bureau: genentech

RichardWardgrant/research support: gambro renal Products

KurtWargo,DavidWarnockgrant/research support: genzyme, amgen; Consultant/scientific advisor: genzyme, amgen

SarahWashburn

TiffanyWashington

AmyWaterman

PatWeberFull/Part time employment: genzyme Corporation

MatthewWeirConsultant/scientific advisor: Bristol-Myers Squibb, Sanofi aventis, MSD Pharmaceuticals, Novartis, Boehringer ingelheim; Speaker’s bureau: Bristol-Myers Squibb, Sanofi aventis, MSD Pharmaceuticals, Novartis, Boehringer ingelheim

BarbaraWeisMaloneConsultant/scientific advisor: Wyeth; Speaker’s bureau: amgen

StevenWeisbordgrant/research support: roche; Speaker’s bureau: amgen

JohnJasonWhite

RobertWhitlock

KarenWiesen

AlanWilkinson

WolfgangWinkelmayergrant/research support: glaxoSmithKline, amgen, astellas; Consultant/scientific advisor: genzyme, Fresenius, roche

AlexanderWiseman

JayWishConsultant/scientific advisor: Watson, amgen, Ortho Biotech, roche; Speaker’s bureau: Watson, amgen, Ortho Biotech

MylesWolfgrant/research support: Shire; Consultant/scientific advisor: ineos; Speaker’s bureau: abbott, genzyme

JackWorkConsultant/scientific advisor: vascular access; Speaker’s bureau: vascular access

LindaWrightSpeaker’s bureau: astellas

StevenWu

QingyuWu

AlexanderYevzlinSpeaker’s bureau: Pfizer

KimZubergrant/research support: amgen, genzyme

TransplantCourse:TransplantationTrendsinthe21stCentury

WednesdayApril2,20088:00am–3:45pmCourseDirectors:MilagrosD.Samaniego,MDandDianneMcKay,MDSession220

Course Description: The 2008 Transplant Course has been designed to review both the most recent advances in transplant immunosuppression and diagnostics, and current interventions to increase the donor pool and minimize long-term morbidity in the kidney transplant recipient.

The course presents an update on immunosuppressants and new im-munosuppression trends — including steroid withdrawal and avoid-ance protocols. The new diagnostic techniques — including the recent changes in the Banff classification of allograft pathology, and the state-of-the-art of genomic and proteonomic diagnostics — will be reviewed using a case discussion format and computer interaction with the audience.

The course will also address three challenging areas of kidney trans-plantation in the 21st century: the management of chronic kidney disease and dialysis in recipients of other solid organ transplants, the treatment of the kidney transplant candidate and recipient with chronic infections, and the current interventions to diagnose and manage cardiovascular disease in the transplant candidate and recipient.

Target Audience: This course is designed for community nephrologists, transplant nephrologists, nephrology fellows, transplant coordinators, transplant pharmacists and other professionals involved in the care of the kidney transplant patient.

Course Objectives: upon completion of this course the attendee should be able to:n Discuss current and upcoming immunosuppressants, their mecha-

nisms of action, and the new immunosuppression trends.n Discuss the impact of delayed graft function in kidney transplant

outcomes, and the practical aspects of dialysis in kidney and other solid organ transplant recipients with acute kidney injury or CKD.

n Be familiar with the updated Banff 2005 classification of allograft pathology with emphasis on the current terminology of acute and chronic allograft rejection and new diagnostic categories.

n understand the concept and formats of paired kidney exchange programs, and the role of these programs to improve access of dialysis patients to kidney transplantation.

n Manage kidney transplant patients and candidates with chronic viral and fungal infections.

PHySiCiaN PrOgraM Pre-CONFereNCe COurSeS aND WOrKSHOPS


n Know the current strategies to minimize cardiovascular morbid-ity and mortality from the early stages of chronic kidney disease through transplantation.

Preregistration and course fee of $150 are required for meeting

registrants. Participation is limited. Light breakfast, box lunch,

and course syllabus included.

time/faculty

8:00am–8:30am

8:30am–8:45am Milagros D. Samaniego, MD

8:45am–9:15am Milagros D. Samaniego, MD

9:30am–10:15am R. Michael Hofmann, MD

10:15am–10:30am

10:30am–11:00am Jose Torrealba, MD

11:15am–12:00pm Edmund O’Riordan, MD

12:00pm–1:00pm

1:00pm–1:30pm Ajay Israni, MD, MS

1:40pm–2:30pm Alexander Wiseman, MD

topic

Breakfast

introduction

New immunosuppression Trends

Delayed graft Function, Dialysis and CrrT in Organ Transplant recipients

Break

Ta, iF: The aBC of Transplant Pathology – Case Presentations genomics and Proteonomics in Kidney Transplantation: unravel-ing the Molecular imprinting of Transplant Dysfunction

lunch with Faculty Paired-Kidney exchange Programs: The Next Trend

Management of the Transplant Patient with Chronic infection: How i Treat My Patients


time/faculty

2:40pm–3:10pm Alan Wilkinson, MD

3:20pm–3:40pm All Faculty

3:45pm

IntegratedHemodialysis/PeritonealDialysisCourse

WednesdayApril2,20087:30am–5:30pmCourseDirector:JoanneM.Bargman,MD,FRCPCCSession221

Course Description: This course is designed with multiple goals for the kidney health care professional involved in identifying the physiology and techniques of peritoneal dialysis and hemodialysis. The relationship between clinical outcomes and different renal replacement modalities to treat chronic kidney disease will be addressed. The attendee will also gain an understanding of infectious and noninfectious complications, the importance of proper access in both PD and HD, potential compli-cations of access problems, and learn how to identify treatment related complications and discuss treatment strategies.

Target Audience: Practicing nephrologists, nephrology fellows in training, advanced practitioners and nephrology nurses.

Course Objectives: upon completion of this course, the attendees should be able to: n identify the physiology and techniques of peritoneal dialysis and

hemodialysis n understand the relationship between clinical outcomes and different

renal replacement modalities to treat chronic kidney disease. n understand the basis and practical application of dialysis dose pre-

scription in peritoneal and hemodialysis. n understand the infectious and noninfectious complications of perito-

neal and hemodialysis. n understand the importance of proper access in both peritoneal dialy-

sis and hemodialysis and potential complications of access problems. n identify treatment-related complications in peritoneal and hemodi-

alysis and discuss potential treatment strategies.


registrants. Limited to 125 participants. Light breakfast, box

lunch, and course syllabus included.

time/faculty

7:30am–8:00am

8:00am–8:10am Joanne M. Bargman, MD, FRCPC

8:10am–8:50am Peter Blake, MD, FRCPC, FRCPI

8:50am–9:20am John M. Burkart, MD

9:20am–10:00am Robert D. Toto, MD

10:00am–10:40am Joanne M. Bargman, MD, FRCPC

10:40am–10:55am 10:55am–11:30am Robert D. Toto, MD

11:30am–12:05pm John M. Burkart, MD

12:05pm–1:00pm Bertrand L. Jaber, MD, FASN

1:00pm–1:30pm Jack Work, MD

1:30pm–2:00pm Beth Piraino, MD

2:00pm–2:40pm Laura Dember, MD

2:40pm–3:20pm Beth Piraino, MD

topic

Breakfast

introduction

Comparative Outcomes of HD and PD

Modality Selection and initiation of Dialysis

The Hemodialysis Prescription and Monitoring Solute Clearance

Prescribing PD: Why PD is Not HD

Break

Blood Pressure and euvolemia in Hemodialysis

Blood Pressure and euvolemia in PD

luNCH – intradialytic Complica-tions: Selected Case Studies

vascular access for Hemodialysis – Case Studies (Noninfectious)

insertion and Management of the PD Catheter

Hemodialysis-related infections

PD-related infections

topic

Cardiovascular Disease: From CKD to Transplantation and Back

roundtable: Questions and answers Closing remarks



time/faculty

3:20pm–3:35pm

3:35pm–4:15pm Joanne M. Bargman, MD, FRCPC

4:15pm–5:00pm Christopher Chan, MD

5:00pm–5:30pm Thomas Golper, MD, FASN, FACP

5:30pm

InterventionalNephrologyCourse

WednesdayApril2,20087:45am–4:30pmCourseCo-Directors:KennethAbreo,MDandArifAsif,MDSession222

Course Description: Diagnostic and interventional procedures are criti-cal to the care of nephrology patients. This course introduces a variety of interventional and diagnostic procedures that are critical to the care of kidney patients. The procedures include: renal biopsy, placenebt ad reni-vak of temporary and permanent central venous catheters and perito-neal dialysis catheters, and monitoring as well as salvage procedures for failing or thrombosed fistulas and grafts and insertion of intravascular coils and stents. recent updates on hand ischemia and its management as well as intravascular stent insertion and its benefits will also be pro-vided. in addition to didactic sessions, workshops to provide hands-on training, focusing on insertion of tunneled dialysis catherers, percutane-ous balloon angioplasty and declotting procedures.

Target Audience: This course is designed for nephrologists, fellows and other kidney health care professionals.




time/faculty

7:15am–7:45am

7:45am–8:00am Kenneth Abreo, MD and

Arif Asif, MD

8:00am–8:15am Kenneth Abreo, MD

8:15am–8:30am Richard Mishler, MD

8:30am–8:45am Alexander Yevzlin, MD

8:45am–9:00am Tushar Vachharajani, MD,

FASN, FACP

9:00am–9:15am Ivan Maya, MD

9:15am–9:30am Anatole Besarab, MD

9:30am–9:45am Bart Dolmatch, MD

9:45am–10:15am

10:15am–10:30am Arif Asif, MD

10:30am–10:45am Steven Wu, MD

10:45am–11:00am Anil Agarwal, MD

11:00am–11:15am Jeffrey Hoggard, MD

11:15am–11:30am Bharat Sachdeva, MD

topic

Break

Noninfectious Complications of PD

Home Hemodialysis Therapies

it’s about the Money: reimburse-ment guidelines in the Care of Dialysis Patients

Closing remarks

topic

Breakfast Welcome and introduction

vascular anatomy of importance to the interventional Nephrologist

road Map for the interventionilist: Types of avFs and avgs

How to increase the Number and Quality of incident arteriovenous Fistulas

The art of access examination

examining arteriovenous grafts for Problems

The aBCs of Surveillance: is it Necessary?

Fistula Maturation: The interventionalist’s role

Break

excellent vascular access but Ter-rible Hand Pain: What Do you Do?

The Dos and Don’ts of Balloon angioplasty

The Swollen arm: Diagnosis and Treatment of Central vein Stenosis

The Thrombosed vascular access: Thrombolysis and angioplasty

The When, Where, and How of Stents and Stent grafts


time/faculty

11:30am–11:45am Jack Work, MD

11:45am–12:00pm Aris Q. Urbanis, MD

12:00pm–1:30pm 1:30pm–1:45pm Stephen R. Ash, MD, FACP

1:45pm–2:00pm Jamie Ross, MD

2:00pm–2:15pm Gabriel Contreras, MD, MPH

2:15pm–2:30pm Donald Schon, MD

WorkshopSessions

2:30pm–4:30pm WorkshopA (Leader: Stephen R. Ash,

MD, FACP)

Jamie Ross, MD

Anil K. Agarwal, MD

Ivan D. Maya, MD

Sumit Kumar, MD

Steven Wu, MD WorkshopB (Leader: Donald Schon, MD)

Aris Q. Urbanis, MD

Alexander S. Yevzlin, MD

Bharat Sachdeva, MD

Tushar Vachharajani, MD

Jeffrey Hoggard

DialysisUnitManagementCourse

WednesdayApril2,20088:00am–5:00pmCourseDirector:PeterB.DeOreo,MD,FACPSession223

Course Description: The emphasis of this course will be on the role of the key members of the facility management in leading the physician and patient care staff toward quality outcomes. in the coming era of diminished reimbursement, reimbursement contingent on achieving quality outcomes, the facility leadership will increasingly be faced with choices and trade-offs. efficient management leads to the operating margin that sustains the quality mission. Topics will include the understanding of national quality goals, trade-offs in cost, quality and value as well as understanding the ethical dilemmas created by quality contingent reimbursement.

Target Audience: Designed for physician directors and nurse managers. The course will also be of interest to patient care supervisors, adminis-trators and quality managers.

Course Objectives: upon completion of this course, the attendees should be able to:n understand the national quality goals n understand the trade-offs in cost, quality, valuen understand the ethical dilemmas created by quality contingent

reimbursementn understand the impact of bundling on facility revenuen understand the role of the key professionals in measuring and

managing qualityn understand the new aaMi water standards and water system

disaster recovery




topic

Complications of endovascular Procedures: Prevention and Treatment

Contrast Nephropathy, Contrast allergy, and Conscious Sedation: Minimizing the Dangers

lunch

Tunneled Hemodialysis Catheters: Hate Them but Can’t Do Without Them

The Bad and The ugly of Tunneled Hemodialysis Catheters

Peritoneal Dialysis: The endan-gered Dialysis Modality

Where Do i Begin: interventional Training and interventional Centers

location: San antonio 1Tunneled Hemodialysis Catheter insertion

location: San antonio 4Balloon angioplasty Workshop



time/faculty

8:00am–8:30am

8:30am–9:30am Jay B. Wish, MD

9:30am–10:30am Mary Ann Baily, PhD

10:30am–10:45am

10:45am–11:45am John W. Hartman, MD

11:45am–12:45pm George Aronoff, MD

12:45pm–1:15pm 1:15pm–2:15pm Alan S. Kliger, MD

2:15pm–2:45pm Carol Roe, RN, JD

2:45pm–3:00pm

3:00pm–3:45pm Peter B. DeOreo, MD, FACP

3:45pm–4:45pm Richard A. Ward, PhD

4:45pm–5:00pm

NephrologyRecertification:AnAudienceParticipationForumforFun,EducationandABIMCredit

Wednesday,April2,20089:00am–5:00pmSession224CourseDirector:HaroldM.Szerlip,MD

Course Description: One of the requirements for nephrology recertifica-tion is to successfully obtain a total of 100 points with a minimum of 20 points in medical knowledge. This hurdle must be cleared before taking the secure exam. Participation in the NKF’s “Nephrology recertifica-tion audience Participations Test for Credit” is a painless, fun and an educational way to complete one of those booklets. each multiple choice question will be answered by the audience using a computerized response system. The results will be displayed and then an expert will discuss the question, present appropriate background information and make a conclusion as to what he/she thinks is the correct answer. au-dience discussion will be encouraged. at this time, each member of the audience will have the opportunity to record their “official” answer for credit. at the end of the day you will have completed one of the require-ments for recertification, learned a great deal and have fun doing it!

Course Requirements: The Nephrology recertification Course will review SeP Nephrology Module 27-r as well as the 2007 update (a7-e). ForthoseattendeesalreadyenrolledintheABIMMaintenanceofCertificationProgram(MOC),pleaseconfirmthatyoubringthesebookletsandtheanswersheetson-site.

Course Objectives: upon completion of this course, participants will be able to:n identify aspects of general nephrologyn identify new developments in the fieldn Obtain credit towards recertification in nephrology.




topic

Welcome and Breakfast

The National Quality agenda Pay for Performance

The ethics of adverse Selection in the era of Pay for Performance

Break

using Data to Drive improvement “good enough is good enough”

intelligent Design in Medication Protocols

lunch Break

The role of the Medical Director in Quality and Safety

The role of the registered Nurse in Quality and Safety

Break

What’s Happening in Financing of eSrD

update on aaMi Water Standards and Water System Disaster recovery

Questions and Closing Comments


Course Faculty:

John Jason White, MD Harold M. Szerlip, MD, FaCP, FCCP

time

7:30am–8:00am

8:00am–11:30am

11:30am–12:00pm

12:00pm–1:00pm

1:00pm–4:30pm

4:30pm–5:00pm

5:00pm

RayW.GiffordJr.,MDHypertensionSymposium

Session225WednesdayApril2,20087:30am–5:30pmCourseDirector:MarcA.Pohl,MD

Target Audience: This activity is designed for advanced nephrologists, physicians in training, as well as other physicians who are interested and involved with the management of hypertension and cardiovascular disease.

Course Objectives: upon completion of this course, attendees will be able to:n review the latest advances in basic physiology, biochemistry, and mo-

lecular biology relative to hypertension, vascular damage, myocardial infarction, and heart failure

n acquire the latest information and new direction in the management of atherosclerosis and cardiovascular disease

n review the pathophysiology of hypertension and the implications for therapy

n examine recent clinical trials in hypertension

Pre-registration and course fee of $50 ($25 for fellows) are required

for meeting registrants. Participation is limited. Light breakfast,

box lunch, and course syllabus included.

time

7:30am–8:00am

8:00am–8:15am Marc A. Pohl, MD

8:15am–8:45pm Stanley S. Franklin, MD, FACP,

FACC

8:45pm–9:15pm Larry G. Hunsicker, MD

9:15pm–9:30pm

9:30pm–10:00pm Norman K. Hollenberg, MD, PhD

10:00pm–10:30pm Thu H. Le, MD

10:30pm–10:45pm

10:45pm–11:00pm

11:00pm–11:30pm K. Bridget Brosnihan, PhD

11:30pm–12:00pm Stephen C. Textor, MD

12:00pm–12:15pm

12:15pm–1:15pm

topic

Breakfast

review of SeP Nephrology Module 27-r

Question and answer Session

lunch

review of the 2007 update (a7-e)

Question and answer Session

Concluding remarks

topic

registration and Continental-Breakfast

Welcome, introduction, and Some reflections on ray W. gifford, Jr., MD

Concurrent use of Pulse Pressure and Mean arterial Pressure Best Defines Hypertensive Cardiovascular risk: New Data from the Framingham Heart Study

is There a Blood Pressure That is Too low?

Discussion

What is Someone from the North-east uSa Doing in a Tropical rain Forest, and What Has That got to Do with Well Being?

genetic Determinants of Hyper-tension and Kidney injury in a Mouse Model of Chronic Kidney Disease

Discussion

Break

aCe2 and ang-(1-7) in Normoten-sive and Hypertensive Pregnancy

BOlD Mr to evaluate Tissue Oxy-genation in renovascular Disease

Discussion

luNCHeON


time topic


1:15pm–1:45pm Marc Penn, MD, PhD

1:45pm–2:15pm Qingyu Wu, MD, PhD

2:15pm–2:30pm

2:30pm–3:00pm Paul W. Sanders, MD

3:00pm–3:30pm Daniel I. Feig, MD, PhD, MS

3:30pm–3:45pm

3:45pm–4:00pm

4:00pm–4:30pm Ronald G. Victor, MD

4:30pm–5:00pm Emmanuel L. Bravo, MD

5:00pm–5:15pm

5:15pm–5:30pm

5:30pm

Nephrology201ForAdvancedPractitioners

Session620WednesdayApril2,20087:30am–5:30pm

Please see page 64 for course details.

Separate Registration and Fee Required.

Heart Felt lesson on Stem Cell Based ischemic Tissue repair

The Cardiac Protease Corin and Hypertension

Discussion

Dietary Salt and endothelial Function

uric acid: a Mediator of early Onset essential Hypertension

Discussion

BreaK

The Sympathetic Nervous System in Hypertensive Disorders

aldosterone and the Kidney: From Bench to Bedside

Discussion

Concluding remarks

adjourn

©2007 Novartis 2/07 NTP-OT-0059-A

L e a d i n g t h e W a y . . . y e s t e r d a y , t o d a y & t o m o r r o W .

Since the 1970s, Novartis researchers have been actively working to improve quality of life and survival for every person undergoing transplant surgery. Today, Novartis remains committed to

research and development, targeting new ways to ensure even greater transplant success. By researching new pathways, Novartis strives to improve the function and sustainability of

every transplanted organ with reduced side effects from treatment.

Together we can make a bigger difference.

notp04_Journal Ad_Final.indd 1 3/7/08 10:31:06 AM


WOrKSHOPS

SeparateRegistrationandFeeRequired

Anadditionalfeeof$30perworkshopisrequired(includesaboxlunch).TicketsfortheseworkshopsmaybepurchasedattheNKFTicketSalesBoothintheRegistrationArea.Spaceislimited,soparticipationisavailableonafirst-come,first-servedbasis.

ControversiesinLivingDonorTransplantation

Session230Thursday,April3,12:00pm–1:30pmChair:MilagrosD.Samaniego,MD

access to kidney transplantation has been curtailed by the lack of sufficient deceased donor organs. in order to overcome the imbalance between organ demand and offer, living donors have become the pre-ferred source of organs for kidney transplantation. To increase living donation, the monetary compensation of the donor or the provision of medical care following donation has been proposed. These proposi-tions pose both financial and ethical difficulties.

To discuss the alternatives and current proposals in front of Congress, two world leaders in kidney transplantation: Dr. Francis Delmonico – former President of the Board of Directors of uNOS, and Dr. arthur Matas – current President of the american Society of Transplant Surgeons, will discuss the different alternatives to increase living donation, the current initiatives to eliminate the sale of organs abroad, and the Pros and Cons of donor compensation.

ImpactofSurveillanceonAVGraftOutcomes

Session231Friday,April4,12:00pm–1:15pmCo-Chairs:CharmaineLok,MDandMichaelAllon,MD

This workshop promises a high energy debate on the impact of access surveillance on arteriovenous grafts outcomes. The various methods of access surveillance, their advantages, challenges, and costs will be reviewed and examined in this dynamic lunchtime session. extra time is provided to allow the participant to interact with expert speakers to explore the future directions in this important area of access care.

ManagementofHyperphosphatemiaUsingCalciumvs.Non-CalciumBasedBinders

Session232Friday,April4,12:00pm–1:15pmChair:StuartM.Sprague,DO

VolumeOverloadintheDialysisPatient

Session233Saturday,April5,12:00pm–1:15pmChair:JoelGlickman,MD,FACP

Chronic fluid overload is a major cause of left ventricular hypertrophy (lvH) in dialysis patients. Moreover, since lvH may be a modifiable risk factor, volume control may improve life expectancy by decreasing car-diovascular risk. given that prevention is always the best strategy, the first talk will address novel methods to increase dietary sodium adher-ence. in the second talk, we will review the benefits of diuretic use to provide consistent and improved volume status. We will conclude with a lively question and answer period — please feel free to bring a challenging case!

HemoglobinTargetsforAnemiaManagementinCKD

Session234Saturday,April5,12:00pm–1:15pmChair:JeffreyBerns,MD

recent randomized controlled trials in patients with CKD, showing either lack of benefit or harm with targeting hemoglobin levels above 12 or 13 g/dl with eSa therapy have led to reexamination of the ap-propriate hemoglobin target in these patients. additional information regarding risks of eSa therapy in patients with cancer appears to have influenced considerations about the appropriate hemoglobin target in CKD patients. The FDa has also focused attention in this matter. There has also been much discussion of the difference between hemoglobin “target” and achieved hemoglobin levels. This discussion will consider the pros and cons of targeting and maintaining hemoglobin levels above and below 12 g/dl.


AccreditationThe National Kidney Foundation is accredited by the accreditation Council for Continuing Medical education to provide continuing medi-cal education for physicians. The National Kidney Foundation takes responsibility for the content, quality and scientific integrity of this CMe activity.

CME CreditThe National Kidney Foundation designates this educational activity for a maximum of 40.5

AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Note: acquiring 40.5 hours requires continu-ous participation from Wednesday morning through Saturday morning. Many participants opt for periodic breaks, which make their re-ported credit hours somewhat less. additional credits are provided for courses requiring separate registration, as noted ahead.

Credit Hours: Pre-Conference Courses

5.25 Transplant Trends in the 21st Century 9.0 integrated Hemodialysis/Peritoneal Dialysis 6.75 interventional Nephrology 7.5 Dialysis unit Management 8.0 Nephrology recertification 7.5 Nephrology 201 for advanced Practitioners 8.0 gifford Hypertension Symposium

PHySiCiaN PrOgraM

Vist the KDIGO booth #719.The First Global Nephrology Guidelines Are Now Available

Prevention, Diagnosis, Evaluation and Treatment of Hepatitis C in Chronic Kidney Disease,published in Kidney International,April 2008

www.kdigo.org©2008 National Kidney Foundation, Inc. All rights reserved. 02-77-435A

WeDNeSDay, aPril 2

PHySiCiaN PrOgraM

time/location session # session notes Course Director(s) credits

8:00am–3:45pm

| Texas D 220 | TransplantationTrendsinthe21stCentury Milagros D. Samaniego, MD 5.25

Dianne McKay, MD

7:30am–5:30pm

| Texas C 221 | IntegratedHemodialysis/Peritoneal Joanne M. Bargman, MD, FrCPC 9.0

DialysisCourse

| grapevine 1 225 | RayW.GiffordJr.,MDHypertensionSymposium Marc a. Pohl, MD 8.0


Merck & Co., Inc.

8:30am–5:30pm

| Texas 6 222 | InterventionalNephrologyCourse Kenneth abreo, MD 6.75

arif asif, MD

8:00am–5:00pm

| Texas 1/2 223 | DialysisUnitManagementCourse Peter B. DeOreo, MD, FaCP 7.5

9:00am–5:00pm

| Texas 3/4 224 | NephrologyRecertificationCourse Herald M. Szerlip, MD 8.0

7:30pm–9:30pm

| grapevine D 801 | AssociationofMineralMetabolism,VitaminD Chair: Myles Wolf, MD, MMSc 1.5

Therapy,andCalcimimetricsonChronicKidney

DiseasePatientsSurvival

Supported by an educational grant from Abbott

| Welcome and introductions Myles Wolf, MD, MMSc

| associations of Mineral Metabolism with Myles Wolf, MD, MMSc

Patient Survival

| impact of vitamin D Therapy on Patient Survival Daniel Coyne, MD

| Does Direct Modulations of the Car affect Stuart Sprague, DO

Patient Survival?

| Questions and answers all Faculty


Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘


THurSDay, aPril 3 time/location session # session notes faculty credits

6:00am–8:00am

| grapevine C 802 | TheImpactofGlycemisControlinPatients Chair: Martin J. abrahamson, MD 1.75

withDiabetesandChronicKidneyDisease


Novo Nordisk

| Welcome and introductions Martin J. abrahamson, MD

| glycemic Control in Patients with CKD Mark S. roberts, MD, MPP

| How low Should you go? Martin J. abrahamson, MD

| When and How to use insulin in Patients with

Chronic renal Failure arturo r. rolla, MD

| Panel Discussion/Question and answer Session all Faculty

| grapevine D 803 | TrendsandChallengesinCKDProgression Chair: ann O’Hare, MD 1.5

andManagementinOlderAdults


Ortho Biotech, L.P.

| epidemiology of Chronic Kidney Disease in lesley Stevens, MD, MS, FrCPC

Older adults

| Natural History of Chronic Kidney Disease Brenda Hemmelgarn, MD

in the elderly

| reasons Why evidence for the Management ann O’Hare, MD

of CKD in younger individuals May Not Be

generalizable to Older adults with CKD

8:00am–9:45am

| Texas C 260 | SecondaryHypertension Chair: Marc a. Pohl, MD 1.75

| When to Suspect Secondary Hypertension ronald victor, MD

| endocrine Causes of Hypertension emmanuel Bravo, MD

| Secondary Hypertension Due to Drugs Matthew r. Weir, MD

| Texas 1/2 272 | ControversiesinTransplantation Co-Chairs: alan Wilkinson, MD 1.75

and r. Michael Hofmann, MD

| re-Transplantation: Patient Selection and Panduranga S. rao, MD, DNB, MS

Management of Candidates on Dialysis

| Kidney Transplantation for Other Solid-Organ Thomas a. gonwa, MD, FaSN, FaCP

recipients: a Nephrologist’s Point of view

| Transplantation of the elderly alan Wilkinson, MD

| From CKD to Transplantation: Dianne McKay, MD

Management of the Pregnant Patient Joint with Councils

¯

Joint with Physicians

·

Separate Registration and/or Fee R

equired˘


PHySiCiaN PrOgraM

THurSDay, aPril 3 Continued

time/location session # session notes faculty credits

8:00am–9:45am

| Texas D 261 | NephrogenicSystemicFibrosis Chair: Kamyar Kalantar-Zadeh, MD 1.75

| lessons learned from the NSF registry Mark a. Perazella, MD

| Pathophysiology and Treatment Options robert reilly, MD

for NSF: What are the Data?

| risk-Benefit of gadolinium vs. iodinated roger rodby, MD

Contrast in CKD

| 9:45am–10:00am | Break

10:00am–12:00pm

| Texas C 262 | AcuteKidneyInjury Co-Chairs: Michele Mokryzcki, MD 2.0

and ravindra Mehta, MD

| impact of aKi on long-Term Kidney Outcomes Paul W. eggers, PhD

| impact of aKi on Patient Outcomes ravindra Mehta, MD

| urinary Markers for aKi Paul M. Palevsky, MD

| Strategies for Prevention of Contrast Nephropathy emil Paganini, MD

| Texas D 263 | ImprovingVascularAccessOutcomes Co-Chairs: ivan D. Maya, MD 2.0

and Charmaine lok, MD

| Salvage of early Fistula Failure antoine Samaha, MD

| Pharmacologic Strategies to Delay access Stenosis Prabir roy-Chaudhury, MD

| Debate:FistulaFirst–IsItRightforEveryone?

yes arif asif, MD

No Thomas vesely, MD

12:00pm–1:30pm

| Ft. Worth 6/7 230 | Workshop:Controversiesin ˘ Chair: Milagros D. Samaniego, MD 1.5

LivingDonorTransplantation

| Debate: increasing the Donor Pool:

is it Time to Compensate Donors?

Pro arthur Matas, MD

Con Francis Delmonico, MD

12:00pm–2:00pm

| grapevine C 804 | DietaryPhosphorusandOutcomesin Chair: Stuart Sprague, DO 1.5

PatientswithCKD



| DeBaTe: Should Phosphorus be Controlled

by Dietary restrictions in CKD?

Dietary Phosphorus Control increases Death risk! Kamyar Kalantar-Zadeh, MD

Dietary Phosphorus Control improves Survival! Daniel Coyne, MD

Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘




2:00pm–3:00pm

| Texas a/B 264 | NKFPresidentialAddress–TheNational allan J. Collins, MD, FaCP 1.0

KidneyFoundation:AdvancingPublicHealth

intheU.S.andAroundtheWorld

| ShaulMassryDistinguishedLecture–Randomized Tom greene, PhD

andObservationalStudiesinNephrology:

HowStrongistheEvidence?

| 3:00pm–3:30pm | Break

3:30pm–5:15pm

| Texas a/B 265 | LateBreakingNews Co-Chairs: Michael allon, MD 1.75

and Beth Piraino, MD

| AggrenoxPreventionofGraftStenosis: Bradley Dixon, MD

| Primary results for the Dialysis access Harold Feldman, MD

| Consortium (DaC) Study group gerald Beck, PhD

| DailyDialysisStudies:AnUpdate

| Frequent HD Network Trial Nathan levin, MD

| international Quotidian registry robert lindsay, MD

| FreeDOM Study Bertrand l. Jaber, MD

6:00pm–7:30pm

| exhibit Hall | OpeningCeremoniesintheExhibitHall–VisitPosters/Exhibits

7:30pm–9:30pm

| grapevine C 815 | AnEvidence-BasedReviewofthe Chair: vincent Dennis, MD 1.5 ManagementofHyperphosphatemiaandIts PharmacoeconomicImpactonPatientswith Stage5CKD:NewPerspectivesforOptimal

Outcomesin2008


Fresenius Medical Care – North America

| a review of recent Clinical Studies of Patients lynda Szczech, MD

with Stage 5 CKD: impact on Clinical Practice

| a Pharmacoeconomic analysis of Phosphate Wolfgang Winkelmayer, MD

Binders in the Treatment of Patients with Stage 5

CKD: impact on the Health Care System

Joint with Councils

¯


·


equired˘


PHySiCiaN PrOgraM

FriDay, aPril 4 time/location session # session notes faculty credits

6:00am–8:00am

| grapevine D 809 | AssessingtheRoleofProteinuriainthe 1.5

ProgressionofChronicKidneyDisease

Supported by an educational grant from Genzyme

| Proteinuria and Progression: Primary and Barry Brenner, MD

Secondary Prevention

| Fabry Disease; Proteinuria Without Hypertension: David Warnock, MD

Targets for Therapy

| Proteinuria: The Primary Outcomes Determinate Daniel C. Batlle, MD

in Progression of CKD

| grapevine C 810 | NewDOPPSFindingsonOptimizingPractices fortheHemodialysisTeam–AMulti-Discipline PanelDiscussion

Supported by an educational grant from Amgen

| improving Delivery of Pre-eSrD Care, Case Discussion ronald Pisoni, PhD, MS

| Has Catheter use increased Due to Fistula First? lawrence Spergel, MD, FaCS No! Case Discussion

| Managing Multiple Targets for Best Patient Outcomes, David Mendelssohn, MD, FrCPC

Case Discussion

| 7:00am–8:00am | ContinentalBreakfastinExhibitHall–VisitPosters/Exhibits

8:00am–10:00am

| Texas C 266 | UpdateonNephrolithiasis Co-Chairs: Michael J. Choi, MD 2.0

and David goldfarb, MD

| Obesity, Dieting and Kidney Disease Orson Moe, MD

| Bariatric Surgery and Kidney Stones John asplin, MD

| urologic Treatment of Stone Disease Michael grasso, MD

| Case Discussions Michael J. Choi, MD

| Texas D 267 | ManagementofAKI Chair: ivan D. Maya, MD 2.0

| Management of Cardio-renal Syndrome Patrick Murray, MD

| Management of Hepato-renal Syndrome Warren Kupin, MD

| Debate:CRRTvs.IHDforARF

CrrT is Bettter ashita Tolwani, MD, MSc

iHD is Better emil Paganini, MD

| Texas B 284 | What’sNewinPD Chair: Michael Flessner, MD, PhD 2.0

Optimizing Peritoneal Membrane

Transport and Function Michael Flessner, MD, PhD

| Prevention and Treatment of Peritonitis Beth Piraino, MD

| PD for Management of CHF John M. Burkart, MD

| 10:00am–10:15am | Break

Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘

FriDay, aPril 4 Continued



10:15am–12:00pm

| Texas D 268 | End-of-LifeIssuesinCKD Chair: Beth Piraino, MD 1.75

| incorporating Palliative Care into the Dialysis unit alvin Moss, MD | CPr vs DNr in the Dialysis unit Jean l. Holley, MD

| Withholding and Withdrawing Dialysis Mi-Kyung Song, PhD, rN

12:00pm–1:15pm

| exhibit Hall | LunchintheExhibitHall–VisitPosters/Exhibits

| austin 1/2/3 231 | Workshop:ImpactofSurveillanceon ˘ Co-Chairs: Charmine lok, MD 1.25

AVGraftOutcomes and Michael allon, MD

| Debate:AccessSurveillanceImproves

GraftOutcomes

yes! anatole Besarab, MD

No! Jack Work, MD

12:00pm–1:15pm

| austin 4/5/6 232 | Workshop:ManagementofHyperphosphatemia ˘ Chair: Stuart M. Sprague, DO 1.25

UsingCalciumvs.Non-CalciumBasedBinders

| Non-Calcium Binders Wadi N. Suki, MD

| Calcium Binders Wajeh Qunibi, MD

1:15pm–3:15pm

| Texas C 269 | HomeDialysisforthe21stCentury Chair: Beth Piraino, MD 2.0

| innovative approaches to Dialysis Modalities robert S. lockridge, Jr., MD

| assessing adequacy across Dialysis Modalities/ Joanne M. Bargman, MD, FrCP

Timing of Home Dialysis Modalities

| Debate:IsConventionalDialysisOutdated?

HD3xweeklyvs.DailyHD

Pro Michael rocco, MD, MSCe

Con Thomas Depner, MD

| Texas D 270 | ObesityandCKD Chair: Srinivasan Beddhu, MD 2.0

| late-Breaking Controlled Trials: Sulodexide vs. Placebo

for Treatment of Diabetic Nephropathy edmund J. lewis, MD

| interactions Between Obesity and inflammation in CKD Srinivasan Beddhu, MD

| Debate:IsObesityGoodorBadinCKDPatients?

Obesity is “good” Csaba Kovesdy, MD, FaSN

Obesity is “Bad” allon Friedman, MD

| 3:15pm–3:30pm | Break

Joint with Councils

¯


·


equired˘




3:30pm–5:30pm

| Texas D 271 | FluidandElectrolytes Chair: Miguel vazquez, MD 2.0

| update on Management of Hyperkalemia Daniel Batlle, MD

| update of Hypophosphatemia Zalman S. agus, MD

| update on Hyponatremia Therapy Tomas Berl, MD

| update on Metabolic alkalosis l. lee Hamm, MD

| Texas B 285 | InternationalandNationalGuidelineActivities:2008 Co-Chairs: garabed eknoyan, MD 2.0

and Michael rocco, MD, MSCe

| KDigO: Opening remarks and guideline update: garabed eknoyan, MD

Hepatitis C in CKD; Care of the Transplant Patient

| an Overview of the KDigO CKD-MBD guidelines Sharon Moe, MD, and

Tilman Drüeke, MD

| KDOQi 2008 and Beyond Michael rocco, MD, MSCe

| KDOQi Clinical Practice guidelines for Nutrition in Bradley Warady, MD, and

| Children with CKD: 2008 update Donna Secker, PhD

5:30pm–7:00pm

| exhibit Hall | NetworkingReceptionintheExhibitHall–VisitPosters/Exhibits

7:00pm–9:00pm

| grapevine D 811 | CardiovascularDiseaseinCKDPatients Chair: Mark J. Sarnak, MD 1.5

Pre-DialysisandOnDialysis


| Sudden Cardiac Death in Pre-Dialysis CKD Charles Herzog, MD

Patients and in Patients undergoing Dialysis

| Calcium and Phosphorus as Cardiovascular David Bushinsky, MD

risk Factors

| Coronary artery Disease: Screening and Therapy Mark J. Sarnak, MD

| grapevine C 812 | OptimalPatientOutcomes:IdentificationandTreatment Chair: anatole Besarab, MD 1.5

ofIronDeficiencyAnemiainEarlyCKD


AMAG Pharmaceuticals, Inc.

| Prevalence and Diagnosis of anemia in Patients with CKD allen r. Nissenson, MD

| State of the art in Treatment of iron Deficiency anemia: ajay K. Singh, MB, MrCP Current and Future Directions

| Case review and Panel Discussion anatole Besarab, MD

PHySiCiaN PrOgraM

Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘


SaTurDay, aPril 5 time/location session # session notes faculty credits

6:00am–8:00am

| grapevine D 814 | ExploringtheLinkBetweenChronicKidney Chair: Tammy Ho, MD 1.5 DiseaseandCardiovascularDisease:

ReducingMortality


| Welcome and introductions Tammy Ho, MD

| exploring the association Between Cardiovascular Tammy Ho, MD

Disease and Chronic Kidney Disease

| Mechanisms that Contribute to altered ravi Thadhani, MD

Cardiovascular regulation in Chronic

Kidney Disease

| Management Strategies for reducing Kamyar Kalantar-Zadeh, MD

Cardiovascular risk Factors in Chronic

Kidney Disease


| grapevine C 813 | ChronicKidneyDiseaseInterventions: Chair: Peter McCullough, MD 1.5 ImprovingCKDandCVDOutcomes

A Breakfast Symposium

| KeeP Overview and Social Conceptions of allan J. Collins, MD

Kidney Disease: Myths vs. realities

| glycemic Control in Kidney Disease Samy McFarlane, MD

| interventions and CvD interactions in Diabetics Peter McCullough, MD

with Proteinuria

| impact of Blood Pressure Control in CKD george Bakris, MD

8:00am–10:00am

| Texas a 273 | HemodialysisCatheters:MinimizingRiskand Co-Chairs: Michele Mokrzycki, MD 2.0

MaximizingOutcomes and Charmaine lok, MD

| Prevention of HD Catheter infections Charmaine lok, MD

| individualized Management of HD Catheter- Michael allon, MD

related Bacteremia

| Treatment and Prevention of HD Michele Mokrzycki, MD

Catheter Thrombosis

| Texas B 274 | NutritionandInflammationinCKD Co-Chairs: Srinivasan Beddhu, MD 2.0

and Kamyar Kalantar-Zadeh, MD

| inflammation and Wasting Syndromes ravi Thadhani, MD

| is Malnutrition a Misnomer in Dialysis Patients? Srinivasan Beddhu, MD

| insulin resistance and Muscle Wasting in CKD edward Siew, MD

Joint with Councils

¯


·


equired˘


Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘

SaTurDay, aPril 5 Continued


| 10:00am–12:00pm | BrunchServedinExhibitHall–VisitPosters/Exhibits

| 10:00am–10:15am | Break

10:15am–12:00pm

| Texas D 275 | UpdateonPrimaryGlomerularDisease Co-Chairs: Michael J. Choi, MD 1.75

and gerald appel, MD

| Focal Segmental glomerulosclerosis Stephen M. Korbet, MD

| Membranous Nephropathy Jai radhakrishnan, MD

| iga Nephropathy gerald appel, MD

| Texas C 276 | PharmacyandCKD Co-Chairs: Maria Taylor, PharmD 1.75

and Kurt Wargo, PharmD

| Drug Dosing in CKD: Which gFr equations to use Kurt Wargo, PharmD

| Prescribing Cardiovascular Medications in alfred Cheung, MD

Dialysis Patients

| Pharmacist role in the Management of CKD anne liles, PharmD

12:00pm–1:15pm

| austin 1/2/3 233 | Workshop:VolumeOverloadintheDialysisPatient ˘ Chair: Joel glickman, MD 1.25

| enhancing Dietary adherence to Sodium restriction Mary ann Sevick, rN, ScD

| use of Diuretics in Patients on Dialysis Filitsa H. Bender, MD

| austin 4/5/6 234 | Workshop:HemoglobinTargetsforAnemia ˘ Chair: Jeffrey S. Berns, MD 1.25

ManagementinCKD

| Debate:ShouldWeTargetHemoglobin

Levels>12inCKD

Hemoglobin > 12 g/dl is good! Kamyar Kalantar-Zadeh, MD

Hemoglobin > 12 g/dl is Bad! lynda Szczech, MD, MCSe, FaSN

1:15pm–3:15pm

| Texas D 277 | WhyisHomeDialysisUnder-UtilizedintheU.S.? Chair: Fredric Finkelstein, MD 2.0

| National Disparities in PD Salim Mujais, MD

| Factors affecting Dialysis Modality Choice in the u.S. rajnish Mehrotra, MD, FaCP, FaSN

| approaches to increasing utilization of PD in the u.S. Fredric Finkelstein, MD

| Texas a 278 | LupusNephritis:ControversiesandConsensus Co-Chairs: Julia B. lewis, MD 2.0

and Michael J. Choi, MD

| Debate:InductionTherapyofLupusNephritis

use Cyclophosphamide edmund J. lewis, MD

use Mycophenolate gerald appel, MD

| Debate:MaintenanceTherapyofLupusNephritis

use Cyclophosphamide edmund J. lewis, MD

use Mycophernolate gerald appel, MD

| NewTherapiesforLupusNephritis Mary anne Dooley, MD, MPH

|3:15pm–3:30pm | Break

PHySiCiaN PrOgraM

Joint with Councils

¯


·


equired˘




3:30pm–5:30pm

| Texas C 279 | SymptomsinCKDPatients Chair: Maria Taylor, PharmD 2.0

| Complaints of Dialysis Patients Steven Weisbord, MD

| Sleep Disorders in Dialysis Patients Mark unruh, MD, MSc

| Pain Management in Dialysis Patients Maria Taylor, PharmD

| Depression in Dialysis Patients Fredric Finkelstein, MD

| Texas a 280 | ESRDQualityImprovement Chair: William McClellan, MD 2.0

| The eSrD Program: History of Quality William McClellan, MD

improvement Data

| Pay for Performance: What lies ahead? alan S. Kliger, MD

| Debate:PayforPerformance:

WillitImprovePatientOutcomes?

Pro Jonathan Himmelfarb, MD

Con John C. Stivelman, MD

| Texas D 490 | “DecreasetheIncrease”:AModelofPreventative ¯ glen H. Stanbaugh, MD 2.0

Medicineinthe21stCentury;Delayingthe anton C. Schoolwerth, MD, FaHa

ProgressionofCKDtoESRD eduardo Sanchez, MD, MPH

robert Duncan, MPH

5:30pm–7:00pm

| grapevine B 101 | FellowsEvent:CareerChoicesinNephrology/ Co-Chairs: Milagros D. Samaniego, MD

FacultyReception(ByInvitationOnly) and Sharon Moe, MD


Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘

PHySiCiaN PrOgraM

SuNDay, aPril 6 time/location session # session notes faculty credits

8:00am–10:00am

| grapevine D 281 | SecondaryNephroticSyndrome Co-Chairs: Michael J. Choi, MD 2.0

and gerald appel, MD

| light Chain-related glomerular Disease laura Dember, MD

| Debate:HIVAssociatedNephropathy:

IsBiopsyNeededforDiagnosis

Biopsy is Not required lynda Szczech, MD

Biopsy is required Paul Kimmel, MD

| Thrombotic Microangiopathy Michael J. Choi, MD

| grapevine a 282 | CaringfortheDialysisPatient Chair: Miguel vazquez, MD 2.0

| Treatment of Blood Pressure in Dialysis Patients John Burkart, MD

| Management of intradialytic Hypotension Thomas Depner, MD

| Primary Care of the Dialysis Patient Suzanne Bergman, MD

| Screening for Malignancy in the Dialysis Patient Jean l. Holley, MD

| 10:00am–10:15am | Break

10:15am–12:15pm

| grapevine D 283 | ANCAVasculitis:TreatmentsandOutcomes Co-Chairs: Julia B. lewis, MD 2.0

and Kirsten de groot, MD

| induction Therapy in aNCa vasculitis Kirsten de groot, MD

| Maintenance Therapy in aNCa vasculitis loic guillevin, MD

| Controversial issues in Small vessel David Hellmann, MD

vaculitis: a rheumatologist view

| Panel Discussion all Faculty

|12:15pm | MeetingAdjourns


Program CommitteeLaurieE.Benton,RN,PA-C,BS,MPAS Program Co-Chair

Scott and White Hospital, Temple, Tx

BarbaraWeisMalone,BSN,RN,CFNP Program Co-Chair

university of Colorado Health ScienceCenter, aurora, CO

DeborahGlidden,ARNP,BC,CNN Nephrology associates of Central Florida, Orlando, Fl

TriciaHoward,MHS,PA-CSouth university, Savannah, ga

Host CommitteeCheriGoldstein,PA-CDallas Nephrology associates, Dallas, Tx

TamiHyziewiczCase,PA-CScott and White Hospital, Temple, Tx

Program GoalTo improve patient outcomes by enhancing the advanced practitioners’ knowledge base and skills that affect the kidney and clinical practice.

Continuing Education InformationaaPa accepts Category i credit from aOaC-CMe, prescribed credit from aaFP, and aMa Category i CMe credit for the Pra from orga-nizations accredited by aCCMe.

This program is pending approval with the american academy of Nurse Practitioners.

The National Kidney Foundation is accredited by the accreditation Council for Continuing Medical education to provide continuing medi-cal education for physicians. The National Kidney Foundation designates this educational activity for a maximum of 32.0AMA PRA

category 1 creditsTM. Physicians should claim credit commensurate with the extent of their participation in the activity.

aDvaNCeD PraCTiTiONer PrOgraM

Join us on Friday, april 4, 20083:30 pM – 5:30 pM

Join us for a special session...

2008 international andnational Guideline activities:

• KDIGO Update Hepatitis C and Transplant Guidelines

• KDIGO Preview of KDIGO CKD-MBD Guidelines

• KDOQI 2008 and Beyond

• KDOQI Clinical Practice Guidelines for Nutrition in Children with CKD 2008 Update

rooM texas c ©20

08 N

atio

nal K

idne

y Fo

unda

tion,

Inc.

All

right

s re

serv

ed.

02-7

7-43

5A

time/faculty

7:30am–8:00am

8:00am–8:15am Laurie E. Benton, RN, PA-C,

BS, MPAS

8:15 am–9:45am Michael J. Choi, MD

9:45am–10:00am 10:00am–11:00am Mohanram Narayanan,

MD, FASN

11:00am–12:00pm Kathleen Brady, MS, BC-ANP

12:00pm–1:00pm

1:00pm–2:00pm Tricia Howard, MHS, PA-C

2:00pm–3:00pm Deborah Gidden ARNP,

BC, CNN

3:00pm–3:15pm

3:15pm–4:15pm Charles J. Foulks, MD

4:15pm–5:15pm Paul Szcybor, PA-C

5:15pm–5:30pm


Session620Wednesday,April12,7:30am–5:30pmCourseDirector:LaurieE.Benton,RN,PA-C,BS,MPAS

Course Description: This course is designed to take you from the anatomy and physiology of the kidney through the clinical challenges specific to the treatment of the different stages of kidney disease and co-morbidities. lectures and topics are presented by physicians and advanced practitioners specializing in the field of nephrology. The con-tent is selected to help you understand, diagnose and treat the basic, to the most complex, nephrology patients. Whether you are a begin-ning or seasoned practitioner, it provides an outstanding opportunity to learn through case studies relevant to your everyday clinical practice.

Target Audience: This course is designed for physician assistants and nurse practitioners.




aDvaNCeD PraCTiTiONer Pre-CONFereNCe COurSeS


topic

Continental Breakfast

Welcome and introductions

Nephrotic vs. Nephritic Syndrome

Break

Transplant Medications (all types)

CKD Start to Finish

lunch

Diagnostic Dilemmas in Dialysis, Part 1

Diagnostic Dilemmas in Dialysis, Part 2

Break

Nephrology Case Presentations

acute renal Failure

Closing remarks/adjourn


TransplantationTrendsinthe21stCentury

Session220Wednesday,April2,8:00am–3:45pm

See page 42 for course details.











WeDNeSDay, aPril 2 time/location session # session notes Course Director(s) credits

7:30am–5:30pm

| Texas 5 620 | Nephrology201forAdvancedPractitioners ˘ laurie e. Benton, Pa-C, 7.5

rN, BS, MPaS

| Texas C 221 | IntegratedHemodialysis/Peritoneal ˘· Joanne M. Bargman, MD, FrCPC 9.0

DialysisCourse

8:00am–3:45pm

| Texas D 220 | TransplantationTrendsinthe21stCentury ˘· Milagros D. Samaniego, MD 5.25

Dianne McKay, MD

8:00am–5:00pm

| Texas 1/2 223 | DialysisUnitManagementCourse ˘· Peter B. DeOreo, MD, FaCP 7.5

Joint with Councils

¯


·


equired˘

WeDNeSDay, aPril 2 Continued



7:30pm–9:30pm

| grapevine D 801 | AssociationofMineralMetabolism,VitaminD · Chair: Myles Wolf, MD, MMSc 1.5






Patient Survival



Patient Survival?



6:00am–8:00am

| grapevine C 802 | TheImpactofGlycemisControlinPatients · Chair: Martin J. abrahamson, MD 1.5



Novo Nordisk







| grapevine D 803 | TrendsandChallengesinCKDProgression · Chair: ann O’Hare, MD 1.5



Ortho Biotech, L.P.


Older adults


in the elderly





Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘




8:30am–10:00am

| austin 4/5 630 | WORKSHOP:MicroscopyofUrinalysisSlides ˘ Peter Juergensen, Pa-C 1.5

10:00am–11:00am

| austin 4/5 660 | TheRenalTransplantEvaluation alexander Wiseman, MD 1.0

10:00am–11:00am

| grapevine 5/6 675 | NKFandStudents:ANewModelforKEEP Cynthia lord, MHS, Pa-C 1.0

11:00am–12:00pm

| austin 4/5 661 | DermDilemmasinNephrology elizabeth adams, Pa, MS 1.0

|12:00pm–2:00pm | CAPNetworkingLuncheon(Allarewelcome!)

appaloosa 4

12:00pm–2:00pm

| grapevine C 804 | DietaryPhosphorusandOutcomesin · Chair: Stuart Sprague, DO 1.5

PatientswithCKD







2:00pm–3:00pm

| Texas a/B 264 | NKFPresidentialAddress– allan J. Collins, MD, FaCP 1.0

The National Kidney Foundation: advancing Public

Health in the u.S. and around the World

| ShaulMassryDistinguishedLecture– Tom greene, PhD

randomized and Observational Studies in

Nephrology: How Strong is the evidence? ·

3:00pm–4:00pm

| Texas 5/6 662 | HypertensionandtheGeriatricPatient ¯ Charles J. Foulks, MD 1.0

4:00pm–5:00pm

| Texas 4 363 | SleepDisordersandRestlessLegs ¯ Kimberly english, rN, FNP 1.0

6:00pm–7:30pm

|exhibit Hall | OpeningCeremoniesintheExhibitHall–VisitPosters/Exhibits

Joint with Councils

¯


·


equired˘


Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘




7:30pm–9:30pm

| grapevine C 815 | AnEvidence-BasedReviewofthe · Chair: vincent Dennis, MD 1.5 ManagementofHyperphosphatemiaandIts PharmacoeconomicImpactonPatientswith Stage5CKD:NewPerspectivesforOptimal

Outcomesin2008









6:00am–8:00am

| grapevine D 809 | AssessingtheRoleofProteinuriainthe · 1.5






Targets for Therapy



| grapevine C 810 | NewDOPPSFindingsonOptimizingPractices

fortheHemodialysisTeam–AMulti-Discipline

PanelDiscussion



| Has Catheter use increased Due to Fistula First? lawrence Spergel, MD, FaCS

No! Case Discussion


Case Discussion

|7:00am–8:00am | ContinentalBreakfastinExhibitHall–VisitPosters/Exhibits

8:00am–9:00am

| Texas 5/6 664 | UnderstandingandReadingtheRenalUltrasound David DeWalch, MSPa, Pa-C, MS, Ma 1.0

Joint with Councils

¯


·


equired˘




9:00am–10:00am

| Texas 5/6 665 | CholesterolChallengesinCKD robert Page, PharmD, FCCP, 1.0

FaHa, BCPS

|10:00am–10:15am | Break

10:15am–12:00pm

| Texas D 268 | End-of-LifeIssuesinCKD · Chair: Beth Piraino, MD 1.75

| incorporating Palliative Care into the Dialysis unit alvin Moss, MD

| CPr vs. DNr in the Dialysis unit Jean l. Holley, MD


|12:00pm–1:15pm | LunchintheExhibitHall–VisitPosters/Exhibits

12:00pm–1:15pm

| San antonio 1/2/3 631 | Workshop:Chair-SideHemodialysisEvaluation ˘ arif asif, MD 1.25

1:15pm–2:15pm

| Texas 5/6 666 | PediatricRenalDiseases ronald Hogg, MB, ChB 1.0

2:15pm–3:15pm

| Texas 5/6 667 | SurvivingMalpractice:APracticalApproach Kristen larson, rN, aNP, gNP, CNN 1.0

and lisa Zokas Kindy, JD

|3:15pm–3:30pm | Break

3:30pm–4:30pm

| Texas 5/6 668 | Over-the-CounterMedicationComplications Johann Herberth, MD, FaCP, FaSN 1.0

3:30pm–5:30pm

| Texas B 285 | InternationalandNationalGuidelineActivities:2008 · Co-Chairs: garabed eknoyan, MD 2.0





Tilman Drüeke, MD




5:30pm–7:30pm

|exhibit Hall | NetworkingReceptionintheExhibitHall–VisitPosters/Exhibits

7:00pm–9:00pm

| grapevine D 811 | CardiovascularDiseaseinCKDPatients · Chair: Mark J. Sarnak, MD 1.5






risk Factors



Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘




7:00pm–9:00pm

| grapevine C 812 | OptimalPatientOutcomes:IdentificationandTreatment · Chair: anatole Besarab, MD 1.5





| State of the art in Treatment of iron Deficiency anemia: ajay K. Singh, MB, MrCP

Current and Future Directions



6:00am–8:00am

| grapevine C 813 | ChronicKidneyDiseaseInterventions: Chair: Peter McCullough, MD 1.5

ImprovingCKDandCVDOutcomes






with Proteinuria


| grapevine D 814 | ExploringtheLinkBetweenChronicKidneyDisease Chair: Tammy Ho, MD 1.5

andCardiovascularDisease:ReducingMortality







Kidney Disease

| Management Strategies for reducing Cardiovascular Kamyar Kalantar-Zadeh, MD

risk Factors in Chronic Kidney Disease


Joint with Councils

¯


·


equired˘




8:00am–9:00am

| Texas 5/6 669 | LupusNephritisUpdates:FromBenchtoBedside Harvey a. Feldman, MD, FaCP 1.0

9:00am–10:00am

| Texas 5/6 670 | MakingCKDPartofPrimaryCare andrew S. Narva, MD, FaCP 1.0

|10:00am–10:15am | Break

|10:00am–12:00pm | BrunchServedinExhibitHall–VisitPosters/Exhibits

10:15am–11:15am

| Texas 5/6 671 | ClinicalTrials:TheMoneyAngle Kim Zuber, PaC, MSPS 1.0

1:15pm–2:15pm

| Texas 5/6 672 | AppropriateTreatmentsfortheDiabeticPatient:PartI Miriam Michael, MD 1.0

2:15pm–3:15pm

| Texas 5/6 673 | AppropriateTreatmentsfortheDiabeticPatient:PartII Joseph vande griend, PharmD 1.0

6:00pm–7:00pm

| grapevine a 100 | AlliedHealthNetworkingReception ¯


8:00am–10:00am

| grapevine a 282 | CaringfortheDialysisPatient · Chair: Miguel vazquez, MD 2.0



| Primary Care of the Dialysis Patient Suzanne Bergman, MD


10:15am–12:15pm

| grapevine D 283 | ANCAVasculitis:TreatmentsandOutcomes · Co-Chairs: Julia B. lewis, MD 2.0

and Kirsten de groot, MD

| induction Therapy in aNCa vasculitis Kirsten de groot, MD

| Maintenance Therapy in aNCa vasculitis loic guillevin, MD

| Controversial issues in Small vessel David Hellmann, MD

vaculitis: a rheumatologist view

| Panel Discussion all Faculty


Program CommitteeCarolynAtkins,RN,BS,CCTCProgram Chair

Children’s Medical Center Dallas, Dallas, Tx

BobbieKnotek,RN,BSN,CNNProgram Co-Chair

eSrD Network of Texas, inc., Dallas, Tx

ElaineGo,RN,NPSt. Joseph Hospital, laguna Niguel, Ca

ElizabethHenry,RN,CNNScott and White Hospital, Temple, Tx

MarianneNeumann,RN,CNNalbany Dialysis Center, albany, Ny

BeverlySneed,RN,BSNContinuing Education Chair

abbott renal Care, grand Prairie, Tx

Host CommitteeGayGrauke,BAeSrD Network of Texas, inc., Dallas, Tx

GlendaHarbert,RN,CNN,CPHQeSrD Network of Texas, inc., Dallas, Tx

SandraHinton,RN,BSNMedical City Dallas Hospital, Dallas, Tx

NancyNardelli,RN,CCRCMedical City Dallas Hospital, Duncanville, Tx

Program GoalThe goal of this program is to improve patient outcomes by enhancing the kidney health care professional’s knowledge base and skills which affect the kidney and clinical practice.

Continuing Education InformationThe National Kidney Foundation is an approved provider of continuing nursing education by the New york State Nurses association, which is accredited as an approver of continuing nursing education by the american Nurses Credential-ing Center’s Commission on accredition.

it has been assigned code 6exQ7J-Prv-06.

This educational activity has been approved for 38.5 contact hours.

NePHrOlOgy NurSe aND TeCHNiCiaN PrOgraM


ChronicKidneyDisease(CKD)101

Wednesday,April2,20087:30am–4:30pmCourseDirector:MarianneNeumann,RN,CNNSession320

Course Description: The one-day intensive course discusses the five stages of CKD: presentation, evaluation, complications and treat-ments. upon completion of this course, participants will be able to de-scribe normal renal anatomy and physiology, list the major causes of kidney disease in the adult population, and outline treatment choices for patients with CKD who require renal replacement therapies.

Target Audience: Nurses and technicians who are new to the field of nephrology or who wish to refresh their knowledge.

Pre-conference courses require a separate registration fee of $100.

Light breakfast, box lunch, and course syllabus included.

Participation is limited.

NePHrOlOgy NurSe aND TeCHNiCiaN PrOgraM Pre-CONFereNCe COurSeS aND exaMS

time/faculty

7:30am–8:00am

8:00am–8:30am Sheldon C. Chaffer, MD



10:00am–10:15am


11:00am–12:00pm Sheldon C. Chaffer, MD

12:00pm–1:00pm

1:00pm–1:45pm Marianne Neumann, RN, CNN

1:45pm–2:30pm Bonnie Conrad, RN, CDN

2:30pm–2:45pm

2:45pm–3:30pm Gail Sansivero, RN, MS, ANP

3:30pm–4:15pm Jean Colaneri, MS, ACNP

4:15pm–4:30pm

topic

registration and Continental Breakfast review of Normal renal anatomy and Physiology

CKD Stage 1

CKD Stage 2

Break

CKD Stage 3

CKD Stage 4 and introduction to Stage 5

lunch Break

Hemodialysis

Peritoneal Dialysis

Break

vascular access

introduction to Transplant

Questions and adjourn



Session620Wednesday,7:30am–5:30pm



TransplantCourse:TransplantationTrendsinthe21stCentury








NePHrOlOgy NurSe aND TeCHNiCiaN PrOgraM Pre-CONFereNCe COurSeS aND exaMS Continued





NNCOCertificationExams

Session300Sunday,April6,8:30am–12:30pm

The National Nephrology Certification Organization (NNCO) endorses the concept of voluntary, periodic certification by examination for all individuals in the field of nephrology technology. Certification is one part of a process called credentialing. it focuses specifically on the individual and is an indication of current competence in a specialized area of practice. Certification in nephrology technology is highly valued and provides formal recognition in the profession of nephrology tech-nology. The NNCO examinations in Clinical Nephrology Technology and Biomedical Nephrology Technology are written examinations com-posed of a maximum of 200 multiple-choice objective questions with a total testing time of four (4) hours each. Certification in Nephrology Technology is recognized for a period of four years at which time the candidate must retake and pass the current Certification examination in Clinical Nephrology Technology or Biomedical Nephrology Tech-nology or meet such alternative requirements as are in effect at that time in order to retain certification. eligible candidates who pass this examination are eligible to use the registered designation CBNT after their names and will receive certificates from the NNCO.


WeDNeSDay, aPril 2 time/location session # session notes course director(s) credits

7:30am–4:30pm

| Ft. Worth 4/5/6 320 | CKD101 ˘ Marianne Neumann, rN, CNN 6.75

7:30am–5:30pm

| Texas 5 620 | Nephrology201forAdvancedPractitioners ¯˘ laurie e. Benton, rN, Pa-C, BS, MPaS 7.5

8:00am–3:45pm

| Texas D 220 | Transplantation ·˘ Milagros D. Samaniego, MD 5.25

Trendsinthe21stCentury Dianne McKay, MD

7:30am–5:30pm

| Texas C 221 | IntegratedHemodialysis/Peritoneal ·˘ Joanne M. Bargman, MD, FrCPC 9.0

DialysisCourse

8:00am–5:00pm

| Texas 1/2 223 | DialysisUnitManagementCourse ·˘ Peter B. DeOreo, MD, FaCP 7.5

7:30pm–9:30pm







Patient Survival



Patient Survival?



Joint with Councils

¯


·


equired˘



6:00am–8:00am




Ortho Biotech, L.P.


Older adults


in the elderly




8:00am–9:45am

| grapevine 1/2 560 | MulticulturalApproachestoHealthCare ¯ Kirk Hughes, MD 1.75

| Texas 1/2 272 | ControversiesinTransplantation · Co-Chairs: alan Wilkinson, MD 1.75

and r. Michael Hofmann, MD

| re-Transplantation: Patient Selection and Panduranga S. rao, MD, DNB, MS

Management of Candidates on Dialysis

| Kidney Transplantation for Other Solid-Organ Thomas a. gonwa, MD, FaCP, FaSN

recipients: a Nephrologist’s Point of view

| Transplantation of the elderly alan Wilkinson, MD

From CKD to Transplantation:

| Management of the Pregnant Patient Dianne McKay, MD

10:00am–12:00pm

| Texas D 263 | ImprovingVascularAccessOutcomes · Co-Chairs: ivan D. Maya, MD 2.0

and Charmaine lok, MD

| Salvage of early Fistula Failure antoine Samaha, MD

| Pharmacologic Strategies to Delay access Stenosis Prabir roy-Chaudhury, MD

| Debate:FistulaFirst–IsItRightforEveryone?

yes arif asif, MD

No Thomas vesely, MD, FSir


Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘




10:00am–11:00am

| Texas 1/2 360 | NewRegulations:WorkingTogethertoLessenthe Carolyn atkins, rN, BS, CCTC 1.0

ImpactontheYoungAdult

11:00am–12:15pm

| Texas 1/2 376 | WhattheDialysisNurseNeedstoKnowAboutthe Barbara Weis Malone, BSN, rN, CFNP 1.25

NewTransplantConditionsofParticipation Kay Hall, BSN, rN, CNN

12:30pm–2:00pm

| grapevine B 362 | CNNTNetworkingLuncheonandResearchPresentation: Donna Calvin, aPrN, BC-FNP, CNN 0.5

AfricanAmericansPerceptionofRiskfor

DiabetesComplications

2:00pm–3:00pm




| ShaulMassryDistinguishedLecture– Tom greene, PhD



3:00pm–4:00pm

| Texas 5/6 662 | HypertensionandtheGeriatricPatient ¯ Charles J. Foulks, MD 1.0

3:00pm–5:00pm

| Texas 1/2 366 | TheWhat,Where,andWhyofData: Jan Deane, rN, CNN 2.0

HowItImpactsWhatWeDo

4:00pm–5:00pm

| Texas 4 363 | RestlessLegSyndromeandObstructive

SleepApneainNephrologyPatients · Kimberly english, rN, FNP 1.0

6:00pm–7:30pm

| | ExhibitHallOpeningCeremonies–VisitPosters/Exhibits

Joint with Councils

¯


·


equired˘




6:00am–8:00am







Targets for Therapy



| grapevine C 810 | NewDOPPSFindingsonOptimizingPractices fortheHemodialysisTeam–AMulti-Discipline PanelDiscussion



| Has Catheter use increased Due to Fistula First? lawrence Spergel, MD, FaCS No! Case Discussion


Case Discussion

| 7:00am–8:00am | ContinentalBreakfastintheExhibitHall–VisitPosters/Exhibits

8:00am–11:15am

| grapevine 6 364 | OnCoursewithCannulation lynda Ball, BSN, CNN, rN 3.25

8:00am–9:00am

| Texas 3 369 | TheFateofDialysisCatheters lesley Dinwiddie, MSN, 1.0

rN, FNP, CNN

| Texas 1/2 365 | HowtoSatisfyMedicare:HelpfulHintsonHowto Jackie Crouch 1.0

HaveFewerDeficienciesintheWaterTreatmentArea

9:00am–10:00am

| Texas 1/2 361 | ImprovingImmunizations:TheSafeandTimely Jan Deane, rN, CNN 1.0

ImmunizationCoalition

10:15am–12:00pm





10:15am–12:15pm

| Texas 4 489 | PediatricsandTransplant ¯ Bruce Morgenstern, MD 2.0

Sandra Coorough, aCSW, lCSW

Janelle e. gonyea, rD, lD

Mary Murphy, rN, CTTC

Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘




| 12:15pm–1:15pm | LunchintheExhibitHall–VisitPosters/Exhibits

1:15pm–3:15pm

| Texas C 269 | HomeDialysisforthe21stCentury · Chair: Beth Piraino, MD 2.0

| innovative approaches to Dialysis Modalities robert S. lockridge, Jr., MD

assessing adequacy across Dialysis Modalities

| Timing of Home Dialysis Modalities Joanne M. Bargman, MD, FrCP

| Debate:IsConventionalDialysisOutdated?

HD3xweeklyvs DailyHD

Pro Michael rocco, MD, MSCe

Con Thomas Depner, MD

1:15pm–2:15pm

| Texas 3 368 | UsingResearchtoFacilitateSelf-Care Cleo J. richard, rN, PhD 1.0

2:15pm–3:15pm

| Texas 1/2 367 | EmergingInfectiousDiseases: Pat Preston, MS 1.0

ImpactontheHealthCareWorker

3:30pm–5:30pm

| Texas 1/2 375 | Bio-Terrorism:WhatHealthcare Jeffrey C. Metzger, MD 2.0

ProfessionalsNeedtoKnow






Tilman Drüeke, MD



Children with CKD: 2008 update Donna Secker, PhD

5:30pm–7:00pm

| | NetworkingReceptionintheExhibitHall–VisitPosters/Exhibits

7:00pm–9:00pm







risk Factors


Joint with Councils

¯


·


equired˘




6:00am–8:00am

| grapevine C 813 | ChronicKidneyDiseaseInterventions: · Chair: Peter McCullough, MD 1.5 ImprovingCKDandCVDOutcomes






with Proteinuria


8:00am–9:00am

| Texas 1/2 370 | TriagingDisaster:LessonsLearned ira Nemeth, MD 1.0

9:00am–10:00am

| Texas 1/2 371 | Earthquakes,Tornados,Floods,OhMy! Jim Curtis, CHT, CNCT 1.0

DevelopingPoliciesforAnyPossibleDisaster lisa Hall, MSSW, lCSW

9:00am–12:15pm

| grapevine 6 372 | OnCoursewithCannulation lynda K. Ball, BSN, CNN 3.25

|10:00am–12:00pm | BrunchServedinExhibitHall–VisitPosters/Exhibits

10:15am–11:15am

| Texas 4 485 | TransplantTourism ¯ Michael Talamantes, lCSW, MSSW 1.25

10:15am–12:15pm

| Texas 1/2 374 | WhyAdvanceDirectivesRequirePhysicianOrders ronald Miller, MD 2.0

forImplementation

12:15pm–1:15pm

| | LunchBreak

1:15pm–3:15pm

| Texas B 488 | TheCMSTransitiontoNewESRDRegulations ¯ Judith Kari 2.0

3:30pm–5:30pm

| Texas a 280 | ESRDQualityImprovement · Chair: William McClellan, MD 2.0

| The eSrD Program: History of Quality William McClellan, MD

improvement Data

| Pay for Performance: What lies ahead? alan S. Kliger, MD

| Debate:PayforPerformance:

WillitImprovePatientOutcomes?

Pro Jonathan Himmelfarb, MD

Con John C. Stivelman, MD

Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘




3:30pm–4:30pm

| Texas 1/2 373 | Truths,MythsandMistakesintheDialysisProcedure Danilo B. Concepcion, CCHT, CHT 1.0

4:30pm–5:30pm

| Texas B 377 | LearningFromandListeningtoTheirBodies: Cleo J. richard, rN, PhD 1.0

ClientsExperiencesDuringHemodialysis 6:00pm–7:00pm

| 100 | AlliedHealthNetworkingReception ¯


8:00am–10:00am

| grapevine a 282 | CaringfortheDialysisPatient · Chair: Miguel vazquez, MD 2.0



| Primary Care of the Dialysis Patient Suzanne Bergman,MD


8:30am–12:30pm

| appaloosa 2 300 | NNCOCertificationExam ˘

11:15am–12:15pm

| grapevine B 590 | CKDandDiabetesManagement: ¯ Debbie Hinnen, arNP, 1.0

ClinicalPearlsandPatientTeachingStrategies BC-aDM, CDe

|12:15pm | Adjourn

Joint with Councils

¯


·


equired˘

Program CommitteePamelaS.Kent,MS,RD,CSR,LDProgram Chair

genzyme renal, vermilion, OH

MarianneHutton,RD,CDEProgram Co-Chair

Fresenius Medical Care – North america, Santa rose, Ca

CarolynCochran,RD,LD,MS,CDEDallas Nephrology associates, Dallas, Tx

AimeeJaremowicz,RDDSi – Diversified Specialty institute, Chicago, il

JoniPagenkemper,MS,MA,RD,LMNTCreighton university Medical Center, Omaha, Ne

MandyTrolinger,MS,RDDavita littleton Dialysis, littleton, CO

Host CommitteeValerieBrinkman-Kaplan,MS,RD,LDu.S. renal Care/Tarrant Dialysis Centers Central Fort Worth Fort Worth, Tx

DonnaCavil,RD,LDHaltom, Tx

MaryAnnFuller,RD,LDDavita arlington Dialysis lake Dallas, Tx

MindyGentile,MS,RD,LDNutrePletionTM resources McKinney, Tx

ArfrancesJohnson,LD,RD,MSliberty Dialysis Fort Worth, Tx

NadiyaLakhani,RD,LDFresenius Dallas, Tx

DebbieLindsay,RD,LDMansfield, Tx

MichelleTrahanMS,RD,LDgenzyme renal richardson, Tx

JudyYang,RD,LDuSrC/TDC-PD Clinic Fort Worth, Tx

Continuing Education Information

a total of 48.0 CPe credits have been applied for through the Commission on Dietetic reg-istration of the american Dietetic association.

reNal aND CliNCal DieTiTiaN PrOgraM


reNal aND CliNiCal DieTiTiaN PrOgraM Pre-CONFereNCe COurSeS


StrategiesI:BuildingaFoundation

Wednesday,April2,20087:30am–5:00pmCourseCo-Directors:MaureenMcCarthy,MPH,RD,CSR,LD,andLouiseClement,MS,RD,CSR,LDSession520

Course Description: Technologies of dialysis, nutrition guidelines, and introductions to dialysis adequacy, anemia management and bone disease management will be presented. Case studies will be utilized to illustrate principles. These case studies will also include nutrition diagnostic statements using standardized language, as encouraged by the Standardized language Task Force of the american Dietetic association. Participants will gain a solid foundation to practice as an entry-level nutrition specialist in the dialysis setting or in other settings where treatment of chronic kidney disease, and end-stage kidney disease, are practiced.

Target Audience: This course is designed for dietitians who are new to renal nutrition, as well as for dietitians who work in non-renal settings but wish to strengthen their basic knowledge in this dynamic area.

This course requires a separate registration fee of $100. Light break-

fast, box lunch and course syllabus included. Participation is limited.

time/faculty

10:00am–10:10am

10:10am–10:30am Maureen McCarthy, MPH, RD,

CSR, LD

NutritionGuidelines

10:30am–11:40am Marianne Hutton, RD, CDE

11:40am–12:15pm Karen Wiesen, MS, RD, CSR

12:15pm–1:00pm

1:00pm–2:00pm Cathi Martin, RD, LDN

SpecialIssues

2:00pm–2:35pm Patricia Weber, MS, RD, CDE

2:35pm–2:50pm

2:50pm–4:20pm Jennifer McGuoirk, MS, RD, LDN

4:20pm–4:50pm Kara Abbas, MS, RD, CSR

4:50pm–5:00pm

5:00pm

topic

Break

Subjective global assessment

Hemodialysis

Peritoneal Dialysis

lunch

understanding Biochemical Markers

Diabetes and the Kidneys

Break

Basic Principles of Bone Disease in eSrD

Basic Principles of anemia

Closing remarks/evaluations

adjourn

time/faculty

7:30am


CSR, LD


CSR, LD

8:30am–9:30am Lee Cauble, CHT, LPN

9:30am–10:00am Louise Clement, MS, RD, CSR, LD

topic

Breakfast Welcome and introductions

Physiology of the Kidneys

Technology of Hemodialysis and Peritoneal Dialysis

introductions to the eSrD Popu-lation and Programs: Overview of government and Professional Programs, and Other resources


reNal aND CliNiCal DieTiTiaN PrOgraM Pre-CONFereNCe COurSeS Continued

StrategiesII:ApplyingthePrinciples

Wednesday,April2,20087:15am–5:00pmCourseDirector:JessiePavlinac,MS,RD,CSR,LDSession521

Course Description: Participants will benefit from an in-depth review of cutting-edge topics in renal disease presented in this full-day course. experts will examine advanced concepts in patient care, physical as-sessment, and research for the renal dietitian. Nationally recognized leaders in the field of renal nutrition will present topics.

Target Audience: This course is designed for experienced renal dietitians.



Course Faculty:

Judith Beto, PhD, rD Maureen McCarthy, MPH, rD, CSr, lD

time/faculty

7:15am–7:55am

8:00am–8:10am

8:10am–9:45am

9:45am–10:00am

10:00am–11:30am

11:30am–12:30pm

12:30pm–2:00pm

2:00pm–2:15pm

2:15pm–4:15pm

4:15pm–4:55pm

4:55pm–5:00pm

5:00pm

topic

registration and Continental Breakfast


Nutrition Care Process and Standardized language for Nutrition Diagnosis

Break Nutrition Diagnosis Terminology and interactive Case Studies

lunch

Nutrition intervention Terminology and interactive Case Studies Break

Nutrition Monitoring, evaluation and assessment Terminology and interactive Case Studies

implementing Standardized language in your Organization

Closing remarks/evaluation

adjourn


WeDNeSDay, aPril 2 time/location session # session notes course director(s) credits

7:30am–5:00pm

| austin 1/2/3 520 | StrategiesI:BuildingaFoundation ˘ Maureen McCarthy, 7.5

MPH, rD, CSr, lD

louise Clement, MS, rD, CSr, lD

7:15am–5:00pm

| austin 4/5/6 521 | StrategiesII:ApplyingthePrinciples ˘ Jessie Pavlinac, MS, rD, CSr, lD 7.5

7:30pm–9:30pm







Patient Survival



Patient Survival?



6:00am–8:00am

| grapevine C 802 | TheImpactofGlycemisControlinPatients · Chair: Martin J. abrahamson, MD 1.75



Novo Nordisk








Joint with Councils

¯


·


equired˘






Ortho Biotech, L.P.


Older adults


in the elderly




8:00am–9:45am

| grapevine 1/2 560 | MulticulturalApproachestoHealthCare ¯ Kirk Hughes, PhD 1.5

10:00am–12:00pm

| grapevine 1/2 561 | CreativeStrategiesforPatientCompliance Donna Morton de Souza, MPH, rD 2.0

| grapevine 3/4 562 | TaintingoftheGoldenYears:CKDinthe Julie Barboza, aPrN-BC, MSN, rD 2.0

GeriatricPopulation

12:00pm–2:00pm

| grapevine C 804 | DietaryPhosphorusandOutcomesin · Chair: Stuart Sprague, DO 1.5

PatientswithCKD







12:30pm–2:00pm

| grapevine D 563 | CRNNetworkingLuncheon

2:00am–3:00pm




| ShaulG.MassryDistinguishedLecture– Tom greene, PhD



3:00pm–3:30pm

| grapevine 1/2 564 | JoelD.KoppleAwardPresentation– recipient: alison Steiber, 0.5

Dietitian:PowerhouseBehindthePatients rD, PhD, lD



Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘




3:30pm–4:30pm

| grapevine 3/4 565 | PromotingPatientParticipationintheDialysisSetting Mandy Trolinger, MS, rD 1.0

| grapevine 1/2 566 | What’sUpatNight?NutritionalManagementofthe Mary ellen Brabec, rD, CSr. 1.0

NocturnalHemodialysisPatient lDN, MHS

4:30pm–5:30pm

| grapevine 3/4 588 | BreakingNewsBits:LatestResearch 1.0

| Sevelamer HCl use and Circulating endotoxin Phyllis Sun, MS, rD, lDN

and inflammatory Biomarkers in HD Patients:

a Preliminary report

| Plasma B6 vitamins in HD Subjects Taking louise Clement, MS, rD, CSr, lD

Prescription or Over the Counter renal

Mvi Supplements

4:30pm–5:30pm

| grapevine 5/6 567 | Defining,Recognizing,andAchievingAdequate Faith Tootell, MS, rD, CSr, FaDa 1.0

HDandPDDialysisDosages 6:00pm–7:30pm


7:30pm–9:30pm

| grapevine C 815 | AnEvidence-BasedReviewofthe · Chair: vincent Dennis, MD 1.5 ManagementofHyperphosphatemiaandIts PharmacoeconomicImpactonPatientswith Stage5CKD:NewPerspectivesforOptimal

Outcomesin2008








6:00am–8:00am







Targets for Therapy



Joint with Councils

¯


·


equired˘


6:00am–8:00am



PanelDiscussion




No! Case Discussion


Case Discussion

| 7:00am–8:00am | ContinentalBreakfastintheExhibitHall–VisitPosters/Exhibits

8:00am–10:00am

| grapevine 1/2 568 | MNTandCKD:MakingaDifference Kathy Schiro Harvey, MS, rD, CSr 2.0

Carolyn Cochran, rD, lD, MS, CDe

| grapevine 3/4 569 | CRRT:DosingtheNutritionandBeyond ann Beemer Cotton, MS, rD 2.0

Kim Hodge, rN

10:15am–12:00pm

| grapevine 1/2 570 | MonitoringGrowthinChildrenwithCKD: Meredith Miller, rD, lD 1.5

PuttingDietaryRecommendationstoPractice






1:15pm–3:15pm

| grapevine 1/2 572 | AnIntroductiontotheSpiritandSkills Dana Sturtevant, MS, rD 2.0

ofMotivationalInterviewing

| grapevine 5/6 580 | ExtremeMakeover:Plant-BasedDietsandCKD Joni Pagekemper, MS, Ma, rD, lMNT 2.0

Duane Sunwold

3:30pm–4:30pm

| grapevine 3/4 573 | IgANephropathyandFishOils ronald Hogg, MD 1.0

| grapevine 1/2 574 | ResistanceTraining–GoodfortheBodyand Stephanie Mcintyre, rD 1.0

GoodforPeopleWithKidneyDisease

3:30pm–5:30pm

| Texas D 271 | FluidandElectrolytes · Chair: Miguel vazquez, MD 2.0

| update on Management of Hyperkalemia Daniel Batlle, MD

| update of Hypophosphatemia Zalman S. agus, MD

| update on Hyponatremia Therapy Tomas Berl, MD

| update on Metabolic alkalosis l. lee Hamm, MD



Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘




3:30pm–5:30pm






Tilman Drüeke, MD




4:30pm–5:30pm

| grapevine 1/2 575 | EnteralNutritionChallengesintheCKDPatient Marcia Kalista richards, 1.0

MPH, rD, CNSD, lDN

| grapevine 3/4 589 | BreakingNews:LatestResearch 1.0

| Nutrition Practices of renal Dietitians in Joyce vergili, MS, rD, lDN, CDe

Hemodialysis Centers

| Complementary intradialytic Nutrition Mary B. Sundell, rD, lDN, CCrP

Supplementation in Dialysis Patients

| Does Nutrition Specific Quality of life Questionnaire Haewook Han, PhD, rD, CSr, lDN Measure the impact of Nutrition on the Health related Quality of life in HD Patients?

5:30pm–7:00pm

| | NetworkingReceptionintheExhibitHall–VisitPosters/Exhibits

7:00pm–9:00pm







risk Factors


Joint with Councils

¯


·


equired˘




7:00pm–9:00pm

| grapevine C 812 | OptimalPatientOutcomes:IdentificationandTreatment · Chair: anatole Besarab, MD 1.5





| State of the art in Treatment of iron Deficiency anemia: ajay K. Singh, MB, MrCP

Current and Future Directions



6:00am–8:00am

| grapevine D 814 | ExploringtheLinkBetweenChronicKidney Chair: Tammy Ho, MD 1.5

DiseaseandCardiovascularDisease:

ReducingMortality







Kidney Disease

| Management Strategies for reducing Kamyar Kalantar-Zadeh, MD

Cardiovascular risk Factors in Chronic

Kidney Disease


| grapevine C 813 | ChronicKidneyDiseaseInterventions: Chair: Peter McCullough, MD 1.5

ImprovingCKDandCVDOutcomes






with Proteinuria



Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘




8:00am–10:00am

| Texas B 274 | NutritionandInflammationinCKD · Co-Chairs: Srinivasan Beddhu, MD 2.0

and Kamyar Kalantar-Zadeh, MD

| inflammation and Wasting Syndromes ravi Thadhani, MD

| is Malnutrition a Misnomer in Dialysis Patients Srinivasan Beddhu, MD

| insulin resistance and Muscle Wasting in CKD edward Siew, MD

8:00am–9:00am

| grapevine 1/2 576 | OralHealthandCKD Cheryl Thomas, rDH 1.0

9:00am–10:00am

| grapevine 3/4 577 | GutHealth:PrebioticsandProbiotics Jeanette Hasse, PhD, rD, 1.0

FaDa, CNSD

| 10:00am–12:00pm | BrunchServedintheExhibitHall–VisitPosters/Exhibits

10:15am–12:00pm

| grapevine 1/2 578 | SensationsofTastingandSmelling Sarah Washburn, MS, rD, CD 1.5

Barbara Fromm, MS, rD

12:15pm–1:15pm

| grapevine a 487 | ClinicalConversationsLuncheon ˘¯ See page 100 for topics and

faculty information

1:15pm–3:15pm


3:30pm–4:30pm

| grapevine 3/4 582 | StayingAheadtoKeepAhead:WhatYouNeed Mary Hastings Hagar, PhD, rD, FaDa 1.0

toKnowAboutPublicPolicy Dolph Chianchiano, JD, MPa

| grapevine 1/2 583 | UsingtheNewStandardizedLanguage Maureen McCarthy, 1.0

inYourChartNotes MPH, rD, CSr, lD

4:30pm–5:30pm

| grapevine 1/2 584 | It’sNotAllinYourHead: Beth McQuiston, MD, MS, rD, lDN 1.0

NeurologicalIssuesinRenalPatients

| Texas 5/6 581 | Transplantation Jeanette Hasse, 1.0

PhD, rD, FaDa, CNSD 6:00pm–7:00pm

| grapevine B 100 | AlliedHealthNetworkingReception ¯

Joint with Councils

¯


·


equired˘




8:00am–8:50am

| grapevine B 585 | StageManagementofCKDandDiabetes: Janelle e. gonyea, rD, lD 1.0

ANutritionalModel 8:55am–9:45am

| grapevine B 586 | Cutting-EdgeTherapiesforDiabetesManagement Priscilla Hollander, MD 1.0

10:00am–10:50am

| grapevine B 587 | AnOdysseyfor2008:RenalPharmacology Mary Schira, PhD, aPrN, BC, aCNP 1.0

10:55am–11:45am

| grapevine B 590 | CKDandDiabetesManagement: Debbie Hinnen, aPrN, CDe, 1.0

ClinicalPearlsandPatientTeachingStrategies BC-aDM, FaaN

11:45am–12:15pm

| grapevine B 591 | DiabetesPanelQuestionandAnswer all Sunday Morning Faculty

12:15pm | MeetingAdjourns

Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘

Program CommitteeStephanieStewart,LICSWProgram Chair

Mayo Clinic, rochester, MN

AndreaDeKam,LMSWProgram Co-Chair

university of Michigan Dialysis, livonia, Mi

SandraCoorough,ACSW,LCSWContinuing Education Coordinator

Phoenix Children’s Hospital Kids Kidney Center, Phoenix, aZ

JessicaFarrell,MSW,LCSW-PDuke university Medical Center, Durham, NC

JohnQ.Gowan,LMSWeSrD Network #14, Dallas, Tx

RebeccaHays,MSWuniversity of Wisconsin Hospital and Clinics, Madison, Wi

CindyMiller,MSW,LCSWadvanced renal Care, Tampa, Fl

KristinStockard,LICSWChildren’s Hospital and region Medical Center, Seattle, Wa

LaraTushla,LCSW,MSWrush Presbyterian Hospital, Chicago, il

Host CommitteeMarybethCallahan,ACSW,LCSW,ACPDallas Transplant institute Dallas, Tx

JosefinaHouchins,LMSWDavita Oak Cliff Dialysis Center Dallas, Tx

MarianneMoncrief,LMSWDallas Transplant institute Dallas, Tx

KatiMalarcher,LMSWFresenius Medical Center – North america Plano, Tx

ChristinaDenman,LMSWFresenius Medical Center – North america Plano, Tx

JodiPatterson,LMSWMcKinney Dialysis Center McKinney, Tx

MaggieMarek,LMSWBaylor all Saints Fort Worth Fort Worth, Tx

LisaPratka,LMSWMedical City Transplant Dallas, Tx

DebraJordan,LMSWDavita North Dallas Dialysis Center Dallas, Tx

Continuing Education Informationa minimum of 38.0 continuing education credit hours for social workers (for the entire program) have been applied for through the following agencies:n The National Kidney Foundation Council

of Nephrology Social Workers, provider #1014, is approved as a provider for social work continuing education by the associa-tion of Social Work Boards (aSWB) www.aswb.org, phone: 1.800.225.6880, through the approved Continuing educa-tion (aCe) program. The National Kidney Foundation Council of Nephrology Social Workers maintains responsibility for the program.

n Florida Board of Clinical Social Work, Mar-riage and Family Therapy and Mental Health Counseling, Provider Number BaP 614, expires March 31, 2009.

n The National Kidney Foundation Council of Nephrology Social Workers, approval num-ber PCe 2410, is approved as a Continuing education Provider by the California Board of Behavioral Sciences. This course meets the qualifications for continuing education credit for lCSWs as required by the California Board of Behavioral Sciences.

n Massachusetts social workers may receive Category ii continuing education credit hours upon their own submission.

it is the conference registrants responsibility to make sure their home state (if not noted above) accepts the aSWB aCe provider as suf-ficient for Ceus, or if they need to do anything additional to independently receive state Ceus.

2008 Program Goalsn Participants will gain the knowledge and

skills for outcome-oriented clinical nephrol-ogy social work practice.

n Participants will gain knowledge of biopsy-chosocial variables affecting chronic kidney disease patients and their families.

n Participants will learn skills to ameliorate and address biopsychosocial variables affecting kidney disease patients and their families.

n Participants will gain knowledge and skills to address issues of diversity among chronic kidney disease patients and health care professionals.

NePHrOlOgy SOCial WOrKer PrOgraM



NePHrOlOgy SOCial WOrKer PrOgraM Pre-CONFereNCe COurSe

NephrologySocialWork:AnOutcomes-DrivenPracticeModel

Wednesday,April2,20088:00am–5:00pmCourseDirectors:MaryBethCallahan,ACP,ACSW,LCSW,StephanieJohnstone,LCSW,MSW,andMeganPrescott,MSWSession420

Course Description: This full-day training will focus on a contemporary model of Nephrology Social Work practice that targets specific variables such as adherence behavior, depression, social support, satisfaction with care, conflict resolution, team training, quality-of-life measurement and modality selection to enhance overall outcome goals. The training will also focus on restructuring social work services within your organization and applying case management and time-saving strategies to make the delivery of those services possible.

Target Audience: Nephrology Social Workers



time

8:45am–9:00am

9:00am–9:30am

9:30am–10:30am

10:30am–10:45am

10:45am–11:30am

11:30am–12:00pm

12:00pm–12:30pm

12:30pm–1:30pm

1:30pm–1:40pm

1:40pm–2:25pm

2:25pm–2:45pm

2:45pm–3:00pm

3:00pm–3:15pm

3:15pm–4:15pm

4:15pm–4:45pm

4:45pm–5:00pm

5:00pm

topic


introduction to Outcomes-Driven Nephrology Social Work

Phases of adjustment to CKD: Designing interventions to enhance Outcomes

Break

Phases of adjustment to CKD (continued)

improving adherence Behavior

lunch

improving Transplant Outcomes

Stretch Break

Prevention and Management of Depression

improving rehabilitation Outcomes

Break

Patient, Staff and Team Satisfaction

understanding and Managing the Challenging Patient

evolving into an Outcomes-Driven Model of Practice

Questions and evaluations

adjourn



WeDNeSDay, aPril 2 time/location session # session notes Course Director(s) credits

8:00am–5:00pm

| grapevine 3/4 420 | NephrologySocialWork: ˘ Stephanie Johnstone, lCSW, BCD 8.0

AnOutcomes-DrivenPracticeModel Mary Beth Callahan, aCP, aCSW, lCSW

Megan Prescott, MSW, lCSW


6:00am–8:00am




Ortho Biotech, L.P.


Older adults


in the elderly




8:00am–9:00am

| Texas 3 460 | Trans101:“Miss”understoodand“Miss”represented lois Bates 1.0

9:00am–10:00am

| Texas 3 483 | EthicalControversiesinPublicSolicitationsforOrgans linda Wright, MHSC, MSW, rSW 1.0

| Texas 4 462 | Nephrology101 Bruce Morgenstern, MD 1.0

10:15am–12:15pm

| Texas 3 463 | DiagnosingPersonalityDisorders Sheila Jowsey, MD 2.0

10:15am–12:15pm

| Texas 4 464 | TheDangersofChronicStress, edward g. Silverhardt, 2.0

CompassionFatigueandBurnout MSW, lCSW, lSCSW, BCD

Joint with Councils

¯


·


equired˘





12:30pm–2:00pm

| grapevine a 466 | CNSWNetworkingLuncheon Patricia M. McKevitt, 0.5

MSW, aCSW, lCSW

2:00pm–3:00pm

| Texas a/B 264 | NKFPresidentialAddress– · allan J. Collins, MD, FaCP 1.0

The National Kidney Foundation: advancing

Public Health in the u.S. and around the World

| ShaulG.MassryDistinguishedLecture– Tom greene, PhD


Nephrology: How Strong is the evidence?

3:30pm–5:30pm

| Texas 3 467 | DepressionintheCKDSetting:TheTimeto Mark Meier, liCSW, MSW 2.0

ActisNow

| San antonio 4/5/6 468 | SpiritualityandChronicIllness: Claire J. Casselman, MSW, 2.0

OnBeingSomeBodyandSoul liCSW, lMSW 6:00pm–7:30pm



6:00am–8:00am



PanelDiscussion




No! Case Discussion


Case Discussion

7:00am–8:00am

| | ContinentalBreakfastintheExhibitHall–VisitPosters/Exhibits

8:00am–10:00am

| Texas 4 469 | BriefIntroductiontotheClinicalAssessment ramiro valdez, PhD 2.0

ofCompetence rita-an Kiely, aCSW, lCSW

8:00am–9:00am

| San antonio 4/5/6 470 | Research:DoingWhatYouLove–ShowingWhatWorks Jessica Cabness, PhD, MSW 1.0

Cindy Miller, MSW, lCSW

Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘




9:00am–10:00am

| San antonio 4/5/6 471 | Research:LiteratureReviewandMeasurement Teri Browne, MSW, lSW 2.0

SelectioninRenalSocialWorkResearch Tiffany Washington, MSW

10:15am–12:15pm

| San antonio 4/5/6 472 | ResearchDesignandDataAnalysisforRenal Joseph Merighi, MSW, PhD 2.0

SocialWorkers:AUser-FriendlyApproach

10:15am–12:15pm

| Texas 4 489 | PediatricsandTransplant ¯ Bruce Morgenstern, MD 2.0


Janelle e. gonyea, rD, lD

Mary Murphy, rN, CCTC


1:15pm–2:15pm

| Texas 4 473 | NegotiatingGoalsofCare ronald J. Crossno, MD 1.0

| San antonio 4/5/6 476 | Research:EffectiveStrategiesforPublishing Joseph Merighi, MSW, PhD 1.0

RenalSocialWorkResearch

2:15pm–3:15pm

| Texas 4 474 | RespectingChoicesinEnd-of-LifeCare anne Moore, lMSW 1.0

| San antonio 4/5/6 477 | Research:JNSW/CNSWGrantProcess Joseph Merighi, MSW, PhD 1.0

Norma J. Knowles, MSW, lCSW

Jeff Harder, MSW, liCSW

3:30pm–5:30pm

| Texas 4 478 | ImmigrationPanelDiscussion ramiro valdez, PhD 2.0

Charlie Thomas, CiSW, aCSW,

lCSW, MSW

elena lucio, MSW


Theodor vogels, MSW

3:30pm–4:30pm

| San antonio 4/5/6 479 | Research:CNSWResearchGrantWinner robert Whitlock, MSSW, lCSW, MHa 1.0


4:30pm–5:30pm

| San antonio 4/5/6 480 | ResearchPanelDiscussion Joseph Merighi, MSW, PhD 1.0

Teri Browne, MSW, lSW

Jeff Harder, MSW, liCSW


| 5:30pm–7:00pm | NetworkingReceptionintheExhibitHall–VisitPosters/Exhibits

Joint with Councils

¯


·


equired˘


6:00am–8:00am

| grapevine C 813 | ChronicKidneyDiseaseInterventions: · Chair: Peter McCullough, MD 1.5 ImprovingCKDandCVDOutcomes






with Proteinuria


8:00am–10:00am

| Texas 4 481 | EthicalDilemmasinPediatricPractice Cassandra aspinall, liCSW, MSW 2.0

Kathryn Thurber-Smith, liCSW

8:00am–9:00am

| San antonio 4/5/6 461 | DaretoSelf-Care Kristie lewis, llMSW 1.0

Tracey a. Tyus-Bailey, MSW,

lMSW, aCSW

9:00am–10:00am

| San antonio 4/5/6 482 | DialaDonor:TheLivingDonor andrea Kostick, MSW, liCSW 1.0

| TelephoneScreeningProcess

|10:00am–12:00pm | BrunchServedintheExhibitHall–VisitPosters/Exhibits

10:15am–12:15pm

| San antonio 4/5/6 484 | PediatricPractice:ClinicalStudiesandSkillsBuilding Mikhaelle Heald, lMSW 2.0

Karen egolso, MSW, BSW,

lSW, lNSW

Kristin Stockard, liCSW

10:15am–11:15am

| Texas 4 485 | TransplantTourism Michael Talamantes, lCSW, MSSW 1.0

11:15am–12:15pm

| Texas 3 491 | UpdateontheProposedKidney Trent Tipple, MD, FaaP 1.0

OrganAllocationSystem



Join

t with

Cou

ncils

¯

Join

t with

Phy

sici

ans

·

Sepa

rate

Reg

istr

atio

n an

d/or

Fee

Req

uire

d˘




12:15pm–1:15pm

| grapevine a 487 | ClinicalConversationsLuncheon ˘¯ See page 100 for topics

and faculty

1:15pm–3:15pm


3:30pm–5:30pm

| Texas D 490 | “DecreasetheIncrease”RegardingCKD ¯ glen H. Stanbaugh, MD 2.0

anton C. Schoolwerth, MD, FaHa

eduardo Sanchez, MD, MPH

robert Duncan

3:30pm–4:30pm

| San antonio 4/5/6 486 | GettingPatientsThroughTransplantFast amy Waterman, PhD 1.0

andWithoutDroppingOut:

WhatReallyMakestheDifference

4:30pm–5:30pm

| San antonio 4/5/6 492 | LifewithaKidneyTransplant James r. rodrigue, PhD 1.0

6:00pm–7:00pm

| grapevine a 100 | AlliedHealthNetworkingReception ¯

SuNDay, aPril 6


8:00am–10:00am

| grapevine1/2 493 | EthicsandtheManyShadesofGray ellen Case, BSW, MSW, liCSW 2.0

Stephanie Stewart, liCSW 10:15am–12:15pm

| grapevine1/2 494 | CNSWTownHallMeeting CNSW executive Committee

This session is a must for all nephrology social work

attendees! Join us to learn all about the new nephrology

social work certification, in-depth information about

CNSW projects and opportunities, and to ask questions

and make suggestions to the CNSW executive Committee.

12:15pm MeetingAdjourns

Joint with Councils

¯


·


equired˘

Indulgeinstimulatingmoderateddiscussionswithyourcolleagues:

Theseroundtablediscussionspresentvarioustopicsthatareclinicallyrelevanttothecareandtreatmentofyourpatients.

Topicsandpresenters:

Renal and Clinical Dietitian Program:1 CKDandMNT:MakingaDifference // Carolyn Cochran, rD, lD, MS, CDe and Kathy Shiro Harvey, MS, rD, CSr2 ResistanceTraining:GoodfortheBodyandGoodforPeoplewithKidneyDisease // Stephanie Mcintyre, rD3 OralHealthandCKD // Cheryl Thomas, rDH4 EnteralNutritionChallengesintheCKDPatient // Marcia Kalista richards, MPH, rD, CNSD, lDN5 a.NutritionPracticesofRenalDietitiansinHemodialysisCenters // Joyce vergili, MS, rD, lDN, CDe b.DoesNutritionSpecificQualityofLifeQuestionnaireMeasuretheImpactofNutritionontheHealthRelated QualityofLifeinHDPatients?// Haewook Han, PhD, rD, CSr6 a.ComplementaryIntradialyticNutritionSupplementationinDialysisPatients // Mary Sundell, rD, lD b.SevelamerHCLUseandCirculatingEndotoxinandInflammatoryBiomarkersinHDPatients:APreliminaryReport // Phyllis Sun, rD

Nephrology Social Worker Program:7 Trans101 // lois Bates8 TheLivingDonorTelephoneScreeningProcess // andrea Kostick, MSW, liCSW9 Immigration // ramiro valdez, PhD, Charlie Thomas, CiSW, aCSW, lCSW and Theodor vogels, MSW10 PediatricsandTransplant// Bruce Morgenstern, MD, Sandra Coorough, aCSW, lCSW, Janelle e. gonyea, rD, lD, and Mary Murphy, rN, CTrN

One topic per table. Tickets, which include lunch, are $25.00 and are available at the ticket sales booth in the NKF registration area. Tickets are available on a first come, first served basis. register early—tables fill up quickly!

Looking for that perfect fit?Visit NKF’s online Kidney Career Center, a leading resource for making employment connections in the fast-growing fi eld of kidney health care.

The one-size-fi ts-all approach of the mega job boards may not be the best way to fi nd the physicians, pharmacists, nurses, technicians, dietitians and social workers you’re looking for.

The Kidney Career Center, is the only job site that offers employers targeted access to

quality kidney health care professionals, as well as quick and easy job posting and online job activity reports.

Job-seeking professionals enjoy free and confi dential resume posting, automated e-mail notifi cation of new job listings and

the ability to save jobs for later review.

Save 20% on job postings on theNational Kidney Foundation’s Kidney Career Center

©2008 National Kidney Foundation, Inc. All Rights Reserved. 02-75-483A

NOW THROUGH APRIL 9, 2008

Kidney Career Centerwww.careers.kidney.org


CliNiCal CONverSaTiONS luNCHeSSaTurDay, aPril 5, 12:15PM–1:15PM


STO

RID

F

RE

GIS

TRA

TIO

N

GU

ES

T

ELE

C

OFF

ICE

IDF

OFF

ICE

STO

RO

FFIC

E

ELE

C

RE

GIS

TRA

TIO

NR

EG

ISTR

ATI

ON

STO

RA

GE

OFF

ICE

ELE

C

OFF

ICE

IDF

OP

ER

AB

LE W

ALL

IDF

OP

ER

AB

LE W

ALL

OP

ER

AB

LE W

ALL

IDF

IDF

RO

LL-U

P D

OO

RR

OLL

-UP

DO

OR

RO

LL-U

P D

OO

RR

OLL

-UP

DO

OR

EX

ITE

XIT

EX

ITE

XIT

EX

ITE

XIT

EX

ITE

XIT

EX

ITE

XIT

EX

ITE

XIT

STA

FF O

FFIC

ES

TAFF

OFF

ICE

PA

RC

EL

22920

'

20'

300

302

304

30520

'30

6

310

312

314

318

320

322

32920

'

401

40'

40'

404

20'

411

30'

30'

419

30'

30'

428

20'

42320

'

30'

437

439

441

52320

'

30'

536

537

538

539

540

541

544

601

40'

40'

61120

'

30'

61920

'

30'

62920

'

20'

635

636

637

639

640

641

644

645

646

711

810

713

812

715

719

30'

30'

729

40'

40'

734

736

738

739

740

741

744

801

30'

40'

811

81330

'

82120

'

20'

839

840

841

844

845

846

90120

'

905

907

915

91920

'

30'

92920

'

937

938

939

940

941

944

1000

1005

1007

1010

1011

1012

1013

1015

1019

1021

1023

1032

1034

1035

1036

1037

1039

1040

1041

Mai

nE

ntra

nce

91120

'

1004

20'

100120

'

1028

20'

93320

'

912

910

916

914

323

321

418

319

420

20'

334

30'

30'

31120

'

20'

1031

1029

1033

NA

TIO

NA

L K

IDN

EY

FOU

ND

ATI

ON

SP

RIN

G C

LIN

ICA

L M

EE

TIN

GA

PR

IL 2

-6, 2

008

GA

YLO

RD

TE

XAN

LO

NG

HO

RN

EXH

IBIT

HA

LL C

-FG

RA

PE

VIN

E, T

EXA

S

LON

GH

OR

N E

XH

IBIT

HA

LL -

24'

CE

ILIN

G H

EIG

HTS

:

RE

GIS

TR

AT

ION

& L

OB

BY

AR

EA

S -

12'

MO

UN

TE

D O

N A

LL C

OLU

MN

S E

XC

EP

T R

OW

NE

AR

ES

T10

0 A

MP

, 3 0

, 5 W

IRE

HE

AV

Y D

UTY

RE

CE

PTA

CLE

ELE

CT

RIC

AL

& T

ELE

PH

ON

E /

DA

TA W

ITH

120

/280

V,

= F

LOO

R D

RA

IN

SO

UT

H W

ALL

, & F

LOO

RS

WH

ER

E D

ES

IGN

ATE

D.

LEG

EN

D:

= F

RE

IGH

T E

LEVA

TOR

= P

AS

SE

NG

ER

ELE

VATO

R

= W

OM

EN

'S R

ES

T R

OO

M

= M

EN

'S R

ES

T R

OO

M

FH

V =

FIR

E H

OS

E V

ALV

E

= 2

'8"

x 2'

8" C

OLU

MN

FA =

FIR

E A

LAR

M

SH

OW

LE

GE

ND

& N

OTE

S

FX =

FIR

E E

XTIN

GU

ISH

ER

= 2

'8"

x 5'

6" C

OLU

MN


CM08 exHiBiTOrS

company // booth

abbott // 601

abbott Nutrition // 711

alaven Pharmaceutical, llC. // 1000

alcavis HDC // 939

aMag Pharmaceuticals, inc. // 919

american academy of Nurse Practitioners // 537

american academy of Physician assistants // 538

american association of Kidney Patients // 302

american regent, inc. // 404

american Society of Nephrology // 1005

amgen // 229

amgen // 401

angioDynamics // 319

arrow international // 1015

astellas Pharma uS, inc. // 619

Baxter Healthcare // 611

The Binding Site, inc. // 1004

Boehringer ingelheim // 419

Breckenridge Pharmaceutical, inc. // 418

Courier Med // 738

Covidien // 1012

Davita // 314

DCa—Dialysis Corporation of america// 916

Dialysis and Transplantation // 910

Dialysis at Sea // 639

Dialysis recruiting Specialists/ The Fortus group // 912

Diazyme laboratories // 637

Dva laboratory Services, inc. // 937

elsevier, inc. // 1011

evercare // 1036

FMQai // 439

Foundation Medical Staffing // 1029

Fresenius Medical Care // 423

Fresenius Medical Care // 523

genzyme Corporation // 729

The gideons international // 1032

Hawthorn Pharaceuticals // 536

Health informatics, inc. // 306

HemoCue, inc., a Quest Diagnostics Company // 1007

innovation 4 Dialysis // 839

Keryx Biopharmaceuticals, inc. // 901

Kidney Community early response Coalition // 437

llorens Pharmaceutical int'l Division // 914

Meals for liFe // 312

MedComp // 903

Medical Nutrition uSa, inc. // 907

Merck & Co., inc. // 1001

National association of Nephrology Technicians/Technologists (NaNT) // 1033

National Kidney and urologic Disease information Clearinghouse (NKuDiC) // 736

National Kidney Foundation // 719 aJKD KDigO KDOQi KeeP KlS

NKF cyberNephrology experience // 334

NKF “People like us” Constituent Council "Hope Street” // 821

NKF Professional Councils // 813

National Kidney Foundation of North Texas // 1013

National renal alliance // 329

Natural Balance Bodywork // 938

Nature Publishing group // 1010

Nephrocor // 810

Nephrology News and issues // 812

Nephrology Nursing Certification Commission // 320

Nephro-Path // 420

Nephro-Tech // 1023

Nipro Medical Corporation // 715

Nova Biomedical // 318

Novartis // 321

Novo Nordisk inc. // 929

Nutrepletion resources // 811

Omron Healthcare // 322

Ortho Biotech Products, lP // 801

Pentec Health // 933

Pfizer // 629

Physician’s Capital investment // 713

PKD Foundation // 539

Quality Dialysis // 636

renal and urology News // 1021

renal Business Today/ virgo Publishing Medical group // 304

renal Physicians association // 734

Satellite Healthcare, inc. // 1028

Satellite laboratory Services // 311

Scantibodies Clinical laboratory // 310

Shire // 411

Sigma-Tau Pharmaceuticals, inc. // 305

Solinmed Billing & Transcription // 739

Specta laboratories // 428

Teva Pharmaceuticals // 1019

university of Minnesota Medical Center, Fairview // 441

u.S. renal Care, inc. // 635

u.S. renal Data System (uSrDS) // 300

Watson Nephrology // 911

Wyeth Pharmaceuticals // 915

ABBOTTBooths601abbott is a global, broad-based health care company devoted to discov-ering new medicines, new technologies and new ways to manage health.

ABBOTT NUTRITIONBooth711is THe world leader in adult nutrition. Nepro with Carb Steady is thera-peutic nutrition for people on dialysis clinically shown to help manage blood glucose response and Suplena with Carb Steady is therapeutic nutrition for people with CKD.

ALAVEN PHARMACEUTICAL, LLCBooth1000uniFiber® (powdered cellulose) is an insoluble fiber supplement clinically proven to restore and maintain bowel regularity. uniFiber is sodium, potassium, phosphorus and gluten free and contains less than one net carb per serving. uniFiber has no minimum liquid requirement. www.unifiber.com

ALCAVIS HDCBooth939alcavis HDC is dedicated to supporting the renal community through education and aid with innovative and progressive antiseptics, disin-fectants and medical devices. Our core products are electolytically produced sodium hypochlorite based solutions available in several concentrations for applications that include skin and wound care and connectivity. alcavis HDC also distributes peracidic acid for dialyzer reprocessing and the MaKy and arM ii reuse machines.

AMAG PHARMACEUTICALS, INC.Booth919aMag Pharmaceuticals is a biopharmaceutical company that utilizes its proprietary nanoparticle superparamagnetic iron oxide technol-ogy for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. visit us at http://www.amagpharma.com

AMERICAN ACADEMY OF NURSE PRACTITIONERSBooth537The american academy of Nurse Practitioners (aaNP), formed in 1985 to provide NPs with a unified way to network and to advocate for NP issues at the local, state and federal levels, was the first national organization created for nurse practitioners of all specialties. With ap-proximately 23,000 individual members and more than 140 group mem-bers, aaNP represents the interests of approximately 100,000 NPs as providers of high-quality, cost-effective and personalized healthcare.

AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS Booth538The american academy of Physician assistants is the only national organization to represent all physician assistants (Pas) in all medi-cal specialties. For more information about the academy and the Pa profession, visit our Web site at www.aapa.org.

AMERICAN ASSOCIATION OF KIDNEY PATIENTS Booth302The american association of Kidney Patients (aaKP) is the national, patient organization which, for over 35 years, has been dedicated to improving the lives of kidney patients and their families by helping them cope with the emotional, physical and social impact of kidney disease, thereby enabling them to resume productive and satisfying lives.

AMERICAN REGENT, INC.Booth404american regent, “your iv iron Company,” is the manufacturer and distributor of venofer®, (iron sucrose injection, uSP), the #1 prescribed iv iron in the u.S.1 venofer® is available in 100mg/5ml single dose vi-als (preservative free). venofer® is covered nationally by CMS/Medicare and has been assigned a permanent national HCPCS Code “J1756” for services provided on or after January 1, 2003.1 Based on iMS Health, National Sales Perspectives™ - 3rd Quarter 2007 results (October 2007) - Total Sales volume ($) and units (100 mg equivalents).

AMERICAN SOCIETY OF NEPHROLOGY Booth1005The american Society of Nephrology (aSN) was founded in 1967 as a nonprofit corporation to enhance and assist the study and practice of nephrology, to provide a forum for the promulgation of research, and to meet the professional and continuing education needs of its members.

AMGENBooths229&401amgen (NaSDaQ:aMgN), a biotechnology pioneer, discovers, devel-ops and delivers innovative human therapeutics. Our medicines have helped millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, we continue to advance science to serve patients.

2008 exHiBiTOrSexHiBiTOr PrODuCT/ServiCe DeSCriPTiONS


ANGIODYNAMICS Booth319(www.angiodynamics.com) is a leading provider of innovative medical de-vices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. angioDynamics’ diverse product line includes radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products.

ARROW INTERNATIONALBooth1015arrow international, a leader in central venous devices, presents a broad range of products for the dialysis access community. These products include acute and chronic hemodialysis catheters and clot management devices for dialysis grafts and fistula. Our featured prod-ucts will include the arrow Cannon Plus chronic hemodialysis catheter along with the arrow-Trerotola PTD.

ASTELLAS PHARMA US, INC. Booth619astellas Pharma, inc. manufactures and markets proprietary phar-maceutical products in specialty therapeutic areas where there is an unmet medical need. astellas Pharma's global mission to explore the frontiers of human health underscores the company's commitment to the field of immunology, where aggressive research and development initiatives have helped to put astellas at the forefront of transplantation.

BAXTER HEALTHCARE Booth611Baxter Healthcare is a leading provider of a complete and comple-mentary portfolio of dialysis products to support people with kidney disease around the world, including Peritoneal Dialysis, Hemo Dialysis, education tools, and Continuous renal replacement Therapy (CrrT) for acute renal failure.

THE BINDING SITE, INC.Booth1004Freelite serum free light chain assays are more sensitive than current methodologies for detecting multiple myeloma and al amyloidosis patients, many of whom first present with renal failure. They replace the need for urine assays.

BOEHRINGER INGELHEIM Booth419Boehringer ingelheim Pharmaceuticals, inc., the uS subsidiary of Boehringer ingelheim, headquartered in germany, operates globally in 47 countries with approximately 38,400 employees. The company is com-mitted to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

BRECKENRIDGE PHARMACEUTICAL, INC. Booth418Breckenridge Pharmaceutical, inc. is a privately held pharmaceutical marketing, research and development company which has a broad range of branded and generic prescription products in many therapeutic categories.

COURIER MED Booth738a Durable Medical equipment and Supply Company that specializes in reimbursement and delivery of Dialysis related medical supplies to patients at their home anywhere in the uSa. among many products, Courier Med carries: CD-1000 Catheter access Protector Dressing that allows patients living with Catheters to safely resume high risk activities such as showering (covered by Medicare and most Private insurances), Diabetic Supplies, Free Monitors, less-N-Pain, an afford-able Topical anesthetic, and SureSeal Pressure Bandages that reduce clotting time, allowing the patient to leave dialysis sooner.

COVIDIENBooth1012Covidien, formerly Tyco Healthcare, is a global $10 billion manufac-turer of leading medical devices and supplies, imaging products and pharmaceuticals. The Company employs more than 43,000 people worldwide and is dedicated to working with medical professionals to improve patient outcomes.

DAVITABooth314Davita is one of the largest providers of kidney services in the united States. We care for nearly 100,000 patients through our nationwide network with over 1,200 outpatient centers located in 42 states and the District of Columbia.

DCA - DIALYSIS CORPORATION OF AMERICABooth916Dialysis Corporation of america is a physician-focused organization. at the core of our company is a philosophy of developing a true alliance with our physicians. We seek to partner with Nephrologists who want to expand their dialysis presence, be afforded the opportunity to share in ownership of dialysis units, seek out management expertise, and gain control over the clinical quality their patients are currently receiving.



DIALYSIS AND TRANSPLANTATION Booth910available from John Wiley & Sons, Dialysis & Transplantation (D&T) pub-lishes original research pertaining to all aspects of renal replacement therapy and renal transplant, with a focus on clinical application. D&T has the largest multidisciplinary audience among nephrology journals in the united States and is read in more than 120 foreign countries. visit www.eneph.com for submission guidelines/free access to online issues.

DIALYSIS AT SEA Booth639Dialysis at Sea Cruises is the largest provider of dialysis treatment aboard cruise ships. We provide nephrologists, nurses and suppliers onboard select sailings ensuring a stress-free environment for dialysis patients to enjoy the enchantment of cruising.

DIALYSIS RECRUITING SPECIALISTS/ THE FORTUS GROUP Booth912The First full service executive search firm specializing in Dialysis and Transplantation, providing recruitment and permanent placement of dialysis professionals worldwide, including permanent physicians, Travel nursing and locum Tenens. Place your future in the hands of the “Dialysis recruiting Specialist.” We set the standard in advancing careers and responding to employers professional needs.

DIAZYME LABORATORIES Booth637Diazyme laboratories is developing a capillary whole blood point of care device for the rapid determination of Cystatin C based gFr for use in the physician office or clinic. Diazyme's products include diagnostic blood markers for diabetes, renal, cancer, liver and cardiac. Diazyme is a life science division of general atomics.

DVA LABORATORY SERVICES, INC.Booth937Dva laboratory Services offers state-of-the-art eSrD laboratory testing. We recognize the need for precise patient data, and address it with a comprehensive range of laboratory services including: dialysis specific testing, client support staff, rapid turn-around times, peritoneal dialysis testing, water analysis and a leading-edge order entry and reporting sys-tem – labScope Online®. Now you can access labScope from anywhere, anytime using lSO On The go from any computer with internet access.

ELSEVIER, INC. Booth1011elSevier is proud to publish the American Journal of Kidney Diseases, the official journal of the National Kidney Foundation. Please stop by our booth to view the latest issue of the journal and browse our other books and journals in the field of Nephrology.

EVERCARE Booth1036evercare end Stage renal Disease Program – uses well-established evercare Clinical Model to promote member’s disease self-management and care. The program bridges dialysis and the community by providing management assistance in the unit, home, and during hospitalization.

FMQAI Booth439The Centers for Medicare and Medicaid Service (CMS) welcome you to preview the next generation of renal information collection – CrOWN-Web. CrOWNWeb provides a secure web interface that enables dialysis facilities to submit and monitor patients’ clinical data in real time, thus helping facilities improve patient care and consequently their overall quality of life.

FOUNDATION MEDICAL STAFFING Booth1029Foundation Medical Staffing is the nation's leading provider of staffing services for nephrologists and dialysis nurses. Our expert agents focus on your specialty exclusively to find premier travel opportunities and permanent positions.

FRESENIUS MEDICAL CAREBooths423&523Fresenius Medical Care, the dialysis equipment and products market leader, offers a comprehensive portfolio of clinically valid, cost-effective treatment enhancement tools that positively impact dialysis therapy. Success@home, our comprehensive home therapies program, provides nephrologists and clinicians with the therapy choices, treatment flex-ibility, support, and education programs that achieve better outcomes.

GENZYME CORPORATIONBooth729genzyme, a global health care company, delivers innovative biotechnol-ogy products and services in therapeutics, surgery and diagnostic ar-eas. genzyme is the manufacturer of renvela® (sevelamer carbonate), renagel® (sevelamer hydrochloride), and Hectorol® (doxercalciferol). genzyme is a leader in health care awareness and education for renal care specialists and patients worldwide. For more information visit www.genzyme.com or call 1.800.847.0069


THE GIDEONS INTERNATIONALBooth1032White New Testaments bound in gold with Psalms and Proverbs. available to all in the medical field free of charge.

HAWTHORN PHARMACEUTICALS Booth536Hawthorn Pharmaceuticals, inc., is a specialty pharmaceutical com-pany focused on the sales, marketing and development of niche prod-ucts in areas such as Nephrology. Hawthorn's professional sales force is committed to meeting the needs of patients and physicians in these target markets. Hawthorn endeavors to be a distinguished leader and partner in the Nephrology marketplace while bringing innovative prod-ucts and technologies to market.

HEALTH INFORMATICS, INC. Booth306Health informatics, inc. (Hii) is the renal industry leader in electronic medical records and billing software. The TiMeTM System has been employed in dialysis units for over 20 years and over 42 states. Hii's TiMeTM System is the backbone of its outsourced billing solutions for both dialysis facilities and multi-specialty practices. To learn more about our company and services, please visit us on the web at www.hiiweb.com.

HEMOCUE, INC., A QUEST DIAGNOSTICS COMPANY Booth1007HemoCue is a World leader in Point-Of-Care Testing. The name HemoCue has long been synonymous with precision, accuracy and reliability. HemoCue’s leading point-of-care analyzers allow any healthcare professional the ability to obtain lab quality results anytime, anywhere. www.hemocue.com

INNOVATIONS 4 DIALYSIS Booth839Clear Band: ClearBand provides reliable hemostasis and eliminates manual pressure following needle or sheath removal. ClearBand is a soft plastic that comfortably fits the arm without cutting into it. locking ridges face away from the skin to prevent binding or pinching. Hemo: Hemo is a topical hemostasis pad with calcium ions to speed up the clotting process for reliable hemostasis.

KERYX BIOPHARMACEUTICALS, INC Booth901Keryx is developing ferric citrate, an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Ferric citrate is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or eSrD.

KIDNEY COMMUNITY EARLY RESPONSE COALITION Booth437The Kidney Community emergency response (KCer) Coalition col-laboratively develops, disseminates, implements and maintains a coordinated preparedness and response framework for the kidney community in the event of any type of emergency or disaster.

LLORENS PHARMACEUTICAL INT’L DIVISION, INC.Booth914During the past 22 years, llorens Pharmaceutical has experienced significant growth, introducing a diversity of new products in the united States and Puerto rico. llorens Pharmaceutical is continually working to improve the health and well-being of patients, with products such as Proteinex, Proteinex-18 and Nephronex.

MEALS FOR LIFE Booth312introducing Meals for liFe, a brand new company specializing in delicious microwaveable frozen entrees that are low in Potassium, Phosphorous, and Sodium. Specifically formulated for diabetics and dialysis patients, Meals for liFe is a convenient and healthy alternative and is readily available in the frozen foods section of your local grocery stores.

MEDCOMP Booth903Medcomp is the market leader for dialysis access catheters. The Tesio Catheter and Split Cath long-term products have set the stan-dard for patient care. Medcomp offers a full line of CvCs and acces-sories, designed to save peripheral veins and future access sites.

MEDICAL NUTRITION USA, INC. Booth907Medical Nutrition uSa, inc. develops and distributes products for nutritionally at-risk individuals under medical supervision. Our low- volume Pro-Stat® products are ideal for eSrD patients, as they provide 15 grams of protein and up to 101 calories per ounce. Fiber-Stat, our liquid fiber supplement, delivers 11 grams of soluble fiber per ounce.



MERCK & CO., INC. Booth1001Merck & Co., inc. is a global research-driven pharmaceutical company dedicated to putting patients first. established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. For more information, visit: www.merck.com.

NATIONAL ASSOCIATION OF NEPHROLOGY TECHNICIANS/TECHNOLOGISTS (NANT)Booth1033NaNT promotes education and advances the professional role of the multidisciplinary team in delivering the highest quality of care to the CKD patient. it provides educational opportunities, encourages the development of nephrology professionals in leadership roles and achieves recognition of technology practitioners in the total care of the CKD patient.

NATIONAL KIDNEY AND UROLOGIC DISEASE INFORMATION CLEARINGHOUSE (NKUDIC) Booth736National Kidney and urologic Disease information Clearinghouse (NKuDiC) is an information and referral service of the National insti-tute of Diabetes & Digestive & Kidney Diseases (NiDDK), one of the National institutes of Health. The clearinghouse responds to inquiries, develops and distributes publications, and provides referrals to kidney and urologic organizations.

NATIONAL KIDNEY FOUNDATION Booth719AJKD – American Journal of Kidney Diseases American Journal of Kidney Diseases (aJKD), the official journal of the National Kidney Foundation, is the world's leading journal in clinical nephrology. Please visit the NKF booth to browse aJKD and the two other journals from the National Kidney Foundation and elsevier: Advances in Chronic Kidney Diseases and Journal of Renal Nutrition.

KDIGO – Kidney Disease: Improving Global OutcomesKidney Disease Improving Global Outcomes (KDIGO)visit the booth to learn about KDigO guidelines, including the first global guideline for the Prevention, Diagnosis, evaluation and Treat-ment of Hepatitis C in CKD, and for a demonstration of KDigO's online tool for accessing and comparing the latest nephrology guideline rec-ommendations from around the world. KDigO was established in 2003 as an independently incorporated non-profit foundation governed by an international Board with the stated mission "to improve care and out-comes of kidney patients worldwide through coordination of initiatives to develop and implement clinical practice guidelines." www.kdigo.org

KDOQI – Kidney Disease Outcomes Quality InitiativeStop by the NKF booth to learn about the newest KDOQi activity; Pediatric Nutrition guideline update: 2008 and learn why KDOQi is recognized throughout the world for significantly improving patient outcomes. There are 12 current sets of KDOQi guidelines. visit the booth or the website for more information on KDOQi's new guideline implementation programs: http://www.kidney.org/Professionals/kdoqi/

KEEP – Kidney Early Evaluation ProgramOver 110,000 people across the country have participated in the NKF’s Kidney early evaluation Program (KeeP). To learn more about this free, community-based health screening for people at increased risk for chronic kidney disease (CKD) and all the recent KeeP program updates, stop by booth #719. you can also pick up a free copy of the KeeP annual Data report which will be published in aJKD's april 2008 supplement.

KLS™ – Kidney Learning System The National Kidney Foundation's KiDNey learNiNg SySTeM™ (KlS) provides educational programs and practical tools for physicians and health care professionals, CKD patients and their families and those at increased risk for CKD. KlS incorporates new science into all its educational resources, drawing from the ongoing guideline develop-ment process and regularly published KDOQi guidelines updates which are used by government health agencies, professional societ-ies, physicians, nurses, dieticians, social workers, pharmacists and patient groups. KlS programs are researched, tested, peer-reviewed, produced and fully supported by the professional KlS staff of the National Kidney Foundation. KlS offers a full line of CMe/Ce programs as well as clinical tools and online clinician support resources, such as a gFr calculator and interactive clinical action plans. visit our Web site at www.kidney.org/KlS for a comprehensive presentation of CKD educational resources.

NKF CYBERNEPHROLOGY EXPERIENCEBooth334Come relax and enjoy a special area in the expo hall devoted to cy-berNephrology to gain hands-on experience with some of the many resources available. This booth area is sponsored in part by amgen.


NKF “PEOPLE LIKE US” CONSTITUENT COUNCIL/ "HOPE STREET” Booth821The NKF’s “People like us” initiative empowers, educates and encour-ages people affected by CKD, transplantation and donation to become advocates on public policy and other issues related to their health. "People like us" is comprised of advocates from the NKF's constituent groups: Patient and Family Council (PFC), transaction Council and the National Donor Family Council (NDFC), and living donors. This booth includes a wide variety of patient educational materials and empower-ment tools to help them and their loved ones become their own best advocate. One such tool featured in the booth is "Hope Street," the NKF's comic strip "reality series" of, by and for the dialysis community.

NKF PROFESSIONAL COUNCILS Booth813The National Kidney Foundation Council of Nephrology Nurses and Technicians (CNNT), a 500-strong volunteer professional membership organization, participates in public services directed toward preven-tion, detection and the care of persons with kidney and/or related diseases. The Council advocates and contributes to the professional development of members through education, networking and the dis-semination of information related to professional practice and qual-ity of patient care. CNNT invites all meeting attendees to stop by the Booth to learn more about the council and its activities.

The National Kidney Foundation Council of Nephrology Social Workers (CNSW) upholds and supports the profession of nephrology social work through advocacy and the creation of patient and professional education materials. With over 800 social work members the council provides assistance, education and support to patients and their fami-lies in dealing with the psycho social stresses and lifestyle readjust-ments encountered by patients in all stages of CKD. visit Booth 813 to learn about new publications and professional resources and how to get involved.

The National Kidney Foundation Council on renal Nutrition (CrN), is a 1,700-member volunteer professional organization dedicated to promoting quality nutritional care and education to kidney patients. Members impact regulatory and legislative issues and actively promote the professional education of the renal dietitian. The Council stimulates, supports and disseminates nutrition-related research, and develops patient and professional public education materials encouraging quality nutrition care for CKD patients. Come see us at Booth 813 and view our display of professional resources for renal dietitians.

THE NATIONAL KIDNEY FOUNDATION OF NORTH TEXASBooth1013North Texas affiliate of the National Kidney Foundation which serves Dallas, Fort Worth and 64 surrounding counties.

NATIONAL RENAL ALLIANCE Booth329National renal is a dialysis provider where physicians are partners. if you are a physician who would like to receive the benefits of ownership and be in control of your dialysis unit, please call Kim at (866) 312-9400 ext. 4424.

NATURAL BALANCE BODYWORKBooth938Deep tissue Corrective Massage, Chair Massage, stress reduction education, food/mood connection education, 30 day cleansing program for wellness and weight loss, video demonstration.

NATURE PUBLISHING GROUP Booth1010Nature Publishing group brings leading scientific and medical research to your desk top. The NPg portfolio combines the continued excellence of Nature and its associated research and review journals, over 42 leading academic and society journals, including Kidney

International and eight Nature Clinical Practice journals. visit Booth 1010 for free sample copies.

NEPHROCOR Booth810Nephrocor™ offers renal biopsy and chemistry profiles for the diagno-sis, treatment and management of kidney diseases. a full service ana-tomic and clinical pathology laboratory, Nephrocor™ serves nephrolo-gists throughout the u.S.

NEPHROLOGY NEWS AND ISSUES Booth812Nephrology News & Issues® (www.nephronline.com), is a national, peer-reviewed news journal covering the political, social, and eco-nomic issues surrounding the delivery of dialysis and transplantation. Stop by the booth for the latest issue, along with the 2008 Renal Care

Calendar and Meetings Guide, and Renal Resource and Buyer’s Guide.



NEPHROLOGY NURSING CERTIFICATION COMMISSION Booth320The Nephrology Nursing Certification Commission (NNCC) was es-tablished in 1987 to develop and implement certification examinations for nephrology nursing. The NNCC offers the following examinations: Certified Nephrology Nurse-Nurse Practitioner (CNN-NP), Certified Nephrology Nurse (CNN), Certified Dialysis Nurse (CDN), Certified Clinical Hemodialysis Technician (CCHT). For more information, stop by our booth or visit our website at www.nncc-exam.org

NEPHRO-PATH Booth420under the direction of Patrick D. Walker, MD, NephroPath offers more than 30 years of experience interpreting renal biopsies. Because we understand the critical effect time to diagnosis can have on the outcome of many renal diseases, we offer complete results (light, immunofluorescence, and electron Microscopy) on the same day we receive a biopsy.

NEPHRO-TECH Booth1023Nephro-Tech, inc. provides high quality pharmaceuticals at affordable prices. introducing vital-D rx™; treat vitamin D (25-OH D3) deficiency daily. Nephron Fa® is an iron, vitamin, stool softener combination. great for PD patients! NephPlex® rx is one of the most cost-effective, renal multivitamins on the market that contains zinc. The MagneBind® products are magnesium/calcium combination phosphate binders– reduce calcium intake without compromising binding ability. Calphron is 667 mg calcium acetate and costs $15.00/200 through Nephro-Tech, inc. renaPlex® is a direct sell multivitamin costing $9.00/100 plus $4.95 shipping. Call 800-879-4755 for more information.

NIPRO MEDICAL CORPORATIONBooth715Nipro Medical Corporation is a worldwide manufacturer of disposable medical products specializing in the renal and med-surg markets. includes bloodlines, safety fistula needles, dull needles, dose-saver syringes, safety and non-safety syringes and needles. expert staff specializes in product inservice and technical support in which Ceu credits are earned. Quality and prices ensures you receive the lowest cost care for your facility.

NOVA BIOMEDICAL Booth318Nova’s new StatSensor™ Creatinine Meter is a handheld point-of-care analyzer for accurate, 30-second measurement of creatinine and es-timated glomerular Filtration rate (egFr) on capillary blood. Stat-Sensor's small, 1.2 microliter whole blood samples can be obtained virtually painlessly by fingerstick.

NOVARTIS Booth321For over 20 years, Novartis Pharmaceuticals Corporation has been a leading contributor to the advancement of transplant science and medicine. Our focus remains on developing meaningful therapeutic advances that improve the quality of life of transplant recipients and enhancing the long-term success of transplantation. Please visit our exhibit where Specialists from Novartis will be available to discuss our products, answer questions and supply scientific information.

NOVO NORDISK INC.Booth929Novo Nordisk inc., Princeton, N.J., is the united States headquarters of Novo Nordisk a/S, a global healthcare company leader in diabetes care. it manufactures and markets a comprehensive line of diabetes care products, growth hormone therapy, and treatment for specific types of hemophilia. Novo Nordisk is committed to research to address unmet medical needs.

NUTREPLETION RESOURCES Booth811NutrePletion resources is “your First Choice for Nutritional Solutions.” This specialty pharmacy provides nationwide coverage for the par-enteral nutrition needs of the end stage renal disease patient. Our pharmacists, reimbursement specialists, and field based registered dietitians work closely with dialysis facility staff to provide high quality iDPN and iPN services.

OMRON HEALTHCARE Booth322The most important feature of Omron blood pressure monitors is that they consistently provide accurate results. This is why every Omron blood pressure model has been tested, evaluated and proven to meet the rigorous safety and accuracy standards set by independent organizations.


ORTHO BIOTECH PRODUCTS, L.P. Booth801Ortho Biotech Products, l.P. markets PrOCriT® (epoetin alfa) used to treat anemia associated with serious medical conditions. The company also markets other biotechnology products. it is based in Bridgewater, New Jersey.

PENTEC HEALTH Booth933Pentec Health - a niche specialty pharmacy company that is a provider of iDPN/iPN therapies to the eSrD population tracking outcomes data. website at www.pentechealth.com

PFIZER Booth629Please visit the Pfizer inc, u.S. Pharmaceuticals exhibit featuring: liPiTOr® (atorvastatin calcium)

PHYSICIANS’ CAPITAL INVESTMENT, LLC Booth713Physicians’ Capital investment, llC is the innovator of the seamless ap-proach to patient care facilities. From design, to construction, to finance, to operations; PCi’s staff has over 85 years of combined healthcare experience in providing state of the art healthcare facilities, allowing our physician partners to focus on their number one priority… their patients.

PKD FOUNDATION Booth539Stop by our booth to learn about our new KidneyWise Nutrition Program, featuring a cookbook and website tailored to each stage of kidney disease! The PKD Foundation fights polycystic kidney disease (PKD) through research funding and patient education. learn more today!

QUALITY DIALYSISBooth636Dialysis services are performed at home in an environment, which is safe, secure, and closely monitored to insure that patient care is not compromised. With increasing demand for quality medical care and the reduced funds available to the health care system, medical providers are seeking alternatives that are cost effective without compromising quality care.

RENAL AND UROLOGY NEWS Booth1021Renal & Urology News is a monthly tabloid with a circulation of 16,000 Nephrologists, dialysis nurses and urologists. The publication’s pri-mary editorial mission is to report on new scientific developments of interest to these three specialist groups. News coverage focuses on medical conferences but also includes reporting on recently published papers in peer-reviewed journals. various features and departments complement the news coverage.

RENAL BUSINESS TODAY/VIRGO PUBLISHING MEDIA GROUP Booth304Renal Business Today delivers top-notch editorial content for practice-management professionals. http://www.renalbusiness.com/. www.renalbusiness.com offers daily news, an editorial library, a blog by editor Keith Chartier, Pharma Corner, a free e-newsletter and more.

RENAL PHYSICIANS ASSOCIATION Booth734The renal Physicians association is a national organization with the expertise and successful track record of pro-actively defending the discipline of the nephrology practice. Membership is comprised of healthcare providers in the subspecialty of internal medicine known as nephrology. Stop by to check out rPa’s latest programs and publica-tions or visit us at www.renalmd.org.

SATELLITE HEALTHCARE INC. /WELLBOUNDBooth1028Satellite Healthcare is an established leader in driving clinical excel-lence through joint ventures with nephrologists. Through its partners WellBound and Satellite Dialysis, Satellite Healthcare provides early patient wellness education, superior clinical support services and a complete range of dialysis therapy choices. This comprehensive of-fering allows Satellite Healthcare to advance the standard of chronic kidney disease care while optimizing patient wellness.

SATELLITE LABORATORY SERVICESBooth311Satellite laboratory Services, an independent, full service eSrD labo-ratory provides a complete renal testing menu, simplified management tools and easy access to laboratory services backed by dedicated service personnel. We provide a single source for all your laboratory needs.



SCANTIBODIES CLINICAL LABORATORY Booth310Scantibodies Clinical laboratory (SCl) will showcase a new study demonstrating a dramatic decrease in adynamic bone disease in renal patients resulting from use the PTH accuratio™ Third generation test-ing. SCl invites clinical labs worldwide to join the 10-year initiative to compare accuracy/stability of PTH assays.

SHIRE Booth411Shire is a leading global specialty pharmaceutical company focusing on specialist physicians and their patients in the areas of attention deficit and hyperactivity disorder (aDHD), human genetic therapies (HgT), gastrointestinal (gi) and renal diseases.

SIGMA-TAU PHARMACEUTICALS, INC. Booth305Sigma-Tau Pharmaceuticals is the manufacturer and distributor of Carnitor® (levocarnitine) injection. Carnitor injection is covered nation-ally by CMS/Medicare. The Carnitor injection reimbursement assistance Program provides in-depth support services regarding reimbursement policy, documentation requirements and claims troubleshooting. Contact the reimbursement Hotline at 800-490-3262 for assistance. Please visit www.carnitor.com for more information.

SOLINMED BILLING & TRANSCRIPTIONBooth7391.) ensuring your Financial Health with Medical Billing & Transcription Services. 2.) Medical Billing: 60% cost-reduction to you, patentable technology for errOr-free billing, superfast payment cycle, lowest cost. 3.) Transcription: 99.6-100% accuracy, 12-24 hour turnaround, 6-7 cents/line! 4.) leading with low Cost solutions & errOr-free service. 972-347-9026. www.solinmed.com

SPECTRA LABORATORIESBooth428Spectra is the leading provider of renal-specific laboratory services. Our advanced equipment, specimen packaging, and reporting applica-tions help provide rapid and reliable test results. Our on-site training by a team of renal clinicians and coordination of STaT testing services help customers deliver optimal patient care.

TEVA PHARMACEUTICALS Booth1019Teva Pharmaceuticals, the nation's leading generic manufacturer, markets over 320 products and 1100 SKu's in all major therapeutic areas, including immunosuppressive agents to prevent the rejection of kidney, liver and heart allograft.

U.S. RENAL CARE, INC. Booth635Founded in 2000, uS renal Care works in partnership with nephrolo-gists to develop and operate outpatient dialysis centers. We support our physician partners and clinical staff with strong financial resources, experienced operations management, state of the art technology, and patient and family education.

U.S. RENAL DATA SYSTEM (USRDS) Booth300The uSrDS Coordinating Center, funded by NiDDK, is the national reg-istry that collects, analyzes, and distributes information on trends and patient outcomes in the eSrD population. annual Data report CDs, handouts, and website demonstrations will be available.

UNIVERSITY OF MINNESOTA MEDICAL CENTER, FAIRVIEW Booth441We lead the nation in living donor kidney transplantation. We celebrate 45 years of pioneering research in living donor transplantation. We have performed over 10,000 adult and pediatric transplants in kidney, kidney/pancreas, pancreas, liver, heart, heart/lung, lung, intestinal and islet cells.

WATSON NEPHROLOGY Booth911Watson Nephrology, marketers of Ferrlecit® (sodium ferric gluco-nate complex in sucrose injection), offers specialty products includ-ing injectable iron therapy, oral iron supplements, and renal vitamin formulations. Watson Nephrology, a Division of Watson Pharma, inc. demonstrates their commitment to the nephrology community through anemia education programs and support of national organizations such as the National Kidney Foundation.

WYETH PHARMACEUTICALS Booth915Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women’s health care, cardiovascular disease, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.



Keep Learning & Growing

Join the National Kidney Foundation Today!

If you’re not a member, join now and start receiving NKF membership benefi ts.

Go to the membership desk or www.kidney.org for a complete list of member benefi ts and to register online.

* Current members can save $25 off their NKF Membership Fee when they recruit a new member.

*Offer good through 5/30/08. The renewal and new member forms must be mailed together in order to receive the discount. The new member will pay the full price for their membership. Both renewing and new members will lose the option to complete their transactions online and must mail in their forms together for processing. New members can download the PDF of the member application from www.kidney.org.

© 2008 National Kidney Foundation, Inc. All rights reserved. 0280-366A

If you are a member, renew now at 2007 prices.*

Thousands of renal health care professionals rely on membership in the National Kidney Foundation to help them keep abreast of the latest developments in kidney prevention and treatment through industry-leading journals, news-letters, authoritative guidelines, brochures, online information, clinical meeting and CME courses.

The NKF relies on the support of its members to carry out its mission to

Support kidney patients and families

Encourage organ donation

Offer early detection programs

Provide comprehensive public and professional education

Sponsor scientifi c research

Spearhead advocacy programs to ensure the rights and welfare of kidney patients, their families and kidney professionals.

www.kidney.org

Council of Nephrology Social Workers GrantsMaryBethCallahan,ACSW,LCSWDallas Transplant institute Dallas, Texas Title of Project: Kidney Transplant Patient employment Potential: re-valuation of an important Outcome Measure by use of New Methodologies

CarolineJennette,MSWuniversity of North Carolina Chapel Hill, North Carolina Title of Project: renal replacement Therapy and Barriers to Choice: The Patient’s Perspective

JosephMerighi,PhDBoston university School of Social Work Boston, Massachusetts Title of Project: a Nationwide Survey of Kidney Transplant Social Workers’ Job roles, respon-sibilities, and Occupational Well-Being

Council on Renal Nutrition GrantsJackieCarder,MS,RD,CDE,andKayTaylor,RD,CDEDialysis Center of lincoln lincoln, Nebraska Title of Project: Comparison of Predicted resting Metabolic rate to Measured resting Metabolic rate in Maintenance Dialysis Patients

JoyceVergili,MS,RDColumbia university Teachers College New york, New york Title of Project: Nutritional Practices of renal Dietitians in Hemodialysis Centers Throughout the united States

Council of Nephrology Nurses and Technicians GrantRobertW.MacKinnon,RN,CNNCaritas St. elizabeth’s Medical Center Brighton, Massachusetts Title of Project: The impact of Continuous renal replacement Therapy (CrrT) Staffing and Technique on Nursing resource utilization, Quality of Care and Patient Safety

NaTiONal KiDNey FOuNDaTiON’S PrOFeSSiONal COuNCilS reSearCH graNT reCiPieNTS 2007–2008


gaylOrD TexaN FlOOr PlaN


FaCulTy


KaraAbbas,MS,RD,CSRAbbott

gilbert, aZ

MartinJ.Abrahamson,MDJoslin Diabetes Center

Harvard Medical School

Boston, Ma

KennethAbreo,MDLouisiana State University Health Sciences

Center

Shreveport, la

BethAdams,PAHenry Ford Hospital

Detroit, Mi

SharonAdler,MDUCLA Medical Center

Torrance, Ca

AnilK.Agarwal,MDOhio State University

Dublin, OH

ZalmanS.Agus,MDUniversity of Pennsylvania

School of Medicine

Philadelphia, Pa

MichaelAllon,MDUniversity of Alabama at Birmingham

Birmingham, al

GeraldAppel,MDColumbia University College of Physicians

and Surgeons

New york, Ny

GeorgeAronoff,MDUniversity of Louisville

louisville, Ky

StephenR.Ash,MD,FACPClarian Arnett Health

lafayette, iN

ArifAsif,MDUniversity of Miami School of Medicine

Miami, Fl

CassyAspinall,MSW,LICSWChildren’s Hospital and Regional Medical

Center

Seattle, Wa

JohnR.Asplin,MDLitholink Corporation

Chicago, il

CarolynAtkins,RN,BS,CCTC Children’s Medical Center Dallas Dallas, Tx

MaryAnnBaily,PhD The Hastings Center garrison, Ny

GeorgeBakris,MD,FAHA,FASNUniversity of Chicago

Chicago, il

LyndaK.Ball,RN,BSN,CNNNorthwest Renal Network

Seattle, Wa

JulieBarboza,MSN,RD,APRN-BCEvercare Renal Disease (RD) Program

Berkley, Ma

JoanneM.Bargman,MD,FRCPCToronto General Hospital

Toronto, Ontario, Canada

LoisBatesHoward Brown Health Center

Chicago, il

DanielC.Batlle,MDNorthwestern University

Chicago, il

GeraldA.Beathard,PhDRMS Lifeline

Paige, Tx

GeraldBeck,PhDCleveland Clinic Foundation

Cleveland, OH

SrinivasanBeddhu,MDUniversity of Utah Health Sciences Center

Salt lake City, uT

AnnBeemerCotton,MS,RD,CNSDMethodist Hospital

Westfield, iN

FilitsaH.Bender,MDUniversity of Pittsburgh Medical Center

Pittsburgh, Pa

LaurieE.Benton,RN,PA-C,BS,MPASScott and White Hospital, Texas A&M

Health Science Center College of Medicine

Temple, Tx

SuzanneM.Bergman,MDUniversity of Alabama at Birmingham

Birmingham, al

TomasBerl,MDUniversity of Colorado Health Sciences

Center

Denver, CO

JeffreyS.Berns,MDUniversity of Pennsylvania

School of Medicine

Philadelphia, Pa

AnatoleBesarab,MDHenry Ford Hospital

Detroit, Mi

JudithBeto,PhD,RDLoyola University Medical Center

Maywood, il

PeterBlake,MD,FRCPC,FRCPIVictoria Hospital

london, Ontario, Canada

MaryEllenBrabec,MHS,RD,CSR,LDNDiversified Specialty Institutes

Hazel Crest, il

FaCulTy


KathleenBrady,MS,BC-ANPUniversity of Colorado Health Sciences

Center

Denver, CO

EmmanuelBravo,MDCleveland Clinic Foundation

Cleveland, OH

BarryBrenner,MDHarvard Medical School

Boston, Ma

ValerieBrinkman-Kaplan,MS,RD,LDUS Renal Care/Tarrant Dialysis Centers

Central Fort Werth

Fort Worth, Tx

BridgetK.Brosnihan,PhDWake Forest University School of Medicine

Winston–Salem, NC

TeriBrowne,MSW,LSWUniversity of Chicago

glenview, il

JohnM.Burkart,MDWake Forest University Medical Center

Winston–Salem, NC

DavidBushinsky,MDUniversity of Rochester

rochester, Ny

JessicaCabness,MSW,PhDUniversity of South Florida

St. Petersburg, Fl

MaryBethCallahan,ACSW,LCSWDallas Transplant Institute

Dallas, Tx

DonnaCalvin,APRN,BC-FNP,CNNUniversity of Illinois at Chicago

Olympia Fields, il

EllenCase,MSW,LGSWMayo Clinic

rochester, MN

ClaireCasselman,MSW,LMSW,LICSWUniversity of Michigan Health Systems

ann arbor, Mi

LeeCauble,MPH,RD,CSR,LDDCI/ Desert Dialysis Center

Tucson, aZ

DonnaCalvin,APRN,BC-FNP,CNNUniversity of Illinois at ChicagoChicago, il

SheldonC.Chaffer,MDScott and White Clinic, Texas A&M

University HSC

Temple, Tx

ChristopherChan,MDUniversity of Toronto


AlfredCheung,MDUniversity of Utah

Salt lake City, uT

DolphChianchiano,JDNational Kidney Foundation

New york, Ny

MichaelJ.Choi,MDJohns Hopkins University School of Medicine

Baltimore, MD

LouiseClement,MS,RD,CSR,LDSouth Plains Kidney Disease Center

lubbock, Tx

CarolynCochran,RD,LD,MS,CDEDallas Nephrology Associates

Dallas, Tx

JeanColaneri,ACNP,MSAlbany Medical Center Hospital

albany, Ny

AllanJ.Collins,MD,FACPNational Kidney Foundation

Minneapolis, MN

DannyConcepcion,CCHT,CHTSt. Joseph Hospital Renal Center

Orange, Ca

BonnieConrad,RN,CDNAlbany Regional Kidney Center

albany, Ny

GabrielContreras,MD,MPHUniversity of Miami School of Medicine

Miami, Fl

SandraCoorough,ACSW,LCSWPhoenix Children’s Hospital Kid’s Kidney

Center

Phoenix, aZ

DanielCoyne,MDChromalloy American Kidney Center

St. louis, MO

RonaldJ.Crossno,MDVista Care Hospice

rockdale, Tx

JackieCrouchScott and White Memorial Hospital

Temple, Tx

JimR.Curtis,CHT,CCHTJim Curtis & Associates

Portland, Or

KirstendeGroot,MDKlinikum Offenbach

Offenbach, germany

JanDeane,RN,CNNRenal Network of the Upper Midwest

Saint Paul, MN

AndreaDeKam,LMSWUniversity of Michigan Dialysis

livonia, Mi

FrancisDelmonico,MDMassachusetts General Hospital

Boston, Ma


LauraDember,MDBoston University School of Medicine

Boston, Ma

ChristinaDenman,LMSWCollin County

Plano, Tx

VincentW.Dennis,MDCleveland Clinic

Cleveland, OH

PeterB.DeOreo,MD,FACPCenters For Dialysis Care

Shaker Heights, OH

ThomasDepner,MDUniversity of California, Davis

Sacramento, Ca

DavidDeWalch,MSPA,PA-C,MS,MAAmerican Association of Surgical Physician

Assistants, Tyler Radiology Associates

Tyler, Tx

LesleyDinwiddie,MSN,RN,FNP,CNNInstitute for Clinical Excellence,

Education and Research

Cary, NC

BradleyDixon,MDVeterans Affairs Medical Center and

University of Iowa

iowa City, ia

BartDolmatch,MDUT Southwestern Medical Center

Dallas, Tx

MaryAnneDooley,MD,MPHUniversity of North Carolina

Chapel Hill, NC

TilmanDrüeke,MDHôpital Necker

Paris, France

SenatorRobertDuncanCrenshaw, Dupree and Milamaustin, Tx

PaulW.Eggers,PhDNational Institute of Health

Bethesda, MD

KarenEgloso,BSW,MSW,LSW,CNSWSunrise Children’s Hospital

las vegas, Nv

GarabedEknoyan,MDBaylor College of Medicine

Houston, Tx

KimberlyEnglish,MSN,RN,FNPScott & White Sleep Disorders Clinic

Temple, Tx

JessicaFarrell,MSW,LCSW-PDuke University Medical Center

Durham, NC

DanielI.Feig,MD,PhDTexas Children’s Hospital

Houston, Tx

HarveyA.Feldman,MD,FACPNova Southeastern University

Ft. lauderdale, Fl

HaroldI.Feldman,MD,MSCEUniversity of Pennsylvania

Philadelphia, Pa

FredricO.Finkelstein,MDHospital of St. Raphael, Yale University

New Haven, CT

MichaelFlessner,MD,PhDUniversity of Mississippi Medical Center

Jackson, MS

CharlesJ.Foulks,MDScott and White Hospital, Texas A&M

University HSC

Temple, Tx

StanleyS.Franklin,MD,FACP,FACCUCI Heart Disease Prevention Program

los angeles, Ca

AllonFriedman,MDIndiana University School of Medicine

Carmel, iN

BarbaraFromm,MS,RDHarborview Medical Center, University

of Washington

North Bend, Wa

MaryAnnFuller,RD,LDDaVita Arlington Dialysis

lake Dallas, Tx

AnthonyFurlan,MDCleveland Clinic Cerebrovascular Center

Cleveland, OH

MindyGentile,MS,RD,LDMcKinney, Tx

JoelGlickman,MD,FACPUniversity of Pennsylvania

Philadelphia, Pa

DeborahGlidden,ARNP,BC,CNNNephrology Associates of Central Florida, PA

Orlando, Fl

DavidS.Goldfarb,MDNew York Harbor VA Medical Center/NYU

School of Medicine

New york, Ny

CheriGoldstein,PA-CDallas Nephrology AssociatesDallas, Tx

ThomasGolper,MD,FASN,FACPVanderbilt University Medical Center

Nashville, TN

ThomasA.Gonwa,MD,FASN,FACPMayo Clinic

Jacksonville, Fl

JanelleE.Gonyea,RD,LDMayo Clinic Dialysis Services

rochester, MN

FaCulTy


JohnQ.Gowan,LMSWESRD Network # 14

Dallas, Tx

MichaelGrasso,MDSaint Vincents Medical Center

rye, Ny

TomGreene,PhDUniversity of Utah Health Sciences Center

Salt lake City, uT

LoicGuillevin,MDHopitaln Avicenne

Bobigny Cedex, France

KayHall,BSN,RN,CNNDaVita, Inc.

Brentwood, TN

LisaHall,MSSW,LCSWThe Florida ESRD Network

Tampa, Fl

L.LeeHamm,MDTulane Medical School

New Orleans, la

HaewookHan,PhD,RD,CSR,LDNTufts-New England Medical Center

North Quincy, Ma

JeffHarder,MSW,LICSWUniversity of Washington Medical Center

Seattle, Wa

JohnW.Hartman,MDVisonex, LLC

green Bay, Wi

JeanetteHasse,PhD,RD,FADA,CNSDBaylor Regional Transplant Institute

Baylor University

Dallas, Tx

MaryHastingsHagar,PhD,RD,FADAAmerican Dietetic Association

Washington, DC

RebeccaHays,MSWUniversity of Wisconsin Hospital and Clinics

Madison, Wi

MikhaelleHeald,LMSWThe Children’s Mercy Hospitals and Clinics

Kansas City, KS

DavidJ.Hellmann,MDJohns Hopkins University School of Medicine

Baltimore, MD

BrendaR.Hemmelgarn,MDUniversity of Calgary

Calgary, alberta, Canada

JohannHerberth,MD,FASNUniversity of Kentucky

lexington, Ky

CharlesHerzog,MDHennepin County Medical Center

Minneapolis, MN

JonathanHimmelfarb,MDMaine Medical Center Research Institute

Portland, Me

DebbieHinnen,ARNP,CDE,BC-ADM,FAANMid-America Diabetes Associates

Wichita, KS

SandraHinton,RN,BSNMedical City Transplant Dallas, Tx

TammyHo,MDEvanston Hospital

evanston, il

R.MichaelHofmann,MDUniversity of Wisconsin

Madison, Wi

RonaldHogg,MDScott and White Hospital

Temple, Tx

JefferyHoggard,MDEastern Nephrology Associates

greenville, NC

PriscillaHollander,MDBaylor Endocrine Center

Dallas, Tx

NormanK.Hollenberg,MD,PhDBrigham & Women’s Hospital

Boston, Ma

JeanL.Holley,MDUniversity of Illinois

urbana, il

JosefinaHouchins,LMSWDaVita Oak Cliff Dialysis Center

Dallas, Tx

TriciaHoward,MHS,PA–CMedical Associates of Savannah

Savannah, ga

KirkHughes,MD University of Iowa Hospitals & Clinics

iowa City, ia

MarianneHutton,RD,CDEFresenius Medical Services-North America

Santa rosa, Ca

TamiHyziewiczCase,PA–CScott & White Hospital

Temple, Tx

AjayIsrani,MD,MSHennepin Faculty Associates

Minneapolis, MN

BertrandL.Jaber,MD,MSCaritas Medical Group

Boston, Ma

AimeeJaremowicz,RD,LDDiversified Specialty Institute (DSI)

Chicago, il

ArfrancesJohnson,LD,RD,MSLiberty DialysisFort Worth, Tx

StephanieJohnstone,LCSW,MSWFresenius Medical Care-North America

San Diego, Ca


DebraJordanDaVita North Dallas Dialysis Center

Dallas, Tx

SheilaJowsey,MDMayo Clinic

rochester, MN

PeterJuergensen,PA-CMetabolism Assoicates

Cheshire, CT

KamyarKalantar–Zadeh,MDHarbor-UCLA

Torrance, Ca

MarciaKalistaRichards,MPH,RD,CNSD,LDNPennsylvania State University

Slatington, Pa

JudithKariCenters for Medicare & Medicaid Services

Baltimore, MD

PamelaS.Kent,MS,RD,CSR,LDGenzyme Renal

vermilion, OH

Rita-AnKiley,MSWelm grove, Wi

PaulKimmel,MDGeorge Washington University

Washington, DC

LisaKindy,JDMedical University of South Carolina

Charleston, SC

AlanS.Kliger,MDHospital of St. Raphael

New Haven, CT

BobbieKnotek,RN,BSN,CNN,CPHQESRD Network of Texas, Inc.

Dallas, Tx

NormaKnowles,MSW,LCSWDialysis Clinic, Inc.

Columbia, MO

StephenM.Korbet,MD,FASNRush University Medical Center

Chicago, il

AndreaKostick,MSW,LISWMayo Clinic

rochester, MN

CsabaKovesdy,MD,FASNSalem VA Medical Center

Salem, va

SumitKumar,MDDallas Nephrology Associates

Dallas, Tx

DanaKumjian,MDMedical Associates of Savannah

Savannah, ga

WarrenKupin,MDUniversity of Miami

Miami, Fl

NadiyaLakhani,RD,LDFresenius Medical Center

Dallas, Tx

KristinLarson,RN,ANP,GNP,CNN,MSNNephrology Associates

Salt lake City, uT

ThuH.Le,MDDurham VA Medical Centers

Durham, NC

NathanLevin,MDRenal Research Institute

New york, Ny

KristieLewis,LLMSW,MSWHenry Ford Health System, Greenfield Health

Systems – Taylor Dialysis

Westland, Mi

EdmundJ.Lewis,MDRush University Medical Center

Chicago, il

JuliaB.Lewis,MDVanderbilt University Medical Center

Nashville, TN

AnneLiles,PharmDAuburn University

auburn, al

RobertM.Lindsay,MDThe University of Western Ontario and

London Health Sciences Centre

london, Ontario, Canada

RobertS.Lockridge,MDLynchburg Nephrology Physicians, PLLC

lynchburg, va

CharmaineLok,MDToronto General Hospital


CynthiaLord,MHS,PA-CQuinnipiac University

Cheshire, CT

ElenaLucio,LMSWChristus Santa Rosa Children’s Hospital

San antonio, Tx

KatiMalarcher,LMSWCollin County Dialysis Center

Plano, Tx

MaggieMarekBaylor All Saints Fort Worth

Forth Worth, Tx

CathiMartin,RD,CSRNutrePletion Resources

Nashville, TN

ArthurJ.Matas,MDUniversity of Minnesota

Minneapolis, MN

IvanD.Maya,MDUniversity of Alabama at Birmingham

Birmingham, al

MaureenMcCarthy,MPH,RD,CSR,LDOregon Health & Science University

Portland, Or

WilliamMcClellan,MDEmory University

atlanta, ga

FaCulTy


PeterMcCullough,MD,MPHWilliam Beaumont Hospital,

Beaumont Health Center

Northville, Mi

SamyMcFarlane,MDSUNY Downstate Kings

County Hospital Center

Brooklyn, Ny

JenniferMcGuoirk,MS,RD,LDNAbbott Renal Care

aston, Pa

StephanieMcIntyre,RDavondale, aZ

DianneMcKay,MDThe Scripps Research Institute

la Jolla, Ca

PatriciaM.McKevitt,MSW,ACSW,LCSWWashington University School of Medicine

St. louis, MO

BethMcQuiston,MD,MS,RD,LDNRush University Medical Center

Park ridge, il

RajnishMehrotra,MD,FACP,FASNUCLA Medical Center

Torrance, Ca

RavindraMehta,MDUniversity of California – San Diego

la Jolla, Ca

MarkMeier,LICSW,MSWCreative Workplace Solutions

Minneapolis, MN

DavidMendelssohn,MD,FRCPCUniversity of Toronto


JoeMerighi,MSW,PhDBoston University School of Social Work

Boston, Ma

JefferyC.Metzger,MDUniversity of Texas Southwestern

Medical Center

Dallas, Tx

MariamMichaels,MDHoward University

Washington, DC

RonaldMiller,MD,FACPUniversity of California, Irvine irvine, Ca

CindyMiller,MSW,LCSWAdvanced Renal Care, Inc.

Tampa, Fl

MeredithMiller,RD,LDCleveland Clinic Foundation

Cleveland, OH

RichardMishler,MDArizona Kidney Disease &

Hypertension Center

Phoenix, aZ

OrsonW.Moe,MDUniversity of Texas Southwestern

Medical Center

Dallas, Tx

SharonMoe,MDIndiana University

indianapolis, iN

MicheleH.Mokrzycki,MD,MSMontefiore Medical Center, Albert Einstein

College of Medicine

Bronx, Ny

MarianneMoncrief,Dallas Transplant

Dallas, Tx

AnneMoore,LMSWTexas Partnership for End of Life Care

Sugarland, Tx

BruceZ.Morgenstern,MDPhoenix Children’s Hospital

Phoenix, aZ

DonnaMortondeSouza,MPH,RDProfessional Nutrition Services, Inc.

Sacramento, Ca

AlvinMoss,MDWest Virginia University

Morgantown, Wv

SalimMujais,MDAstellas Pharma US

Mcgaw Park, il

MaryMurphy,RN,CCTCPhoenix Childrens Hospital

Phoenix, aZ

PatrickMurray,MDUniversity of Chicago

Chicago, il

MohanramNarayanan,MD,FASNScott and White Hospital

Temple, Tx

NancyNardelli,RN,CCRCMedical City Dallas Hospital

Dallas, Tx

AndrewS.Narva,MD,FACPNational Institutes of Health

Bethesda, MD

IraNemeth,MDDallas County Health and Human Services

Dallas, Tx

MarianneNeumann,RN,CNNAlbany Dialysis Center

albany, Ny

AllenNissenson,MDDavid Geffen School of Medicine at UCLA

los angeles, Ca

AnnO’Hare,MDUniversity of Washington

Seattle, Wa


EdmundO’Riordan,MB,BCH,BAO,MRCPISalford Royal Foundation Trust

Salford, Manchester

EmilPaganini,MDThe Cleveland Clinic Foundation

Cleveland, OH

RobertL.Page,PharmD,FCCP,FAHA,FASCP,FSGC,CGP,BCPSUniversity of Colorado Health Sciences

Center

aurora, CO

JoniJ.Pagenkemper,MS,MA,RD,LMNTCreighton University Medical Center

Omaha, Ne

PaulM.Palevsky,MDUniversity of Pittsburgh

Pittsburgh, Pa

JodiPatterson,LMSWMcKinney Dialysis Center

McKinney, Tx

JessiePavlinac,MS,RD,CSR,LDOregon Health & Science University

Portland, Or

MarcPenn,MD,PhDThe Cleveland Clinic Foundation

Cleveland, OH

MarkA.Perazella,MDYale University School of Medicine

Cheshire, CT

BethPiraino,MDUniversity of Pittsburgh

Pittsburgh, Pa

RonaldPisoni,PhD,MSArbor Research Collaborative

ann arbor, Mi

MarcPohl,MDThe Cleveland Clinic Foundation

Cleveland, OH

LisaPratka,LMSWMedical City Transplant

Dallas, Tx

MeganPrescott,MSW,LCSWUniversity of Colorado Hospital

aurora, CO

PatPreston,MSPat Preston Medical Enterprises, Inc

astoria, Or

WajehQunibi,MD,FACPUniversity of Texas Health Science Center

San antonio, Tx

JaiRadhakrishnan,MD,MR,MRCPColumbia University

New york, Ny

PandurangaS.Rao,MD,DNB,MSUniversity of Michigan

ann arbor, Mi

RobertReilly,MDUniversity of Texas Southwestern

irving, Tx

CleoRichard,RN,PhDConsultant

Missouri City, Tx

MarkS.Roberts,MD,MPPUniversity of Pittsburg School of Medicine

Pittsburgh, Pa

BruceRobinson,MDArbor Research Collaborative

ann arbor, Mi

MichaelRocco,MD,MSCEWake Forest University School of Medicine

Winston Salem, NC

RogerRodby,MDRush University Medical Center

Chicago, il

JamesR.Rodrigue,PhDHarvard Medical School

Boston, Ma

CarolRoe,RN,JDCenters for Dialysis Care

Shaker Heights, OH

ArturoR.Rolla,MDJoslin Diabetes Center

Boston, Ma

JamieRoss,MDUC Davis

Sacramento, Ca

PrabirRoy-Chaudhury,MDUniversity of Cincinnati

Cincinnati, OH

BharatSachdeva,MDLouisiana State University Health

Science Center

Shreveport, la

AntoineSamaha,MDKidney and Hypertension Center

Cincinnati, OH

MilagrosD.Samaniego,MDUniversity of Wisconsin

Madison, Wi

EduardoSanchez,MD,MPHUniversity of Texas Health Center

austin, Tx

PaulW.Sanders,MDBirmingham VA Medical Center

Birmingham, al

GailSansivero,MS,ANPCommunity Care Physicians

albany, Ny

MarkJ.Sarnak,MDTufts-New England Medical Center

Boston, Ma

MarySchira,PhD,APRN,BC,ACNPUniversity of Texas at Arlington School

of Nursing

arlington, Tx

FaCulTy


KathySchiroHarvey,MS,RD,CSRPuget Sound Kidney Centers

Mountlake Terrace, Wa

DonaldSchon,MDArizona Kidney Disease & Hypertension

Phoenix, aZ

AntonSchoolwerth,MD,FAHADartmouth-Hitchcock Medical Center

Spofford, NH

DonnaSecker,PhDThe Hospital for Sick Children


MaryAnnSevick,ScD,RNUniversity of Pittsburgh

Pittsburgh, Pa

EdwardSiew,MDVanderbilt University Medical Center

Nashville, TN

EdwardG.Silverhardt,LCSW,LSCSW,BCD,MSWSparks Dialysis Center

Sparks, Nv

AjaySingh,MBBS,FRCPBrigham and Woman’s Hospital

Boston, Ma

Mi-KyungSong,PhD,RNUniversity of Pittsburgh

Pittsburgh, Pa

StuartM.Sprague,DONorthwestern University

evanston, il

GlenStanbaugh,MDTexas Renal Coalition

lubbock, Tx

AlisonSteiber,PhD,RD,LDCase Western Reserve University

Cleveland, OH

LesleyStevens,MD,MS,FRCPCTufts – New England Medical Center

Boston, Ma

StephanieStewart,LICSWMayo Clinic

rochester, MN

JohnC.Stivelman,MDUniversity of Washington,

Northwest Kidney Centers

Seattle, Wa

KristinStockard,LICSWChildren’s Hospital and Regional

Medical Center

Seattle, Wa

DanaSturtevant,MS,RDBe Nourished

Portland, Or

WadiN.Suki,MD,FACPThe Kidney Institute

Houston, Tx

PhyllisSun,RDSt. Elizabeth’s Medical Center

Brighton, Ma

MarySundell,RD,LDN,CCRPVanderbilt University Medical Center

Nashville, TN

DuaneSunwoldSpokane Community College

Spokane, Wa

LyndaSzczech,MD,MCSE,FASNDuke University School of Medicine

Durham, NC

PaulSzczybor,PA–CThe Franklin Square Hospital Center

Catonsville, MD

HaroldM.Szerlip,MD,FACP,FCCPMedical College of Georgia

augusta, ga

MichaelTalamantes,MSSW,LCSWUniversity of Colorado Hospital

aurora, CO

MariaTaylor,PharmDUniversity of Alabama at Birmingham

Birmingham, al

StephenC.Textor,MDMayo Clinic Foundation

rochester, MN

RaviThadhani,MDMassachusetts General Hospital

Boston, Ma

CharlieThomas,LCSW,ACSW,MSW,CISWBanner Good Samaritan Medical Center

Phoenix, aZ

CherylThomas,RDHFounder Dental Inspirations, Inc.

galveston, Tx

KathrynThurber-Smith,LICSWChildren’s Hospital and Regional

Medical Center

Seattle, Wa

TrentTipple,MD,FAAPThe Research Institute at Nationwide

Children’s Hospital

Columbus, OH

AshitaTolwani,MD,MScUniversity of Alabama at Birmingham

Birmingham, al

FaithTootell,MS,RD,CSR,FADASatellite Healthcare Inc.

Fremont, Ca

JoseTorrealba,MDUniversity of Wisconsin – Madison

Madison, Wi

RobertD.Toto,MDUT Southwestern Medical Center at Dallas

Dallas, Tx


MichelleTrahan,MS,RD,LDGenzyme Renal

richardson, Tx

MandyTrolinger,MS,RDDaVita Littleton Dialysis

Highlands ranch, CO

LaraTushla,LCSW,MSWRush Presbyterian

Chicago, il

TraceyA.Tyus–Bailey,MSW,LMSW,ACSWGreenfield Health Systems

Southfield, Mi

MarkUnruh,MD,MScUniversity of Pittsburgh

Pittsburgh, Pa

ArisQ.Urbanis,MDRMS Lifeline, Inc.

grosse Pointe Park, Mi

TusharVachharajani,MD,FASN,FACPWake Forest University School of Medicine

Winston Salem, NC

RamiroValdez,PhDValdez Seminars

Denton, Tx

JosephP.VandeGriend,PharmDUniversity of Colorado Denver

School of Pharmacy

aurora, CO

JosephVassalotti,MDNational Kidney Foundation

New york, Ny

MiguelVazquez,MDUT–Southwestern in Dallas

Dallas, Tx

JoyceVergili,MS,RD,CDN,CDEColumbia-Greene Dialysis Centers

Catskill, Ny

ThomasVesely,MD,FSIRSelf-Employed

Saint louis, MO

RonaldVictor,MDUniversity of Texas Southwestern

Dallas, Tx

TheodôrVogels,MSWMáxima Medical Centre

The Netherlands

BradleyWarady,MDChildren’s Mercy Hospitals and Clinics

Kansas City, MO

RichardA.Ward,PhDUniversity of Louisville

louisville, Ky

KurtA.Wargo,PharmD,BCPSUniversity of Alabama – Birmingham

Huntsville, al

DavidG.Warnock,MDUniversity of Alabama – Birmingham

Birmingham, al

SarahWashburn,MS,RD,CDSeattle Cancer Center Alliance Seattle, Wa

TiffanyWashington,MSWUNC Chapel Hill School of Social Work

Chapel Hill, NC

AmyWaterman,PhDWashington University in St. Louis

St. louis, MO

PatWeber,MS,RD,CDE,CSR,LDNGenzyme Corporation

Springville, al

MatthewR.Weir,MDUniversity of Maryland School of Medicine

Baltimore, MD

BarbaraWeisMalone,BSN,RN,MSN,CFNPUniversity of Colorado Health

Sciences Center

aurora, CO

StevenD.Weisbord,MD,MSc,FASNUniversity of Pittsburgh School of Medicine

Pittsburgh, Pa

JohnJasonWhite,MDMedical College of Georgia

augusta, ga

RobertWhitlock,MSSW,LCSW,MHAMissouri Kidney Program

Columbia, MO

KarenWiesen,CHT,LPN,RD,LDWashington University School of Medicine

– Barnes Jewish Dialysis Center

St louis, MO

AlanWilkinson,MDUCLA Medical Center

los angeles, Ca

WolfgangWinkelmayer,MDHarvard Meical School

Cambridge, Ma

AlexanderWiseman,MDUniversity of Colorado Health

Sciences Center

Denver, CO

JayB.Wish,MDCase Western Reserve University

Cleveland, OH

MylesWolf,MD,MMScMassachusetts General Hospital

Harvard Meical School

Brookline, Ma

JackWork,MDEmory University, Dialysis Access Center

atlanta, ga

www.nkfclinicalmeetings.org

LindaWright,MHSC,MSW,RSWUniversity Health Network


QingyuWu,MD,PhDThe Cleveland Clinic Foundation

Cleveland, OH

StevenWu,MDMassachusetts General Hospital

Boston, Ma

JudyYang,RD,LDUSRC/TDC–PD Clinic

Fort Worth, Tx

AlexanderS.Yevzlin,MDUniversity of Wisconsin

Madison, il

KimZuber,PA-C,MSPSMetropolitan Nephrology

alexandria, va

PatriceZyry,RN,BSN,CNNNephros, Inc.

Manalapan, NJ

FaCulTy


www.nkfclinicalmeetings.org

30 east 33rd StreetNew york Ny 10016www.kidney.org

April 2–6, 2008 Gaylord Texan, Dallas, Texas Texan, Dallas, Texas Spring ’08 Clinical Meetings...

Documents

Transcript of April 2–6, 2008 Gaylord Texan, Dallas, Texas Texan, Dallas, Texas Spring ’08 Clinical Meetings...